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Abstract 
Friedreich ataxia (FRDA) is the most common inherited ataxia disorder, caused by a GAA 
repeat expansion mutation within the first intron of the FXN gene. The subsequent deficiency 
of frataxin protein leads to neurological disability, increased risk of diabetes mellitus, 
cardiomyopathy and premature death. The exact FRDA disease mechanism is not yet clear, 
despite some understanding of epigenetic, transcriptional and DNA repair system effects that 
lead to frataxin reduction. Previous studies have shown that mismatch repair (MMR) genes 
can affect other trinucleotide repeat disorders by destabilisation of the repeats. Furthermore, it 
has been proposed that frataxin deficiency might lead to cell malignancy by an as yet 
undefined mode of action. Therefore, the principle aim of this thesis was to use human and 
genetically altered mouse cells and tissues to understand the effects of MMR proteins on 
GAA repeat instability and FXN transcription, and also to identify potential changes in MMR 
transcription that might cause malignancy in FXN-defective human cells.  
Firstly, by using FXN and MMR genetically altered mice, MMR proteins were shown to be 
involved in both intergenerational and somatic GAA repeat instability, although their effects 
in the two systems were different. Thus, Msh2 or Msh3 were both found to protect against 
intergenerational transmission of GAA contractions, while loss of Msh2 or Msh3 reduced 
somatic GAA repeat expansions and increased levels of FXN transcription in brain and 
cerebellum tissues. Loss of Msh6 induced both intergenerational GAA repeat expansions and 
contractions, while the frequency of somatic GAA repeat expansions was reduced. Curiously, 
the level of FXN transcription was also reduced in Msh6-deficient brain and cerebellum 
tissues. On the other hand, Pms2 was found to protect against both intergenerational and 
somatic GAA repeat expansions, with loss of Pms2 causing increased GAA repeat 
expansions and decreased levels of FXN transcription in brain and cerebellum tissues. 
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Finally, loss of Mlh1 led to a reduced frequency of both intergenerational and somatic GAA 
repeat expansions, but the level of FXN transcription was also reduced in brain and 
cerebellum tissues. Furthermore, upregulation of MMR mRNA expression was detected in 
human FRDA fibroblast cells, but downregulation was seen in FRDA cerebellum tissues, 
suggesting tissue-dependent control of FXN and MMR expression. In summary, these studies 
indicate that the MMR system can affect GAA repeat expansion instability and FXN 
transcription through different mechanisms of action. Furthermore, frataxin deficiency can 
also affect the levels of MMR mRNA expression in a tissue-dependent manner. These 
findings will assist future investigations aimed at identifying novel FRDA therapies. 
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1.1 - Ataxia 
The word ataxia comes from the Greek “a-taxia”, meaning literally “no order”. Indeed, it is a 
blanket term referring to a loss of muscle control. Sometimes, loss of position sense may 
result from de-afferentation, with subsequent ataxia (called sensory ataxia). This problem 
generally occurs because of defects in parts of the nervous system that control coordination of 
movement, particularly the cerebellum. Ataxia can be a symptom of many disorders, such as 
multiple sclerosis or cerebellar palsy. However, it is the principle symptom of a group of 
neurological disorders termed “cerebellar ataxias”. 
Generally, diseases of ataxia are sub-divided into two different groups: sporadic and 
hereditary (Table 1.1). Hereditary ataxia is a form that occurs via genetic defects and is 
associated with a familial history. In general, the inherited ataxias are classified into two 
types: early onset disorders (under 25 years old) that are usually autosomal recessive in 
inheritance, such as Friedreich ataxia, and later onset cases of cerebellar degeneration that are 
most often dominantly inherited (Klockgether 2007). Although, classification of the 
hereditary ataxias remains a matter of controversy, they can also be divided into types caused 
by metabolic defect, such as ataxia telangiectasia and abetalipoproteinaemia, and those which 
fit the features of a named disease, such as Friedreich ataxia and spinocerebellar ataxia 
(Cellini et al. 2001; Nardin and Johns 2001; Klockgether 2007; Sas et al. 2007;                      
de Souza-Pinto et al. 2008). 
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Table 1.1 - Classification of progressive ataxias (Klockgether 2007). 
 Hereditary ataxias  
            -  Autosomal recessive ataxias 
                     Friedrich ataxia (FRDA) 
                     Ataxia telangiectasia (AT) 
                     Autosomal recessive ataxia with oculomotor apraxia type 1 (AOA1) 
                     Autosomal recessive ataxia with oculomotor apraxia type 2 (AOA2) 
                     Spinocerebellar ataxia with axonal neuropathy (SCAN1) 
                     Abetalipoproteinaemia  
                     Ataxia with isolated vitamin E deficiency (AVED) 
                     Refsum disease  
                     Cerebrotendinous xanthomatosis  
                     Other autosomal recessive ataxias 
            -  Autosomal dominant ataxias  
                     Spinocerebellar ataxias 
 Non-hereditary degenerative ataxias 
                     Multiple system atrophy, cerebellar type (MSA-C) 
                     Sporadic adult-onset ataxia of unknown origin (SAOA) 
                     Acquired ataxias 
                     Alcoholic cerebellar degeneration 
                     Ataxia due to other toxins 
                     Ataxia caused by acquired vitamin deficiency or metabolic disorders  
                     Paraneoplastic cerebellar degeneration 
                     Immune-mediated ataxias 
 
1.2 - Friedreich ataxia 
Friedreich ataxia (FRDA; OMIM 229300) is a progressive autosomal recessive inherited 
disorder, with usual onset in childhood or adolescence, mainly caused by spinocerebellar 
degeneration. 
1.2.1 - Prevalence  
FRDA is the commonest hereditary ataxia, accounting for approximately half of all inherited 
ataxias. It is recognised as a rare disease with a prevalence of 1-2 per 100,000 individuals. 
The carrier rate was initially reported to be 1:110 in the USA and UK, but lower in Far-East 
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Asian and sub-Saharan African societies. However, accessibility to molecular diagnostic 
techniques has helped to identify affected individuals and carriers more precisely, so that the 
estimated incidence has now increased to 1:30,000 persons and the estimated carrier rate is 
now 1:60-1:90 (Cossee et al. 1997; Epplen et al. 1997; Pandolfo and Montermini 1998; 
Bidichandani et al. 2000; Delatycki et al. 2000; Labuda et al. 2000; Puccio and Koenig 
2000). FRDA is generally first observed under 25 years of age (the average age of onset is 
10-12 years), with an equal range in both genders; although cases of later onset or very late 
onset may also occur rarely (Bidichandani et al. 2000; Berciano et al. 2005; Bhidayasiri et al. 
2005; Condo et al. 2006).  
1.2.2 - Clinical features 
The natural history of FRDA is gradual development of neurological symptoms, followed by 
muscular deficiencies. The main presenting symptoms include gait and limb ataxia (first in 
the lower extremities, followed by all limbs), associated with optic atrophy, deafness, severe 
dysarthria, defect or absence in vibration and position sense (however the temperature and 
pain senses are preserved), loss of reflexes (particularly in the lower extremities), the 
presence of spasticity and extensor plantar responses and muscle atrophy and weakness, 
together with a hypertrophic obstructive cardiomyopathy in most of the patients. Since the 
disorder is aggressive, most of patients are wheelchair bound by 15 years after onset, 
followed by death in the third to fifth decades of life. Following clinical consideration, FRDA 
is diagnosed by molecular analysis (Alper and Narayanan 2003; Koeppen 2011). 
1.2.3 - Pathology 
The crucial sites affected in FRDA are dorsal root ganglia (DRG), dentate nucleus of the 
cerebellum, posterior columns and corticospinal tracts of the spinal cord, and heart. 
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Generally, the FRDA lesion causes several changes throughout the entire DRG, but mainly in 
the sub-capsular regions (Figure 1.1). 
 
Figure 1.1 - Pathology of DRG in FRDA and Normal cells (Koeppen 2011). 
 
Haematoxylin and eosin staining of DRG in (a) FRDA and (b) unaffected individuals show    
a reduced size of sub-capsular neurons in FRDA. The arrow (a) shows a nodule of Nageotte. 
 
 
 
Macroscopically, a small spinal cord is detectable, with reduced dorsal columns, 
spinocerebellar and pyramidal tracts in FRDA. The nervous system changes result in axonal 
atrophy and loss of sensory axons (particularly large myelinated fibres) in peripheral nerves. 
Loss of the large sensory neurons is particularly prominent in the DRG and de-myelination is 
detectable in the posterior columns of the spinal cord. There is only mild neuronal loss in the 
cerebellar cortex. Reduction of phospholipid levels can also be detected in the cerebellar and 
occipital cortex of the brain (Pandolfo 1999; Condo et al. 2006). 
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1.2.4 - Frataxin protein 
FRDA is caused by deficiency of a conserved mitochondrial protein that is found 
ubiquitously in all cells from bacteria to humans, called frataxin (Figure 1.2). The precursor 
form of frataxin is a 210 amino acid protein, containing an N-terminal transit amino-acid 
sequence that conducts its transport into the mitochondria, where two cleavages occur. These 
two proteolytic steps convert the precursor protein to a 19kDa intermediate and a 17kDa 
mature form of frataxin, respectively. The final protein in mitochondria is recognised as the 
mature form of frataxin (Condo et al. 2007). The first idea of frataxin maturation was 
obtained by physical interaction between the mouse frataxin precursor and mouse 
mitochondrial processing peptidase β (MPP-β). It was recognised that by binding MPP-β, 
frataxin was initially cleaved between residues 41-42 to make the initial intermediate form of 
frataxin (amino-acids 42-210) (Koutnikova et al. 1998; Condo et al. 2007). Subsequently, the 
second cleavage on human frataxin in vitro was observed between residues Ala55 and Ser56 
by MPP. This was the first reported mature form of frataxin (m56-210) (Cavadini et al. 2000; 
Condo et al. 2007). Later, other independent in vivo studies identified two mature forms of 
frataxin, cleaved at residues Leu78-Arg79 (m79-210) and Lys80-Ser81 (m81-210). Mass 
spectrometry investigations showed that the m79-210 product is caused by natural 
degradation leading to a non-functional 14.5kDa frataxin. In contrast to m79-210, the           
m81-210 form is recognised as a functional protein, which is not produced from m56-210 
frataxin degradation. This protein has the capability to bind and transfer ferrous iron in iron 
sulfur cluster (ISC) and heme biosynthesis. 
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Figure 1.2 - Multiple alignments of predicted protein sequences of frataxin (Long et al. 
2008). 
 
 
 
The figure shows multiple alignments of predicted frataxin protein sequences from different 
cells. The number of amino acids mentioned at the left of the respective sequences. Black 
highlight sequences are conserved positions conservatively substituted in grey, and variable 
positions are white. Gaps were introduced to optimise the alignment. The mitochondrial 
targeting sequence of T.brucei frataxin is underlined. Asterisks and hash marks denote 
residues implicated in iron and ferrochelatase binding. The position of -helices (H1and H2) 
and -sheets (S1–S6) are indicated above the alignment. 
 
 
The mature form of frataxin (m81-210) can also recover metabolic defects, such as deficiency 
of aconitase activity, caused by the absence of m56-210 frataxin. Overall, these studies 
suggest that m81-210 is the primary mature form in vivo (Figure 1.3), while m56-210 can be 
proteolytically established from the precursor in vivo when generation of the m81-210 form is 
prevented by the blocking of residues 80-81 (Condo et al. 2007; Yoon et al. 2007; 
Schmucker et al. 2008).  
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  Figure 1.3 - Different forms of human frataxin (Schmucker et al. 2008).  
 
The precursor form is targeted to the mitochondria and undergoes a two-step cleavage 
process; the intermediate form and one of three mature forms starting at the amino acid 56 
(intermediate-mature form), 78 (degraded-mature form) or 81 (primary-mature form).   
 
Interestingly, recent data shows that a mature form of frataxin can also be found in the 
cytoplasm. In this study, Condo and colleagues recognised a direct interaction of the human 
extra-mitochondrial frataxin with cytosolic aconitase/iron regulatory protein-1 (IRP1),              
a bi-functional protein involved in enzymatic and RNA-binding function through the              
‘iron-sulfur switch’ mechanism (Condo et al. 2010). 
Analysis of the crystal structure of mature frataxin (Figure 1.4) shows a compact of                     
αβ sandwich, including 7 β-sheets (β1-β5, β6 and β7) interacting with 2 α-helices (α1 and α2).   
The α1- and α2-helices are almost parallel to each other and the large β-sheets (β1-β5). The β6 
and β7 are composed of the β5 C-terminus site (Dhe-Paganon et al. 2000).  
Primary M81-FXN (81-210)  14.2kDa 
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Figure 1.4 - Structure of frataxin (Dhe-Paganon et al. 2000). 
 
 
Ribbon diagram showing the fold of frataxin, a compact αβ sandwich, with helices coloured 
turquoise and β strands in green. 
  
 
The function of frataxin is not completely clear yet, but several gene targeting studies 
indicate that loss of this protein results in cell death, and consequently endangers life. Thus,  
by deletion of frataxin in the hearts of conditional KO mouse model (MCK-KO) and 
comparing to wild-type (WT) mice, frataxin deficiency in the knockout models results in 
development of cardiomyopathy, which is the most prominent cause of death in most of 
FRDA patients (Calabrese et al. 2005). Frataxin depletion in mice also revealed the crucial 
role of this protein in DRG neurons, as one of the most sensitive tissues to frataxin deficiency 
(Sutak et al. 2008). Furthermore, the complete deficit of frataxin results in early mouse 
embryonic lethality and developmental arrest in the nematode Caenorhabditis elegans 
(Cossee et al. 2000; Ventura et al. 2005; Sutak et al. 2008).  
These observations can be extended to all eukaryotic cells, emphasising the fundamental role 
of frataxin in cell survival (Koutnikova et al. 1997; Pianese et al. 1997). However, a similar 
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essential function for frataxin has not always been observed in many prokaryotes (Li et al. 
1999; Vivas et al. 2006). Absence of frataxin results in aberration of many cellular functions. 
Studies of yeast showed that the yeast frataxin homologue gene 1 (Yfh1) deficiency leads to 
dysregulation of mitochondrial and even cytosolic iron levels (Wong et al. 2000). Other 
investigations of yeast suggested a fundamental role for frataxin in iron efflux from 
mitochondria (Radisky et al. 1999; Puccio and Koenig 2000).  
In normal conditions in eukaryotes, frataxin binds ferrous iron through negatively charged 
amino acids on its surface. It promotes the mitochondrial synthesis of iron containing 
molecules, specifically ISCs and heme. Frataxin interacts with the scaffold protein Isu1 at the 
first step of ISC assembly, and is a Fe(II) donor for ferrochelatase in the ultimate step of 
heme synthesis (Park et al. 2003; Yoon and Cowan 2003; Yoon and Cowan 2004;                
Di Prospero and Fischbeck 2005; Gakh et al. 2006; Martelli et al. 2007; Long et al. 2008). 
Two hypotheses have been proposed to explain the role of frataxin in these procedures. The 
first hypothesis suggests that frataxin acts as an iron chaperone, providing proficient iron for 
Fe-S and heme assembly. The second hypothesis suggests an iron storage function for 
frataxin, scavenging toxic iron into a sheltered form. Studies of the Escherichia coli (E.coli) 
frataxin orthologue (CyaY) have shown that frataxin is not only an iron chaperone with an 
intrinsic function in the ISC enzymatic processes, but it can also act as a molecular regulator 
to inhibit formation of 2Fe-2S and store iron in a bio-available form (Figure 1.5) (Adinolfi et 
al. 2009). 
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Figure 1.5 - Schematic model of the frataxin molecular mechanism in mitochondria 
(Adinolfi et al. 2009). 
 
Schematic representation of the frataxin molecular mechanism in: (a) normal iron 
concentrations, (b) excess iron concentrations and (c) frataxin deficit. 
 
 
1.2.4.1 - Frataxin and iron homeostasis 
To date, further to ISC assembly, it is accepted that frataxin is an iron-binding protein in 
eukaryotes, contributing in cellular iron homeostasis (Bradley et al. 2000; Lodi et al. 2001). It 
has been reported that frataxin interaction with another protein that contributes to ISC 
transfer, called HSC20, is crucial for the biogenesis of ISCs and iron homeostasis in 
mammals (Shan and Cortopassi 2012).  
1.2.4.2 - Frataxin and ISC enzymes  
In mammalian cells, frataxin also acts as an iron-chaperone modulating many ISC containing 
enzymes, including aconitase activity in both mitochondria and cytosol, together with 
ferrochelatase and succinate dehydrogenase activities (Bulteau et al. 2004; Condo et al. 2010; 
Shan and Cortopassi 2012). Studies of the frataxin MCK-KO mouse models have shown that 
mitochondrial iron accumulation occurs only after onset of the pathology and Fe-S dependent 
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enzyme inactivation (Puccio et al. 2001), suggesting a direct effect of frataxin on the Fe-S 
dependent enzyme activity. Further investigations of FRDA patients’ mitochondrial heart 
muscle and dentate nuclei showed consistent iron accumulation and reduction of aconitase 
activities, However, respiratory chain and aconitase activity changes were not significant in 
skeletal muscles, brain and cerebellum tissues (Waldvogel et al. 1999; Bradley et al. 2000; 
Koeppen et al. 2007). 
1.2.4.3 - Frataxin and oxidative stress  
It has been shown that overexpression of frataxin leads to Ca
2+
-induced upregulation of      
tricarboxylic acid cycle flux and respiration and subsequently mitochondrial membrane 
potential (∆ψm) and a cellular ATP content elevation. This finding shows key roles for 
frataxin in the regulation of mitochondrial energy conversion, oxidative phosphorylation and 
anti-oxidant defence (Ristow et al. 2000). To investigate the role of frataxin in reactive 
oxygen species (ROS) formation in the liver, Ristow and colleagues established a hepatocyte-
specific frataxin deficient mouse model. They demonstrated that frataxin depletion enhances 
the ROS formation in liver, although no change was observed in the cellular buffering 
capacity against ROS. This data suggests that oxidative stress probably plays a confined role 
in FRDA phenotypic development (Thierbach et al. 2005). To date, it is believed that 
oxidative damage, as a secondary effect of impaired iron homeostasis and respiratory chain 
dysfunction, is caused by frataxin deficiency via imperfection of ISCs and/or heme protein 
biosynthesis (Yoon and Cowan 2003; Rai et al. 2008). Moreover, it has also been shown that 
frataxin not only functions to protect against oxidative stress, but also determines antioxidant 
responses, in the presence or absence of excess iron (O'Neill et al. 2005). By affecting the 
iron level, disruption of frataxin leads to multiple enzyme deficiencies, mitochondrial 
dysfunction and oxidative damage. In other words, loss of frataxin culminates in 
accumulation of iron in mitochondria. This abnormality can induce a pathogenic mechanism 
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culminating in elevation of free radical production and subsequently oxidative stress by 
down-regulating antioxidant elements (Puccio and Koenig 2000). Increasing the 
susceptibility to oxidative stress (Figure 1.6) can also cause decline in oxidative 
phosphorylation, because of a defect in mitochondrial proteins containing iron sulphur 
clusters (Lu and Cortopassi 2007; Martelli et al. 2007). Frataxin deficiency particularly 
affects ISC synthesis and culminates in reduction of some ISC-containing enzyme activities. 
Controlling the ability of iron to perform redox chemistry is another function of the frataxin 
(Rotig et al. 1997; Chen et al. 2002; Pandolfo 2002; Yoon and Cowan 2004; O'Neill et al. 
2005; O'Neill et al. 2005; Lu and Cortopassi 2007). 
 
Figure 1.6 - Frataxin function and oxidative stress in Friedreich ataxia (Pandolfo 2008). 
 
 
Several of the postulated functions of frataxin are represented, including the provision of iron 
for iron–sulfur clusters and heme synthesis, and direct interaction with respiratory chain 
complexes. Green arrows and text indicate molecules and pathways that have decreased 
activity in frataxin deficiency; red arrows and text indicate molecules and pathways that have 
increased activity in frataxin deficiency. Abbreviations: Aco, aconitase; CI, respiratory chain 
complex I; CII, respiratory chain complex II; CIII, respiratory chain complex III; CIV, 
respiratory chain complex IV; CV, respiratory chain complex V; Cys, cysteine; cyt c, 
cytochrome c; e
-
, electron; FECH, ferrochelatase; FRDA, frataxin; GPx, glutathione 
peroxidase; GSH, reduced glutathione; GSSG, oxidised glutathione; H2O2, hydrogen 
peroxide; IscS, cysteine desulfurase; IscU, iron–sulfur cluster scaffold protein; IX, 
protoporphyrin IX; OH , hydroxyl radical; Q, coenzyme Q; SOD, superoxide dismutase. 
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1.2.4.4 - Frataxin and cell malignancy 
Although cell malignancy is not considered as a typical feature of the disease, various types 
of atypical cancer have been detected in the FRDA patients at a young age (Ristow 2004; 
Thierbach et al. 2012). The first FRDA patient case study in 1986 described a primary small 
bowel ganglio-neurobalstoma in a 26 year-old pregnant patient. In this study, Barr and 
colleagues reported that the small bowel tumour had arisen from autonomic nerve cells in the 
myenteric plexus of Auerbach; however, the chance of metastasis from a primary tumour 
elsewhere was not excluded (Barr et al. 1986). Another study then described two siblings 
with FRDA who both presented with gastric adenocarcinoma at an early age, suggesting the 
inheritance of a mutant tumour suppressor gene, which could be a DNA repair gene  
(Ackroyd et al. 1996). Aberration of DNA repair genes may cause many different genetic 
mutations and subsequently different diseases, such as FRDA and different types of cancer 
(Ku et al. 2010). Another FRDA patient, a 16 years old male, was shown to suffer from a 
lymphoblastic T-cell non-Hodgkin lymphoma (De Pas et al. 1999). Yet, another case study 
described the presence of breast cancer in two FRDA patient sisters, whilst the other brother 
and sister of family, with almost the same age, did not show any history of the FRDA or 
breast cancer. The authors of this study could not explain any potential correlation between 
FRDA and breast cancer. Nevertheless, due to the low incidence of FRDA combined with 
breast cancer, they suggested that due to the cardiomyopathy in early life, FRDA patients do 
not generally live long enough to develop breast cancer (Kidd et al. 2001). 
Investigations of the hepatocyte-specific frataxin conditional KO (Alb Fxn
-/-
) mouse liver 
tissue demonstrated reduced activity of ISC enzymes and ATP levels, as well as elevated 
oxidative stress, impaired respiration, apoptosis and cell proliferation. Almost 50% of these 
mice died up to 30 weeks of life. Unexpectedly, the surviving mice after 30 weeks developed 
multiple apparent hepatic tumours at late life stages. In this study, apoptosis was typically 
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observed following ATP reduction and sometimes after ROS induction                             
(Thierbach et al. 2012). On the other hand, study of the same conditional KO mice showed 
that frataxin deficit may promote tumour formation through impairment of activation and 
phosphorylation of the p38 MAP kinase, as a critical ISC tumour suppressor protein for 
growth and tumourigenesis particularly in liver. It has been suggested that the cell 
proliferation in these mice could be due to induction of impaired phosphorylation of p38 
MAP kinase and even enhanced formation of ROS (Thierbach et al. 2005). Considering the 
fact that frataxin is vitally important for mitochondrial ISC biosynthesis and that ISCs are 
required for the proper function of some DNA repair proteins, it has been suggested that one 
of the mechanisms by which a frataxin defect may cause tumourigenesis could be aberration 
of the ISC function containing DNA repair enzymes and subsequently an increased gene 
mutation rate (Thierbach et al. 2012).      
In 2006, investigating the role of frataxin in colon cancer confirmed the Otto Warburg   
hypothesis indicating that cancer might be caused by reduction of mitochondrial energy 
metabolism and increased glycolytic flux. In this study, overexpression of frataxin in various 
colon cancer cell lines exhibited an increase in oxidative metabolism and aconitase activity, 
mitochondrial membrane potential, cellular respiration, ATP content and population doubling 
(PD) times, as well as reduced growth rates and prevention of colony formation capacity in 
soft agar. Injecting each of these cell lines into nude mice also showed a decline in the 
capacity of tumour formation. In addition, to reduce the phosphorylation of extracellular 
signal-regulated kinase (ERK), the authors confirmed that overexpression of frataxin raises 
p38 MAP kinase phosphorylation. Considering the increased oxidative metabolism caused by 
frataxin, and its role in suppressing malignant growth in the mammalian cells, this study also 
suggested a tumour suppressor role for frataxin (Schulz et al. 2006). 
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A reduced level of frataxin was observed in neoplastic astrocytic brain tissues and malignant 
cell lines compared with normal astrocyte cells. Overexpression of frataxin in glioblastoma 
(U87-FXN) cells showed surprisingly increased ROS levels in cytoplasm, whilst reduced 
mitochondrial ROS was observed, as predicted. The higher cytoplasmic ROS levels 
suggested that cytoplasmic antioxidant defences were altered in these cells. Further studies 
demonstrated that higher cytoplasmic ROS levels reduced cytoplasmic antioxidant capacity 
in U87-FXN cells, causing enhanced susceptibility of these cells against oxidative stress 
induced by H2O2 or L-buthionine-S,R-sulfoximine (BSO). In contrast to colon and liver cells, 
U87-FXN cells exhibited faster growth in both in vitro, under hypoxic and growth factor 
restricted conditions, and in vivo models. These data may go against the former hypothesis 
that frataxin generally acts as a tumour suppressor, based on its proposed antioxidant function 
(Kirches et al. 2011). It has also been reported that frataxin expression might contribute to 
malignant cell survival by the regulation of the antioxidant response under hypoxic 
conditions and that it may influence metabolic pathways by modulating the hypoxia-induced 
p53 stress response (Guccini et al. 2011). Hypoxic stress is a characteristic feature that 
promotes most tumours either into the angiogenic switch for tumour survival or cell death 
through necrosis or apoptosis. Hypoxia-inducible factors (HIFs) are essential elements in 
preserving a balance between adaptation to hypoxia and cell death by regulating the hypoxia 
responsive genes (Semenza 2010). It has also been demonstrated that there is a link between 
hypoxia in malignant cells and promoting the leakage of ROS from the mitochondrial 
electron transport chain and regulation of tumour suppressor p53 (Guccini et al. 2011). In 
contrast, Malisan and colleagues showed that frataxin is increased in human glioblastoma and 
colon carcinoma tumours in vivo. Hypoxic stress was shown to increase frataxin expression 
in several malignant cell lines by regulating HIF expression and p53 activation was observed 
in a condition of frataxin upregulation in these malignant cells. These data indicate that 
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frataxin is involved in the hypoxia-induced responses in tumours, and thus modulation of 
frataxin expression can play critical role in malignant cell survival and/or progression 
(Guccini et al. 2011). Taken together, it would appear that frataxin could act as                            
a double-edged sword in different malignant cells; overexpression of frataxin can play an     
anti-apoptotic role, whilst it can also behave as a tumour suppressor. 
1.2.5 - Molecular genetics 
The human FRDA gene (FXN) was mapped to chromosome 9 in 1988 by linkage analysis of 
families (Chamberlain et al 1988) (Figure 1.7).  
 
Figure 1.7 - Molecular location of the FRDA gene. 
 
 
 
Schematic representation of the FXN gene located on the long (q) arm of the chromosome 9 
from position 13 to 21.1. 
 
 
The location of the FRDA gene was narrowed down to 9q13-21.1 by physical mapping 
investigations, followed by identification of the mutated gene in 1996 (Fujita et al. 1989; 
Hanauer et al. 1990; Campuzano et al. 1996). The FXN gene, which was initially called X25, 
contains seven exons (1-5a, 5b, and 6) spread across 95kb of genomic DNA, in which exon 6 
is non-coding (Figure 1.8). The major transcript arises from exons 1-5a, which culminates in 
the generation of a 210 amino acid frataxin protein. By alternative splicing, a 171 amino-acid 
protein can be transcribed from exons 1-5b (Campuzano et al. 1996; Cossee et al. 1997). 
 
    FXN 
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Figure 1.8 - Schematic illustration of the FXN exons and splicing patterns. 
 
The gene extends from centromere to telomere of the 9q chromosome. In normal conditions 
exons 1-5a transcribe and translate into 210 amino acids protein; called frataxin. Alternative 
splicing might produce different lengths of proteins. The GAA repeats are situated in          
intron 1.  
 
 
The human FXN gene is expressed in all cells, but at various levels in different tissues. 
Frataxin expression is generally higher in mitochondria-rich cells, such as cardiomyocytes 
and neurons. It has been shown that frataxin is abundant in the cerebellar cortex, cerebellum, 
DRG and spinal cord (Campuzano et al. 1996; Simon et al. 2004; Al-Mahdawi et al. 2006; 
De Biase et al. 2007; Gottesfeld 2007). However, other studies have shown that frataxin is 
also highly expressed in non-central nervous system tissues with a high metabolic rate, 
including heart, liver, kidney, brown fat, skeletal muscle, kidney and pancreas              
(Koutnikova et al. 1997; Pandolfo 2008). Investigation of the FXN mRNA levels in the 
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peripheral blood samples have shown that FRDA patients have 13% to 30% of normal levels 
and FRDA carriers have 40% of normal levels (Campuzano et al. 1996; Pianese et al. 2004).  
Molecular studies of FRDA have revealed that several FXN mutations may lead to frataxin 
dysfunction. A GAA trinucleotide repeat expansion within intron 1 of the FXN gene is the 
most common mutation, resulting in disruption of FXN transcription (Figure 1.9) and a 
subsequent decrease of frataxin protein levels (Becker and Richardson 2001; Sakamoto et al. 
2001; Clark et al. 2007; De Biase et al. 2007; Llorens et al. 2007).  
 
Figure 1.9 - Schematic presentation of frataxin expression. 
 
 
  
 
 
 
 
 
 
 
 
In most FRDA patients, frataxin expression is reduced because of a GAA repeat expansion 
within intron 1 of the FXN gene. 
 
Studies have shown that 96% of FRDA patients carry GAA repeat expansions in both alleles 
(Bidichandani et al. 2000; Grabczyk and Usdin 2000; Potaman et al. 2004; Lobmayr et al. 
2005). In addition to GAA repeat expansion, cases of missense, nonsense and splice-site 
mutations in the FXN gene may also lead to this disorder. About 4% of FRDA patients are 
compound heterozygous for a point mutation on one allele and a GAA repeat expansion on 
Frataxin 
Normal status: 
(GAA)30 
Exon 1 Exon 2 
Friedreich ataxia: 
     
       (GAA)1000 
 
 
           Intron 1 
Exon 2 Exon 1 
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the other allele. Thus far, 17 different point mutations have been discovered, the most 
prevalent of which are I154F, M1I, and G130V. The I154F mutation is associated with a 
typical FRDA phenotype, while the other mutations present with atypical features, such as 
late onset (Alper and Narayanan 2003). No patient has yet been reported to carry point 
mutations in both alleles of the frataxin gene, indicating that this scenario is incompatible 
with survival.  
 
1.3 - Repeat instability 
Repetitive nucleotide sequences, which comprise approximately 30% of the human genome, 
are hot spots for recombination, resulting in insertion (expansion) or deletion (contraction) 
(Potaman et al. 2004). Repeat instability is a crucial form of mutation that has been detected 
in more than 40 neurological, neurodegenerative and neuromuscular disorders. In contrast to 
other mutations, which are stably transmitted to offspring, a repeat mutation is a dynamic 
process that increases or decreases within tissues and across generations (Kovtun and 
McMurray 2008). 
Abnormal nucleotide repeat expansions consist of different types, including microsatellites            
(e.g. FRDA), minisatellites (e.g. insulin-dependent diabetes) and megasatellites (e.g. 
fascioscapulohumeral muscular dystrophia 1A). Microsatellites, or simple sequence repeats 
(SSRs), generally comprise the multiple repeated sequences of 1-6 nucleotides, which could 
be found in both coding and non-coding region of the genome (Tautz 1989; Beckman and 
Weber 1992; Jurka and Pethiyagoda 1995; Toth et al. 2000; Potaman et al. 2004; Pearson et 
al. 2005; Gaspari et al. 2007; Mrazek et al. 2007). Repeat expansions can cause disorders as 
dinucleotides (e.g. Norrie's disease), tetranucleotides (e.g. dystrophia myotonica type 2) or 
pentanucleotides (e.g. spinocerebellar ataxia 10). However, trinucleotide repeats (TNRs) are 
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the largest category of microsatellites, contributing to many human disorders (Djian et al. 
1996; Kovtun and McMurray 2008).  
1.3.1 - Trinucleotide repeats  
TNR expansion is a mutational mechanism that contributes to several inherited disorders, 
including myotonic dystrophy type 1 (DM1), Huntington disease (HD) and FRDA           
(Cossee et al. 1997). About 10% of all human genes carry at least one trinucleotide sequence 
of four units. Normally TNR positions are divided between two regions; coding, and non-
coding regions. Generally, disorders related to non-coding TNR expansion typically result in 
loss of gene function or toxic effects at the mRNA level, while TNR expansions within 
coding regions usually cause either a polyglutamine or polyalanine tract in the protein 
products, culminating in protein toxicity in the absence or presence of normal protein 
function (Pizzi et al. 2007).  
Studies indicate that more than 14 hereditary neuromuscular diseases are caused by TNR 
expansions localised in particular genes (Jasinska et al. 2008). Expansion of CAG and CTG 
multiple repeats, for instance, lead to HD and DM1 diseases, respectively (Cummings and 
Zoghbi 2000; Savouret et al. 2003; Jasinska et al. 2008). In addition, fragile X syndrome 
(FRAXA) is caused by a GCC/GGC expansion. FRDA is the only disorder known to be 
caused by a GAA/TTC repeat expansion (Cummings and Zoghbi 2000; Al-Mahdawi et al. 
2006; De Biase et al. 2007; Gottesfeld 2007).  
TNR instability can be classified into either somatic or germline instability. Somatic repeat 
instability exhibits different lengths of TNR repeats in different tissues (Pearson et al. 2005). 
It is suggested that tissue-specific and age-dependent repeat instability might be regulated by 
cis-acting factors (cis-elements) and trans-acting factors (trans-elements). Thus, by 
integration of the human FXN locus into transgenic mice, it has been demonstrated that       
cis-elements are necessary for somatic instability of GAA repeats in human FRDA cells 
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(Pearson et al. 2005; Clark et al. 2007). Evidence indicates that tissue-specific repeat 
instability may be affected by DNA repair, DNA replication, epigenetic marks, chromatin 
packaging or transcription of the disease gene. Such effects might be different for each 
genetic locus, different tissues, and even different ages of individuals (Figure 1.10). 
Interestingly, age-dependent instability is a factor in post-mitotic neuronal tissues which 
seems to be the result of genome maintenance repair (Pearson et al. 2005). TNR diseases also 
exhibit germline instability during transmission of the repeat mutation from parent to 
offspring. DNA metabolic activities involved in DNA replication, repair, recombination or 
transcription may contribute to such TNR germline instability during gametogenesis. 
Intergenerational TNR instability can be inherited with either a paternal or maternal 
expansion or contraction bias. Paternal expansion bias might be caused by mutations in the 
mitotic cycles of spermatogenesis. For example, it has been reported that CAG repeats in HD 
patients undergo expansions before meiosis, with expansions already detected in mitotic germ 
cells. FRDA is the other example of a disorder that shows paternal contraction bias, although 
the main cause of this contraction is not yet clear (Pearson et al. 2005). 
In contrast to male germ cells that carry little DNA repair proteins, post-meiotic female germ 
cells bear DNA repair and recombination activities, which can culminate in age-related TNR 
instability due to mutations in oogenic meiosis. This type of expansion has been observed in 
CAG, CGG, and CTG expansions of spinocerebellar ataxia 1 (SCA1), FRAXA and DM1, 
respectively (Pearson et al. 2005). 
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Figure 1.10 - Unstable repeat tracts and the processes associated with repeat instability 
(Pearson et al. 2005). 
 
 
 
 
(a) A representation of the genetic location of non-coding (top) and coding (bottom) disease-
associated repeats (promoter, 5' UTR, exons, introns, 3' UTR or other chromosomal locations 
(includes undetermined locations). The DNA, RNA and amino acid sequence for each repeat is noted. 
For DM1, the CTG tract is located in the 3' UTR of the myotonic dystrophy protein kinase (DMPK) 
gene, as well as the promoter of the sine oculis homeobox homologue 5 (SIX5) gene. (b) The 
processes associated with repeat instability are shown. Instability occurs in proliferative (above the 
dotted line) and non-proliferative (below the dotted line) tissues. The DNA metabolic processes of 
DNA replication, repair and recombination are associated with repeat instability, either independently 
or in conjunction with other processes. The involvement of various processes varies depending on 
tissue and developmental stage (bottom right). The numbers in the tissue and developmental status 
section correspond to those in the DNA metabolism section. 
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1.3.1.1 - GAA repeat instability  
Screening patients who carried a mutation in the FXN gene identified a GAA repeat within 
the first intron of this gene (Figure 1.9) as the major cause of FRDA (Campuzano et al. 
1996). The normal FXN gene carries between 7 and 35 GAA repeats; however, this elevates 
from 66 to 1700 repeats in FRDA patients. Based on the length of the expanded GAA repeat 
(also termed E-allele), the rate and severity of the disease are changed. Thus, E-alleles in 
FRDA patients, who exhibit classical symptoms, are between 500 and 1700 GAA repeats. 
Patients who carry shorter GAA expansion mutations (fewer than 500 triplet repeats) usually 
present with a milder disease (De Biase et al. 2007). Late onset of FRDA is an atypical 
disease that is generally classified into 3 sub-groups. In the first group, late onset FRDA 
(LOFA 25-39 years) and very old onset FRDA (VLOFA ≥ 40 years) possess up to 500 GAA 
repeats. The second group, FRDA with retained tendon reflexes (FARR), has fewer than 300 
repeats and contains at least one E-allele. Acadian FRDA is the third atypical age-dependent 
group, exhibiting an unusually gradual disease progression with a mean age of onset of 27 
years, accompanied by wheelchair confinement (Durr et al. 1996; Filla et al. 1996; 
Montermini et al. 1997; Bidichandani et al. 2000; Berciano et al. 2002). 
Origin of GAA repeat expansions: There is no clear explanation how the GAA repeat 
became expanded in FRDA patients. To find out the cause of the GAA repeat expansions, 
Pandolfo analysed the GAA repeats in the normal chromosomes. He recognised that 83% of 
normal chromosomes contain 6-10 GAA repeats, whilst 17% of chromosomes showed larger 
normal triplets of 12-36 repeats. These results suggested that polymorphism of normal GAA 
alleles is generated by two events. The small changes, most probably deriving from 
occasional events of polymerase ‘stuttering’ during DNA replication, may cause size 
heterogeneity within small or large normal groups. Shifting from small to large normal 
triplets was suggested by linkage disequilibrium results due to the different marker haplotype 
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association to small and large normal alleles. The same conditions were observed during 
investigation of large normal alleles containing more than 34 uninterrupted GAA triplets that 
undergo hyper-expansions to hundreds of triplets in one generation, leading to GAA            
hyper-expansions in the FXN (Pandolfo 1998).    
Molecular mechanism of GAA repeat expansions: Studies have shown that FRDA patients 
who carry expanded GAA repeats in both alleles have very low level of the mature FXN 
mRNA and protein (Sakamoto et al. 2001). Further investigations have demonstrated that a 
decrease in mRNA expression level is the principle cause of dysfunction of the frataxin gene 
and not a problem with post-transcriptional RNA processing. It has been reported that the 
FXN mRNA expression level is inversely correlated to GAA repeat expansion size (Delatycki 
et al. 2000). So far, in vitro and in vivo investigations suggest two different mechanisms by 
which GAA expansions might produce reduction in the level of the FXN mRNA expression: 
non-B DNA conformation and/or heterochromatin mediated gene silencing. Non-B DNA 
conformation can occur due to triplex or sticky DNA structures (Mariappan et al. 1999; 
Sakamoto et al. 1999; Sakamoto et al. 2001). The first report of triplex DNA structures came 
from observing a retarded profile in agarose gel caused by plasmids containing long GAA 
expansions. The GAA.TTC tract is recognised as poly-purine.poly-pyrimidine (Pur.Pyr) 
sequence, containing only purines (R) in one strand and pyrimidine (Y) on the other. In vitro 
and in vivo studies have shown that GAA expansions can form intramolecular triple helical 
structures (Ohshima et al. 1998; Schmucker and Puccio 2010). Mechanistically, a DNA 
triple-helix structure is formed upon binding a “Y” or “R” single stranded DNA to the normal 
grove of double stranded DNA (Figure 1.11a), resulting in RRY or YRY structures 
(Grabczyk and Usdin 2000). In FRDA, GAA repeat expansions form a triplex containing two 
GAA repeat strands along with a single strand of TTC repeats; RRY. This form of the DNA 
triplex can form higher-order conformations inhibiting FXN transcription, called sticky DNA 
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(Figure 1.11b). This type of triplex DNA can be detected by decreasing mobility of the GAA 
content DNA restriction fragments and probably arises from intramolecular association of 
GAA expanded repeat triplexes (Gottesfeld 2007; Schmucker and Puccio 2010).   
  
Figure 1.11 - Schematic structure of a DNA triplex and sticky DNA  (Son et al. 2006).  
 
 
(a) Diagram showing a triple-helix DNA (H-DNA) (Zhao et al. 2010). (b) A sticky DNA 
model in a plasmid presenting the association of two GAA.TTC expanded repeat sequences 
in one DNA molecule. This interaction is dynamic and facilitated by negative supercoiling 
and divalent cations. The green and yellow represent one duplex and the red and blue show 
the second duplex.   
 
 
It is not clear yet whether or not a sticky DNA structure is directly involved in inhibition of 
FXN mRNA transcription. A persistent RNA-DNA hybrid formation, arising during 
transcription of expanded GAA repeats, is the other proposed model, which could result in 
transcriptional arrest at the promoter distal duplex-triplex junction. It has been shown that 
GAA expansions start from a threshold length of 44 repeats. This length correlates with the 
shortest length of GAA repeat expansion in which RNA-DNA hybrid formation was 
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observed. Thus, it is proposed that formation of the transcription-dependent RNA-DNA 
hybrid structure might also cause repeat instability in the cell (Grabczyk et al. 2007).  
In contrast to a DNA structure basis, it has also been proposed that GAA repeat expansions 
could result in chromatin remodelling by forming heterochromatin structures and 
subsequently cause silencing of FXN transcription. Studies of the heterochromatin-sensitive 
human CD2 (hCD2; lymphoid cell surface marker protein) showed that GAA repeat 
expansions cause chromatin packaging and silencing in transgenic mice via position effect 
variegation (PEV) (Saveliev et al. 2003). PEV is recognised as a phenomenon that happens 
when a gene is abnormally located within or near a chromatin silencing region. Silent 
heterochromatin is generally characterised by reduced promoter accessibility and increased 
levels of histone deacetylases (HDACs), DNA methyltransferases, polycomb group proteins 
and certain types of histone modifications, such as histone H3-lysine 9 (H3-K9)                       
tri-methylation and histone hypo-acetylation. To support the effect of chromatin structure on 
the GAA repeat-associated gene silencing, investigations on heterochromatin-sensitive hCD2 
cells showed that GAA repeat expansions inhibit promoter accessibility and DNase I 
digestion (Saveliev et al. 2003). Besides, it is believed that the classical modifier PEV 
heterochromatin protein 1 (HP1), as a highly conserved chromo-domain protein associated 
directly with pericentric heterochromatin, can also regulate transcriptional silencing caused 
by GAA repeat expansions (Elgin and Grewal 2003). In addition, investigations showed that 
overexpression of HP1β protein led to remarkably reduced proportion of the hCD2 
expression in T cells of transgenic mice carrying GAA repeat expansions, whilst no effect of 
HP1β overexpression on the level of hCD2-expressiong T cells was reported in the mice 
without GAA repeat expansions. Thus, these results further support the hypothesis 
implicating the role of GAA repeat expansions on the gene silencing via generation of 
heterochromatin structure (Figure 1.12) (Saveliev et al. 2003). 
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Figure 1.12 - Putative heterochromatin-mediated silencing pathway in FRDA 
(Festenstein 2006).  
 
 
The chromatin organisation of a normal FXN (left) has acetylated histone tails (Ac, acetyl). 
GAA repeat expansions might cause heterochromatin formation via deacetylation of the 
lysines on histones, providing a substrate for histone methyltransferases. Methylation (Me) of 
the histone H3 tail (on Lys9) would provide a binding site for HP1. HP1 dimers might 
condense a higher-order heterochromatin structure that prohibits access of the transcriptional 
machinery to the FXN locus.   
 
    
Further studies of GAA repeat expansion-induced heterochromatin-mediated gene silencing 
have shown a critical role of other epigenetic factors. Usdin and colleagues demonstrated 
increased DNA methylation of specific FXN gene CpG residues in FRDA patient 
lymphoblastoid cells compared with unaffected cells. In particular, they found three DNA 
methylated CpG sites upstream of the expanded GAA repeat in FRDA patient cells, while 
these residues were almost methylation-free sites in normal cells. One of these three sites, 
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located within an E-box, is a critical enhancer of frataxin expression that influences promoter 
activity (Greene et al. 2007). Further studies of lymphoblastoid cells indicated a role for 
histone modifications in GAA repeat expansion-induced gene silencing. These changes 
consist of elevation of di- and tri-methylation of the H3K9 and hypo-acetylation at particular 
lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12) (Herman et al. 2006). 
These findings were confirmed by studies of human FRDA patient tissues and YG8 and 
YG22 FRDA transgenic mouse models (Al-Mahdawi et al. 2008). In these studies, Pook and 
colleagues also showed that upstream FXN GAA CpG sites become hyper-methylated, while 
downstream GAA CpG sites become consistently hypo-methylated in different tissues of 
FRDA patients, implicating DNA hypermethylation of the upstream GAA region in 
downregulation of frataxin transcription (Al-Mahdawi et al. 2008). 
 
1.4 - FRDA drug therapy 
1.4.1 - Current therapies  
Many FRDA therapeutic strategies are now being pursued, based on the findings that 
different epigenetic pathways can affect frataxin expression, together with the subsequent 
effects of oxidative stress and mitochondrial dysfunction (Figure 1.13). 
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Figure 1.13 - Schematic pipeline representation of FRDA treatments.  
 
The pipeline shows the potential therapies being developed to treat FRDA. Each bar shows a 
different agent, highlighted by its mechanism of action on FRDA in the horizontal axis and 
the milestone of preclinical and clinical development in the vertical axis (adapted from 
http://www.curefa.org/pipeline.html).    
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1.4.1.1 - Iron chelators  
Disruption of frataxin causes dysfunction of ISC formation and a subsequent susceptibility to 
oxidative stress and late mitochondrial iron accumulation. Thus, both mitochondrial iron 
chelator-based and antioxidant therapies have been considered for FRDA. Desferrioxamine 
(DFO), the only widespread iron chelator clinically trialled at that time, was initially studied 
as a potential drug to treat FRDA. However, it proved to be ineffective, because it did not 
target mitochondrial iron. Recently, a new generation of drugs are being considered. 
Deferiprone (DFP) is one of the most potent iron chelator drugs used specifically to target 
mitochondrial iron. It has been demonstrated that DFP reduces iron accumulation and 
overload in the liver and heart. It has also been shown to cross the blood-brain barrier to 
reduce brain iron levels in FRDA patients (Hadziahmetovic et al. 2011). However, studies of 
the DFP-treated FRDA fibroblasts has shown that it can also impair aconitase activity, one of 
the main affected ISC enzymes in FRDA (Goncalves et al. 2008). Therefore, some caution 
should be taken when using DFP for FRDA therapy. 
1.4.1.2 - Antioxidants  
Investigations have suggested that frataxin deficiency may cause a delay in antioxidant 
defence responses, particularly coenzyme Q10 (CoQ10) and vitamin E. Recent investigations 
showed that a high percentage of FRDA patients have a reduced level of serum CoQ10 
(Cooper et al. 2008). This data supports the hypothesis that CoQ10 and vitamin E could be 
good therapeutic agents in FRDA patients. A short-term clinical study of ten FRDA patients 
showed that using combined CoQ10 and vitamin E treatment caused significant improvement 
of ATP production in cardiac and skeletal muscle (Lodi et al. 2001). Other CoQ10 and 
vitamin E treatments of the same number of patients over 47 months showed increased 
mitochondrial energy synthesis in cardiac and skeletal muscle and improvement in cardiac 
function (Hart et al. 2005; Cooper and Schapira 2007).  
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Idebenone is a CoQ10 analogue that reduces the cardiac hypertrophy in FRDA. In vitro studies 
reported that idebenone acts as an electron carrier, supporting mitochondrial ATP function, as 
well as an anti-oxidative agent preventing mitochondrial membrane damage. So far, several 
studies have been carried out to determine the toxicity and efficiency of idebenone on FRDA 
pathogenesis (Meier and Buyse 2009). Pilot clinical studies of this agent at a dose of 
5mg/kg/day showed the efficiency of idebenone in cardiomyopathy and controlling early 
onset cardiac hypertrophy of FRDA patients (Hausse et al. 2002). Another long-term       
follow up study showed that using low dose of idebenone (5-20mg/kg/day) could not only 
control FRDA-associated cardiomyopathy in both paediatric (8-18 years old) and adult 
patients, but also significantly improve left ventricular mass in adult. However, these 
observations demonstrated that neurological dysfunction is only stabilised in paediatric 
FRDA patients (Pineda et al. 2008). To find out whether neurological dysfunction could be 
improved in presence of higher doses of idebenone, Fischbeck and colleagues randomised 48 
paediatric FRDA patients and classified them into 4 sub-groups double-blindly receiving 
placebo, 5 mg/kg/day, 15 mg/kg/day or 45 mg/kg/day. The results showed that higher doses 
of this agent are associated with neurological benefits and improvement of functional 
capacity and ameliorating activities of daily living (ADL) in paediatric FRDA patients, 
indicating that higher doses of idebenone might have beneficial effects on neurological 
function (Di Prospero et al. 2007).   
1.4.2 - Epigenetic therapy  
There are three different epigenetic systems that may contribute to human disorders: histone 
modifications, DNA methylation and siRNA-associated silencing (Figure 1.14). Aberration 
of one or more of these interacting systems might cause perturbation of expression or gene 
silencing, and subsequently lead to an epigenetic disorder. It has been demonstrated that 
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FRDA is an epigenetic disorder that might be caused by abnormal chromatin and subsequent 
disruption of frataxin expression (Egger et al. 2004). 
 
Figure 1.14 - Interaction between RNA, histone modification and DNA methylation in 
heritable silencing (Egger et al. 2004). 
 
 
Histone deacetylation and methylation of H3K9 residues cause chromatin condensation and 
block transcriptional initiation. Histone modification can also attract DNA methyltransferases 
to initiate cytosine methylation, which in turn can reinforce histone modification patterns 
conducive to silencing. Experiments in yeast and plants have clearly shown the involvement 
of RNA interference in the establishment of heterochromatic states and silencing. siRNA 
triggering of heritable quiescence might therefore also be involved in higher organisms. 
 
 
1.4.2.1 - DNA methylation  
DNA methylation in mammals occurs by modification of position C5 of the cytosine base in 
CpG dinucleotides. Two components participate in gene silencing by DNA methylation of 
CpG sites: DNA methyltransferases (DNMTs) and methyl CpG binding proteins (MBPs). 
DNMTs establish and maintain DNA methylation as an intrinsic mechanism for 
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transcriptional repression of particular genes and viral sequences against genome instability, 
while MBPs bind to methylation marks to reinforce gene silencing. Recent investigations 
suggest that DNA methylation may regulate the expression of microRNAs, small RNA 
molecules which suppress translation of many genes (Hadnagy et al. 2008). By preventing 
specific transcription factor binding and engaging MBP-associated repressive chromatin 
remodelling activity, DNA methylation suppresses transcription. Aberrant DNA methylation 
is one of the main epigenetic abnormalities, leading to disorders such as cancer, imprinting 
disorders and neurodegenerative disorders caused by microsatellite instability (MSI). DNMT 
inhibitors, including nucleoside or non-nucleoside analogues of cytidine, are the main classes 
of epigenetic drug under investigation of targeting hypermethylation. While non-nucleoside 
analogues can inhibit DNMTs without incorporation of DNA, nucleoside analogues need 
DNA incorporation to block DNMTs (Hadnagy et al. 2008). Studies of FRAXA showed that 
5-aza-2
’
-deoxycytidine (5-aza-CdR) reactivates FMR1 transcription by removing the 
transcriptional blockade caused by promoter methylation, although some side effects have 
also been reported. Firstly, long-term use of 5-aza-CdR is highly toxic. Secondly, it is not 
recommended for post-mitotic neurons, because its action is based upon incorporation into 
dividing cells (Di Prospero and Fischbeck 2005). High instability (even in normal pH, 
because of a fast decomposition of triazine ring) is another negative point reported for this 
agent (Marquez et al. 2005; Hadnagy et al. 2008). Another DNMT inhibitor is a 5-aza-CdR 
derivative named zebularine. Higher stability and less toxicity are two advantages of this drug 
in comparison with 5-aza-CdR. However cytotoxicity is still a side-effect of zebularine 
caused by its incorporation into DNA (Hadnagy et al. 2008). Since several studies have 
shown elevation of DNA methylation in the 5’UTR and upstream of GAA repeat regions of 
FRDA-associated FXN alleles, it is hypothesised that 5-aza-CdR and zebularine might be 
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good therapeutic agents for FRDA treatment (Greene et al. 2007; Al-Mahdawi et al. 2008; 
Castaldo et al. 2008).  
1.4.2.2 - Histone deacetylase (HDAC) inhibitors 
Histones, the major proteins within the nucleosome, can undergo post-translation 
modifications, specially acetylation, phosphorylation and methylation at the terminal side of 
amino acid tails (Figure 1.15) (Zhang and Reinberg 2001; Kondo et al. 2003). Acetylation of 
histones bound to DNA is essential for transcription. This mechanism is regulated by two 
enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation 
of core histones (H2A, H2B, H3, and H4) is catalysed by transcriptional co-activators that 
carry HAT activity, such as CREB binding protein (CBP) (Abel and Zukin 2008). Unlike 
HAT proteins, HDACs play the opposite role in acetylation of many proteins. Thus, HDACs 
can recognise the lysine/arginine amino acids situated at the N-terminal of many proteins 
(particularly core histones), and cause removal of acetyl groups from the protein. This action 
culminates in silencing of gene expression. Regulation is the other function of HDACs by 
which they play a critical role in cell growth, differentiation, and apoptosis. Therefore, 
transcriptional activity might be reduced by HDACs (Carey and La Thangue 2006; Wilson et 
al. 2006; Abel and Zukin 2008). 
To date, 17 types of human HDACs have been detected carrying out various specificities 
within the cell. Generally these are categorised into four subgroups; classes I-IV. Class I, 
which are completely situated in the nucleus, include HDACs 1, 2, 3, and 8 and have high 
homology to HDAC-Rpd3 in yeast. Class II (homologue of HDAC-Hda1 in yeast) contains 
HDACs 4, 5, 6, 7A, 9, and 10, which shuttle between the nucleus and the cytoplasm and are 
expressed in a tissue and cell specific manner.  In comparison with class I HDACs, which are 
Zn-dependent enzymes, class II HDACs are independent of Zn. Class III (also named 
sirtuins; homologues of HDAC-Sir2 in yeast) is a highly conserved gene family classified 
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into 7 members; SIRT 1-7. SIRT-4 and SIRT-6 catalyse protein ribosylation by their        
NAD
+
-dependent ADP ribosylation domain. Finally, HDAC 11 is the only recognised 
member of HDAC class IV (Carey and La Thangue 2006; Abel and Zukin 2008; Spurling et 
al. 2008). 
 
Figure 1.15 - Sites of post-translational modifications on the histone tails (Zhang and 
Reinberg 2001). 
 
 
 
The modifications shown include acetylation (purple), methylation (red), phosphorylation 
(blue), and ubiquitination (orange). Note that Lys 9 in the H3 tail can be either acetylated or 
methylated.   
 
 
The diversity of HDAC functions has made them potential therapeutic targets to treat many 
aberrations, unlike HATs. Thus, HDAC inhibitors (HDACi) have been recognised as a new 
mechanism-based therapy for many disorders. HDACis are generally categorised into four 
different subgroups: 1) short chain fatty acids (e.g. sodium butyrate), 2) hydroxamic acids 
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(e.g. trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA)), 3) epoxyketones 
(e.g. trapoxin) and 4) benzamides (Figure 1.16). Several investigations have shown the 
positive effects of HDACis in cancer therapy by induction of differentiation, arrest of cell 
growth, apoptosis, and de-repression of different genes by their anti-proliferative activities 
(Carey and La Thangue 2006; Minucci and Pelicci 2006; Abel and Zukin 2008).   
 
Figure 1.16 - Structure of representative compounds from the major classes of HDACis 
(Carey and La Thangue 2006).   
   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
(a) Small chain fatty acids: valproic acid is in Phase II oncology trials. (b) Hydroxamate 
small molecule inhibitors SAHA and PXD101 are both in Phase II oncology trials.                
(c) Non-hydroxamate small molecule inhibitors: MS-275 is in Phase II oncology trials.        
(d) Cyclic peptides: depsipeptide is in Phase III oncology trials. 
 
                                  
Chapter 1- Introduction: Friedreich ataxia (FRDA) and DNA mismatch repair 
  38 
 
Interestingly, investigations suggest that inhibition of HDACs (particularly classes I and II) 
might be targeted as a treatment for many neurodegenerative disorders. Applying different 
drugs of the HDACi family, such as sodium butyrate, phenylbutyrate, TSA and SAHA, have 
revealed positive effects on the treatment of a Huntington disease Drosophila model by 
elevating histone acetylation (Steffan et al. 2001; Abel and Zukin 2008). Extending these 
studies to mouse models has emphasised the modifier role of HDACis by increasing motor 
function and reduction of neuronal loss (Ferrante et al. 2003; Hockly et al. 2003; Gardian et 
al. 2005; Abel and Zukin 2008). 
It is recognised that hypoacetylation of histones H3 and H4 may cause FXN silencing in 
FRDA patients carrying expanded GAA trinucleotide repeats. Although the use of some 
HDACi drugs is not recommended because of their toxicity, several studies indicate a 
beneficial effect of commercial HDACi drugs in reverting the effects caused by GAA 
expansions in lymphoblastoid cells. For instance, BML-210 is a benzamide HDACi that can 
increase the level of frataxin expression almost two-fold (Herman et al. 2006; Wells 2008). 
Also the HDACi drug 4b (an analogue of BML-210) can increase FXN mRNA and frataxin 
expression levels in FRDA patient lymphoid cell lines and primary lymphocytes without any 
cytotoxicity. Furthermore, HDACi 106, another member of the benzamide HDACi drug 
family, has been used in FXN-GAA knock-in mice to restore frataxin levels and the gene 
expression profile to that of wild-type mice. HDACi 106 has been proposed to work by 
increasing H3 and H4 lysine (H3K14, H4K5 and H4K12) acetylation in chromatin positioned 
near the GAA nucleotide repeat (Herman et al. 2006; Rai et al. 2008).  
Recent studies suggest the potential therapeutic effects of HDACi class III compounds in the 
treatment of trinucleotide repeat disorders. For example, sirtinol is an HDACi III drug 
characterised by high potency and selective inhibition of SIRT-1 and SIRT-2 that may affect 
SIRT-1 in neurons. SIRT-1 is recognised as a protein that may contribute to FRAXA by 
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reducing FMR1 transcription. It has also been reported that SIRT-1 is involved in H4K16 and 
H3K9 acetylation. Usdin and colleagues have shown that nicotinamide (vitamin B3), a class 
III HDACi, can increase FMR1 transcription 3-fold in FRAXA patient cells (Biacsi et al. 
2008). Splitomicin, another class III HDAC inhibitor, has also been shown to increase 
acetylation of H3K9 on FMR1. In other words, splitomicin can reverse the FMR1 gene 
silencing caused by SIRT-1 via inhibiting deacetylation of H3K9 (Bedalov et al. 2001; Biacsi 
et al. 2008). Furthermore, splitomicin therapy may indirectly inhibit DNA methylation of the 
FMR1 promoter; so it might be more useful than 5-aza-CdR to reverse FMR1 gene silencing 
in neurons which no longer divide (Biacsi et al. 2008). Regarding potential FRDA therapy, 
Pook and colleagues have shown that adding low concentration (0.2µM) of 5-aza-CdR to 
FRDA fibroblast cells significantly elevates FXN mRNA expression level after 24 hours 
compared to vehicle-treated samples, while no increase was observed in higher (0.5 and 
1µM) concentration of this agent. Therefore, it is proposed that higher concentration of this 
agent caused cell toxicity. Furthermore, DNA methylation was also reduced in FRDA 
fibroblasts treated with 5-aza-CdR compared to vehicle-treated cells (C. Sandi, personal 
communication). Taken together, these findings suggest that low concentration of 5-aza-CdR 
could be beneficial to improve frataxin levels in FRDA patients. 
 
1.5 - Development of models for FRDA 
Since FRDA is a neurodegenerative disease, mainly affecting the DRG, cerebellum, heart and 
pancreas, investigation of the many molecular aspects of this disorder in patients is not 
feasible. However, the highly conserved evolution of frataxin across various organisms has 
enabled scientists to develop different in vitro and in vivo models. Thus, human cell lines or 
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animal models have provided insights into FRDA disease molecular pathophysiology and 
have been used for relevant pilot therapeutic studies.  
1.5.1 - Saccharomyces cerevisiae model 
Many studies have been carried out on the Saccharomyces cerevisiae yeast frataxin 
homologue, YFH1, and the corresponding protein Yfh1. The results showed that Yfh1 is an 
essential mitochondrial protein, playing role in mitochondrial DNA maintenance. It has been 
reported that Yfh1 deficiency causes impaired respiratory complex function due to 
accumulation of iron in mitochondria and loss of mitochondrial DNA. To confirm the latter 
finding, investigations showed that introducing a missense mutation, corresponding to one of 
the FRDA patients’ mutations, into YFH1 leads to a reduction of yeast respiratory function 
(Wilson and Roof 1997; Foury 1999). Isaya and colleagues showed that lack of Yfh1 
culminates in mitochondrial iron accumulation, suggesting that Yfh1 is required for iron 
uptake.  This also suggests that oxidative stress, as a secondary effect of frataxin deficiency, 
could also be caused by defect of Yfh1 (Branda et al. 1999). In contrast, another study has 
shown that iron accumulation, due to reduced Yfh1 function, does not significantly affect cell 
growth or cell viability. Further investigations of the same yeast model showed that 
aberration of Yfh1 protein level was not associated with changing the level of soluble iron 
distribution. In addition, this study demonstrated that increased level of iron in mitochondria 
was not accompanied with expression of Yfh1 (Seguin et al. 2010).  
1.5.2 - Caenorhabditis elegans model 
Several investigations have been carried out on C. elegans nematode worm models by 
modifying the relevant frataxin homologue, frh-1, but the results differ. Using RNAi in         
C. elegans, three investigations have shown that downregulation of many mitochondrial 
genes results in prolonged lifespan (Feng et al. 2001; Dillin et al. 2002; Lee et al. 2003). 
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Interestingly, Johnson and colleagues have also demonstrated that RNAi-mediated deficiency 
of frh-1 protein leads to lifespan longevity; however, the worms presented with a smaller 
body size, less fertility and different responses to oxidative stress (Ventura et al. 2005). In 
contrast, other studies have reported that RNAi-mediated deficiency of frh-1 incrementally 
leads to lifespan shortening and increasing sensitivity to oxidative stress, suggesting oxidative 
stress could be the principle cause of reducing lifespan (Vazquez-Manrique et al. 2006; Zarse 
et al. 2007). In addition, Palau and colleagues demonstrated that frh-1 defect causes a 
constant pleiotropic phenotype, including slow growth, abnormal pharyngeal pumping, egg 
laying defects and lethargic behaviour (Vazquez-Manrique et al. 2006). To explain the 
conflicting lifespan results observed in different studies, Johnson established a novel RNAi 
dilution strategy to significantly reduce the expression of 5 major genes involved in the 
mitochondrial electron transport chain (ETC), one of which was frh-1. The results showed 
that the mitochondrial ETC phenotype is dependent on the RNAi dose as well as particular 
period of development. They demonstrated that intermediate suppression leads to lifespan 
extension whilst using high dose of RNAi causes shortening lifespan (Rea et al. 2007). 
1.5.3 - Drosophila melanogaster model 
To generate a transgenic Drosophila fly model mimicking FRDA patients, Philips and 
colleagues used a UAS-GAL4 transgene-based RNAi technique to reduce expression of the 
frataxin homologue, dfh, in different tissues. Suppression of the dfh showed distinguishable 
phenotypes in larvae and adult Drosophila, including giant long-lived larvae and conditional 
short-lived adults. In parallel to this finding, they recognised that dfh silencing causes 
differential dysregulation of ferritin expression in adults but not in larvae. They also showed 
that dfh silencing leads to downregulation of many heme and ISC enzyme activities, defect of 
intracellular iron homeostasis and increased susceptibility to iron toxicity. Finally, they found 
that dfh silencing has no effect on larvae development of peripheral nerves, but significantly 
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reduces the lifespan of these cells in adults. Furthermore, overexpression of the anti-oxidant 
enzymes cytosolic superoxide dismutase (SOD1), mitochondrial superoxide dismutase 
(SOD2) and catalase (CAT) did not improve the dfh-defective phenotype, suggesting a 
minimal role of oxidative stress in this model (Anderson et al. 2005).  
Later, to determine the role of frataxin and oxidative stress in FRDA patients, Molto and 
colleagues induced post-transcriptional silencing of dfh by using double stranded RNAi. They 
generated transgenic flies that expressed 30% residual frataxin and showed shorter life span, 
reduced climbing ability in adulthood and elevated sensitivity to oxidative stress. In addition, 
there was a significant decrease in aconitase activity, caused by hyperoxia, while no change 
was observed in succinate dehydrogenase and respiratory complex I-IV activities. Curiously, 
further studies demonstrated that overexpression of frataxin could also cause oxidative stress 
induced impairment of aconitase activity (Llorens et al. 2007). Yet more studies of the RNAi 
transgenic flies showed that loss of frataxin leads to toxicity caused by accumulation of lipid 
peroxides in glial cells, lifespan shortening, increased sensitivity to oxidative stress, impaired 
locomotor activity and progressive vacuolisation of glia, suggesting that lipid peroxidation 
can somehow cause FRDA-like symptoms in glial cells (Navarro et al. 2010).  
1.5.4 - FRDA mouse models 
Many useful results have been obtained by the investigation of FRDA mouse models, using 
both gene targeting technology and transgenic mice to cause frataxin deficiency.     
1.5.4.1 - Knockout mouse models  
To explore frataxin function and the mechanism of FRDA disease, a mouse model was 
generated by inactivation of the mouse FXN homologue, Fxn.  In this study, Koenig and 
colleagues’ investigations to target exon 4 of Fxn did not result in a viable FRDA mouse 
model, due to the fact that Fxn
-/-
 mice die before birth, indicating the critical role of frataxin 
for life (Cossee et al. 2000). To overcome this early embryonic lethality, as well as to study 
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the effect of a frataxin defect on different tissues, Koenig and colleagues subsequently 
generated two lines of conditional Fxn-KO mice: muscle frataxin deficient and 
neuron/cardiac muscle frataxin deficient lines. To obtain these lines, homozygous mice with a 
conditional allele of Fxn (Fxn
L3/L3
) were crossed with mice heterozygous for a deletion 
located in exon 4 of Fxn that carried a tissue specific Cre transgene under control of the 
muscle creatine kinase (MCK) or the neuron-specific enolase (NSE) promoters to develop 
Fxn
L3/∆
-MCK-Cre
+
 or Fxn
L3/∆
-NSE-Cre
+
 lines, respectively. NSE mutated mice showed low 
birth weight, early onset progressive neurological features, such as ataxia, and short lifespan. 
In contrast, weight loss was observed later in MCK models, followed by progressive features 
of fatigue and early death. in the MCK and NSE mutant mouse lines developed progressive 
biochemical and pathophysiological signs, similar to FRDA in humans, including iron 
accumulation caused by ISC enzyme deficiencies, dysfunction of large sensory neurons with 
no alteration of the small sensory and motor neurons, loss of activities of MRC complexes 
and aconitase, cardiac hypertrophy and premature death (Puccio et al. 2001).   
Later, another conditional knockout mouse model that lacked frataxin in pancreatic β cells 
was established. The levels of reactive oxygen species and frequency of apoptosis were 
increased in these mice, together with a reduced rate of pancreatic β cell proliferation. They 
also showed impaired glucose tolerance, progressing to overt diabetes mellitus, caused by 
defective insulin secretion due to loss of β cell mass (Ristow et al. 2003). 
1.5.4.2 - Knock-in mouse models 
To mimic the mechanisms of human FRDA in mice, (GAA)230 repeats were directly inserted 
into the mouse Fxn intron1 region to generate a FRDA knock-in mouse model. By crossing 
the knock-in mice with frataxin KO mice, studies showed that the resulting                       
knock-in/knockout (KIKO) mice expressed 25-36% of the normal levels of frataxin. However 
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no GAA repeat instability, motor co-ordination abnormality, iron metabolism response due to 
iron loading, or premature death was observed (Miranda et al. 2002).  
1.5.4.3 - FXN YAC transgenic mouse models  
To investigate human frataxin function in a mouse background, Chamberlain and colleagues 
generated transgenic mice containing a human WT-FXN yeast artificial chromosome (YAC) 
with no endogenous mouse frataxin. Interestingly, the results showed that mice with loss of 
endogenous frataxin were rescued from embryonic lethality due to functional human frataxin 
expressed from the FXN-YAC transgene (Pook et al. 2001). To identify the mechanism of 
GAA repeat expansion, two lines of FRDA-YAC transgenic mice were established, YG8 and 
YG22, by integrating a GAA repeat expansion-containing 370kb human YAC clone. The 
difference between YG8 and YG22 lines is that there are  190 GAA repeats in YG22 and two 
arrays of 90 and 190 GAA repeats in YG8 (Al-Mahdawi et al. 2004). The results showed 
expansions of GAA repeat transmission from parent to offspring in these transgenic mice, 
similar to other TNR instability disorders (Figure 1.17, Table 1.2). These findings were 
consistent with a previous study carried out on transgenic mice carrying a 200 GAA repeat 
inserted into tandem arrays of hCD2 reporter constructs (Saveliev et al. 2003), which showed 
GAA repeat instability over generations. 
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Figure 1.17 - Intergenerational GAA repeat instability in FRDA YAC transgenic mice 
(Al-Mahdawi et al. 2004). 
 
 
(A) Ethidium bromide-stained agarose gel and (B) Southern blot autoradiograph of GAA 
PCR products from representative YG22 (190 repeats) and YG8 (90 + 190 repeats) 
transgenic mice showing expansions (↑) up to 235 repeats (YG22) or 223 repeats (YG8) and 
contractions (↓) down to fewer than 9 repeats (both lines). An example of a discrete PCR 
product potentially corresponding to 340 repeats that failed to hybridize with a GAA probe is 
indicated by an asterisk. Each PCR product also contains 451 base pairs (bp) of non-GAA 
FXN intron 1 sequence flanking the actual GAA repeat. 1Kb
+
 and 100bp DNA markers and 
PCR products from wild-type YAC 37FA12 (9 repeats) and modified YAC 1(38)                  
(190 repeats) are shown for comparison. 
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Table 1.2 - Parental age-related effect on GAA instability (Al-Mahdawi et al. 2004). 
 
 
Parental age 
 
 
Instability 
 
GAA alteration per transmission (%) 
YG22                            YG8 
 
 
< 3 months 
 
Expansion 
 
4/60 (7%) 
 
4/37 (11%) 
 
Contraction 
 
6/60 (10%) 
 
1/37 (3%) 
 
 
 
4-6 months 
 
Expansion 
 
7/100 (7%) 
 
7/41 (17%) 
 
Contraction 
 
14/100 (14%) 
 
2/41 (5%) 
 
 
 
> 7 months 
 
Expansion 
 
9/66 (14%)  
 
ND 
 
Contraction 
 
11/66 (17%) 
 
ND 
 
 
 
Total 
 
Expansion 
 
20/226 (9%) 
 
11/78 (14%) 
 
Contraction 
 
31/226 (14%) 
 
3/78 (4%) 
ND: not determined. * Significant expansion bias upon transmission from older parents       
(p< 0.05). All nine cases of expansions were derived from male parents and none from 
females. 
 
Nonetheless, any comparable fluctuation of expansion or contraction was not detected in 
different offspring gender carrying YG8 or YG22 (Table 1.3). 
 
Table 1.3 - Effect of offspring gender on GAA instability (Al-Mahdawi et al. 2004). 
 
 
Offspring gender 
 
 
Instability 
 
GAA alterations per transmission (%) 
YG22                           YG8 
 
Male 
 
Expansion 
 
 
13/226 (6%) 
 
6/78 (8%) 
 
 
Contraction 
 
16/226 (7%) 
 
1/78 (1%) 
 
 
Female 
 
Expansion 
 
7/226 (3%) 
 
5/78 (6%) 
 
 
Contraction 
 
15/226 (7%) 
 
2/78 (3%) 
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In addition, somatic GAA repeat expansions were also observed in the YG8 and YG22 
transgenic mice, particularly in CNS tissues such as cerebellum and spinal cord. Such 
somatic instability has previously been observed in FRDA patient lymphoblastoid cell lines 
and blood samples (Campuzano et al. 1996; Simon et al. 2004). However, YG8 and YG22 
mice demonstrated for the first time that GAA repeat instability could also be dependent on 
age (Figure 1.18), particularly in cerebellar tissue (Al-Mahdawi et al. 2004). 
 
Figure 1.18 - Somatic GAA repeat instability in FRDA YAC transgenic mice               
(Al-Mahdawi et al. 2004).   
 
 
GAA PCR products from somatic tissues of representative transgenic mice. (A) 2-month F4 
YG22, (B) 5-month F8 YG22, (C) 9-month F7 YG22, (D) 12-month F6 YG22, (E) 2-month 
F4 YG8, and (F) 3-month F4 YG8. No GAA repeat instability is detected in either                 
2-month-old YG22 or 2-month-old YG8 mice. Instability is greatest in the cerebellum of       
9- and 12-month-old YG22 mice and the cerebellum and spinal cord of 3-month-old YG8 
mice. Y, YAC 1(38); B, whole brain; Ch, cerebral hemisphere; Bs, brain stem; C, cerebellum; 
S, spinal cord; H, heart; L, liver; K, kidney; Sp, spleen; P, pancreas; Sk, skeletal muscle;        
T, testis; Ta, tail. 
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1.5.5 - Human cell culture models  
FRDA cell lines are needed to identify the potential effects of novel therapeutic approaches. 
The generation of readily available FRDA cell lines, such as fibroblasts and lymphoblasts, 
has aided the understanding of molecular disease mechanisms, including epigenetic silencing 
of FXN expression. However, because they are not the primary affected cells in FRDA 
patients, these cells may not show the disease effects caused by FRDA. To produce more 
relevant disease-like cell models with reduced levels of frataxin mRNA and/or protein, 
different cell lines have been manipulated by siRNA or shRNA-mediated silencing.             
By generating stable FXN-transfected clones, researchers have recognised that frataxin defect 
causes increasing apoptosis in retinoic acid-stimulated cells, suggesting that frataxin 
depletion makes cells more susceptible to apoptosis during appropriate stimulation          
(Santos et al. 2001). In another study, it was shown that reduction of frataxin protein by 
transfecting human HeLa cells with RNAi caused reduction of Fe/S enzyme activities, such 
as aconitase and succinate dehydrogenase, but non-Fe/S enzyme activities remained 
unchanged. This study confirmed that frataxin is a constituent element of human ISC 
assembly machinery that plays an essential role in the maturation of both mitochondrial and 
cytosolic ISC (Stehling et al. 2004). Meanwhile, Ioannou and colleagues constructed             
a bacterial artificial chromosome (BAC) genomic reporter containing two in-frame fusions 
between FXN and enhanced green fluorescent protein (EGFP). This was a good approach to 
detect and evaluate novel compounds that may have an effect on frataxin expression. 
However, due to the short GAA repeats (only 6 GAA repeats), this experiment was only 
useful for evaluating molecules that affect a WT promoter region and not an expanded GAA 
repeat promoter region (Sarsero et al. 2003). Following this study, Herbert and colleagues 
constructed green fluorescent protein (GFP) cell lines containing part of FXN intron 1 with 
either 15 or 148 GAA repeats, fused to the GFP coding sequence. Analysis of the GFP signal 
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by using fluorescent microscopy and western blotting showed significant reduction in the cell 
lines with 148 GAA repeats compared to the cell lines with 15 GAA repeats. These data 
suggested that the reduced GFP signal was caused by the expanded GAA repeat, although 
other factors like a transgene integration site may have also had roles to play (Grant et al. 
2006).  
Since FRDA is a tissue selective disease, investigating various cell types can help to 
understand the mechanisms of disease. However, unlike fibroblasts and lymphocytes, the 
generation of human neuronal and cardiomyocyte cell lines is not easily achieved. Recently, 
the ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) has aided 
the potential generation of patient-specific FRDA-relevant cell lines, including neurons and 
cardiomyocytes. Several FRDA iPSC lines have been generated to date (Ku et al. 2010;            
Liu et al. 2011). Gottesfeld and colleagues have demonstrated that iPSCs can be derived from 
FRDA patients’ skin fibroblasts. They showed that the FXN level is consistently reduced in 
iPSCs and their derivative cells, indicating that iPSCs could be a useful option to investigate 
high-throughput therapeutic screening (Ku et al. 2010; Liu et al. 2011).  
 
1.6 - DNA mismatch repair 
DNA is damaged by both endogenous and exogenous agents, resulting in cancer, due to 
hyper-proliferation, or neurodegenerative disorders, due to cell death. However, DNA repair 
proteins may enable DNA-damaged cells to survive by repair of the aberrant genes. DNA 
repair activities are generally classified into 5 different mechanisms: homologous 
recombination (HR), non-homologous end joining (NHEJ), nucleotide excision repair (NER), 
base excision repair (BER) and mismatch repair (MMR) (Sancar et al. 2004; Savas et al. 
2004). MMR corrects genomic mismatch alterations that occur during DNA replication. 
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MMR genes play a critical role in genomic stability by influencing cell cycle checkpoints and 
programmed cell death. Thus, MMR genes induce apoptosis in severely damaged cells, by 
which tumourigenesis is blocked (Figure 1.19). 
 
Figure 1.19 - Various functions of mismatch repair (MMR) proteins (Jun et al. 2006). 
 
 
 
MMR proteins are involved in diverse genetic pathways through interactions with different 
proteins. MMR proteins increase replication fidelity by repairing errors generated during 
replication. Proliferating cell nuclear antigen (PCNA) and replication factor C (RFC) work 
with MMR proteins during mismatch repair in replication. Various kinds of DNA damage 
trigger MMR protein-dependent DNA damage responses that are implemented through the 
activation of ataxia telangiectasia mutated and Rad3-related (ATR) and p53. Antibody 
diversification is formed by mutations in immunoglobulin genes that are introduced by MMR 
proteins in conjunction with activation-induced cytidine deaminase (AID) and DNA 
polymerase. In addition, MMR proteins regulate recombination and promote meiotic 
crossover.  
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More than 30 years ago, the first evidence of MMR was obtained from S.pneumoniae studies, 
but most bacterial investigations are now based on Escherichia coli (E.coli). In 1989, three 
different MMR proteins were identified in E.coli, called MutS, MutL and MutH. MutS 
proteins have an intrinsic ATPase activity and play a role in recognising and binding as 
homodimers to both base-base mismatches and small nucleotide insertion/deletion loops 
(IDLs). Physical interaction of MutL with MutS results in elevation of mismatch recognition. 
Mechanistically, the mismatch repair pathway starts by binding MutS to the mismatch. In the 
presence of ATP and MutL, DNA helicase II (UvrD) unwinds double-strand DNA (dsDNA) 
towards the mismatch, culminating in single-strand DNA (ssDNA) generation. This ssDNA 
is protected from nuclease attack by ssDNA binding protein (SSB). In the next step, MutH 
determines and makes a strand-specific nick in hemi-methylated dGATC DNA. Depending 
on the position of the nick in the strand, different exonuclease enzymes (ExoI/ExoX for 
3′→5′ exonuclease or ExoVII/RecJ for 5′→3′ exonuclease) excise past the mismatch 
sequence. Finally, the cleaved ssDNA is resynthesised by interaction of MutL, DNA 
polymerase III (δ and γ subunits), SSB and DNA ligase (Li 2008). High stability and strong 
interaction of the DNA polymerase III complex with MutL suggest that another protein 
(clamp loader) is being recruited during the resynthesis step of MMR (Li et al. 2008). 
Repairing mismatches in E.coli is dependent on ATP, suggesting a critical role of MutL and 
particularly MutS ATPase activities. Defect in MutL entirely prevent the MMR function in 
E.coli (Li 2008). Studies have shown that defective ATP hydrolysis in MutL, but not MutS, 
can activate MutH, although it is not able to stimulate the MutH in response to a mismatch or 
MutS, suggesting the crucial role of MutL ATP hydrolysis to mediate the activation of MutH 
by MutS (Junop et al. 2001).  
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MMR is a highly conserved process from prokaryotes to eukaryotes. However, the E.coli 
MutS and MutL proteins act as homodimeric complexes, whereas their human counterparts 
are heterodimers (Table 1.4). 
 
Table 1.4 - MMR components and their functions (Li 2008). 
 
E.coli 
 
 
Human 
 
Function 
 
(MutS)2 
 
hMutSα   (MSH2-MSH6)a 
 
DNA mismatch/damage recognition 
hMutSβ   (MSH2-MSH3) 
 
 
             (MutL)2 
 
 
hMutLα   (MLH1-PMS2)a 
 
Molecular matchmaker; 
endonuclease, termination of 
mismatch-provoked excision 
hMutLβ   (MLH1-PMS1) 
hMutLγ   (MLH1-MLH3) 
 
MutH 
 
?
b 
 
Strand discrimination 
 
UvrD 
 
?
b 
 
DNA helicase 
 
ExoI, ExoVII, ExoX, 
RecJ 
 
 
 
ExoI 
 
 
DNA excision; mismatch excision 
 
Pol III holoenzyme 
 
Pol δ 
 
 
DNA re-synthesis 
 
 
PCNA 
 
 
Initiation of MMR, DNA  
 re-synthesis 
 
 
 
 
 
 
SSB 
 
 
 
 
 
RPA 
 
 
ssDNA binding/protection; 
stimulating mismatch excision; 
termination of DNA excision; 
promoting DNA re-synthesis 
 
 
HMGB1 
 
 
Mismatch-provoked excision 
 
 
 
RFC 
 
 
PCNA loading; 3' nick-directed 
repair; activation of MutLα 
endonuclease 
 
 
DNA Ligase 
 
 
DNA ligase I 
 
 
Nick ligation 
a
 Major components in cells.
 b
 Not yet identified.
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In humans, three MutS proteins form two complexes: MSH2/MSH3 form hMutSβ and 
MSH2/MSH6 form hMutSα. The hMutSα complex recognizes base-base mismatches and 
IDLs of one or two nucleotides, whereas the hMutSβ complex detects larger IDLs. In 
addition, hMutSα and hMutSβ, like MutS in E.coli, also play a role in MMR initiation via 
ATPase activity (Zhang et al. 2005; Jascur and Boland 2006; Hsieh and Yamane 2008). In 
both prokaryotes and eukaryotes, a defect of base-base mismatch repair culminates in single 
base substitutions. However, deficiency in the repair of IDLs results in MSI (Abdel-Rahman 
et al. 2006). MutL comprises 4 different homologues, including hMLH1, hMLH3, hPMS1, 
and hPMS2. Human MLH1 (hMLH1) can form three heterodimeric complexes by interaction 
with hPMS2, hPMS1 or hMLH3, comprising hMutLα, hMutLβ, or hMutLγ, respectively. It 
has been demonstrated that hMutLα is used in MMR and hMutLγ is involved in meiosis, but 
the function of hMutLβ is not clear yet. The hMutLα protein complex, like MutL in E.coli, 
carries an ATPase activity (Li 2008).    
Eukaryotic DNA MMR consists of MutSα or MutSβ, MutLα, DNA polymerase δ and ligase 
I. However, existence of some other proteins is necessary to initiate the function; including: 
RPA, EXO1, HMGB1, PCNA, and RFC (Zhang et al. 2005; Jascur and Boland 2006; Hsieh 
and Yamane 2008). To initiate the MMR processing, proliferating cell nuclear antigen 
(PCNA) interacts with MSH2/MSH3 or MSH6 and MLH1/PMS2 via a conserved PCNA 
interaction motif (Figure 1.20). 
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Figure 1.20 - The process of eukaryotic MMR (Hsieh and Yamane 2008). 
 
 
 
Recognition of a mismatch by MutSα (MSH2–MSH6) or MutSβ (MSH2–MSH3, not shown) 
and MutLα (MLH1–PMS2) results in the formation of a ternary complex whose               
protein–protein and protein–DNA interactions are modulated by ATP/ADP cofactors bound 
by MutSα and MutLα (indicated by red *). PCNA may play an important role in the 
recruitment of MMR proteins to the vicinity of the replication fork via a PIP motif on MSH6 
and MSH3. Nicking by the endonuclease function of PMS2 stimulated by ATP, PCNA, and 
RFC and relevant protein–protein interactions (indicated by green arrow) may establish 
strand discrimination targeting repair to the newly synthesised strand. MMR is bi-directional 
and can be 5’-directed as well; this is not shown. Excision by EXO1 and possibly other as yet 
unidentified exonucleases leads to the formation of an RPA-coated single-strand gap. 
Resynthesis by replicative pol d and ligation restore the integrity of the duplex. 
 
 
 
It is proposed that PCNA might be able to help localise MutSα or MutSβ to mismatch errors 
in the daughter ssDNA. Proper function of this protein is essentially required during 
mismatch provoked 3’nick-directed excision. However, its existence is not necessary during                          
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5’nick-directed MMR (Abdel-Rahman et al. 2006; Jun et al. 2006). EXO1 (a 5’ to                     
3’ exonuclease) cuts 5’directed mismatches in the presence of MutSα or MutSβ and 
replication protein A (RPA). RPA, which is a eukaryotic ssDNA binding protein, acts as an 
excision enhancer. Before MutSα and MutLα, this protein binds to nicked heteroduplex 
DNA. RPA also acts as stimulator of mismatch-provoked excision and alleviates DNA 
resynthesis. As soon as DNA polymerase δ is recruited to the gapped DNA substrate, RPA is 
phosphorylated. It is believed that phosphorylation decline RPA affinity to DNA, indicating 
that phosphorylated RPA is applied to ease MMR-associated DNA resynthesis more 
efficiently. Overall, it seems that this protein is involved in all steps of MMR. High mobility 
group box 1 (HMGB1) protein, a non-histone chromatin protein binding DNA and 
facilitating protein-protein interactions in MMR processing, is a mismatch binding protein 
playing a role in DNA unwinding activity. Despite the fact that its function is not fully 
understood yet, it is believed that HMGB1 may substitute for RPA. For catalysing                
the 3’nick-directed excision, EXO1 cooperates with MutLα endonuclease. However, MutLα 
endonuclease should be activated beforehand by PCNA and replication factor C (RFC) 
interaction. Activation of this complex results in termination of mismatch-provoked excision 
(Kunkel and Erie 2005; Jun et al. 2006).   
Defects of the MMR system increase the range of genetic instabilities and accumulation of 
potential spontaneous mutations, so that damaged cells are predisposed to certain types of 
malignancy (Guo et al. 2004). Defects of MMR genes, particularly MLH1, have been 
reported to have a negative influence of MSI in 10-20% of sporadic tumours                    
(Chew et al. 2008). Germline mutation of MMR genes may cause hereditary cancers, such as 
hereditary non-polyposis colorectal cancer (HNPCC; also called Lynch syndrome), the most 
prevalent autosomal dominant colorectal cancer (CRC) syndrome (Figure 1.21). HNPCC was 
discovered in 1913, but it is now called Lynch syndrome because of work by Lynch and 
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Krush in 1971 (Abdel-Rahman et al. 2006). HNPCC patients are normally predisposed to 
several cancers, particularly CRC, stomach cancer and endometrial adenocarcinoma (Gylling 
et al. 2007; Chew et al. 2008; Walsh et al. 2008).  
 
 
Figure 1.21 - Genetic component in colorectal carcinogenesis (Abdel-Rahman et al. 2006). 
 
 
  
 
Mutations in high penetrance susceptibility genes underlie the development of hereditary 
syndromes, such as Lynch syndrome (HNPCC), Familial Adenomatous Polyposis (FAP), or 
Hamartomatous Polyposis syndromes. Both high and low penetrance susceptibility mutations 
account for the major share of familial colorectal cancer as well as undetermined fraction of 
sporadic colorectal cancer. Modifier genes are likely to influence the effects of the 
predisposition genes while the environment might have a greater role in sporadic cases. 
 
 
 
HNPCC is usually caused by germline mutation in one of the MSH2, MSH6 or MLH1 genes. 
However, studies indicate that PMS1, PMS2 and MLH3 mutations can also be affected at 
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lesser frequencies. Heterozygous germline mutations of MSH2 and MLH1 genes are the most 
prevalent cause of HNPCC (Abdel-Rahman et al. 2006; Vasen et al. 2007). Interestingly, 
investigations proved the hypothesis that MSH2 and MLH1 proteins might be disrupted by 
pre-mRNA splicing (Tournier et al. 2008). Microsatellite instability can frequently be found 
in HNPCC because of MMR gene aberrations. Therefore, it is generally recommended to 
check for MSI at the initial process of HNPCC molecular diagnosis (Abdel-Rahman et al. 
2006). Studies reveal that the risks of cancer development (particularly HNPCC) are more 
prevalent in MSH2 mutants than MLH1 mutants (Vasen et al. 2001). Finding the role of 
MMR proteins on MSIs was a good preface to investigating the correlation of MMR proteins 
and the main molecular cause of many neuromuscular disorders, namely TNR instabilities. 
Several studies indicate an effect of MMR on CAG and CTG repeat expansions, which may 
provide an insight into the molecular basis and subsequently therapeutic approaches to treat 
these disorders (Manley et al. 1999). For instance, investigating the effect of prokaryotic 
MMR proteins on the expanded human HD CTG repeats, artificially inserted into E.coli, 
showed that loss of each of MutS, MutL and MutH proteins promoted stability of the 
expanded CTG repeats. This observation suggested that the presence of MMR proteins could 
cause TNR repeat expansions and contractions (Jaworski et al. 1995).   
1.6.1 - MSH2 gene  
MSH2 (MutS homolog 2) is a fundamental MMR gene in eukaryotes. Interest in MSH2 was 
sparked during investigation of HNPCC because its deficiency was reported as one cause of 
this hereditary malignancy, resulting in MSI. The critical action of MSH2 in association with 
MSH3 and MSH6, as MutSβ and MutSα complexes respectively, is an essential role in the 
recognition of base-base mismatches and IDLs. Therefore, absence of MSH2 stops the MMR 
process via disruption of damaged site recognition, and subsequently, no recruitment of the 
other MMR proteins to follow the repair process. To find out much more about the 
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consequences of Msh2 deficiency in vivo, Msh2 KO mice were generated. These studies 
indicated that Msh2 deficiency leads to a MSI mutator phenotype and tolerance to 
methylating factors (de Wind et al. 1995). MSH2 may also act as an anti-recombinase during 
homologous recombination (HR). HR is a crucial intrinsic process in eukaryotic cells that 
repairs DNA double strand breaks (DSBs) and interstrand crosslinks. HR protects 
chromosomes against false rearrangements. To achieve that, recombinases, which catalyse 
natural recombination reactions, should be regulated. Msh2, as an anti-recombinase regulator, 
prevents unspecific activation of HR. So that, defect of Msh2 results in upregulation of 
recombinases, and subsequently over-activation of HR. Inaccurate matching of sequences 
during recombination can itself cause various genomic difficulties, such as Alu-mediated 
recombination in both somatic and germline cells. Since Alu repeats are the largest         
multi-genes family in human genome, the risks of HR events are highly estimated. Therefore, 
any HR between Alu-elements might culminate in duplication, deletion, and translocation 
(Batzer and Deininger 2002; Maguire and Kmiec 2007; Smith et al. 2007). It has also been 
demonstrated that Msh2 deficiency can contribute to chromosomal abnormality, since the 
loss of Msh2 activity causes aneuploidy in primary mouse embryonic fibroblasts (MEFs). 
Furthermore, several model studies have indicated an important role for Msh2 in TNR 
instability. Investigation of yeast models, containing different tracts of 25-92 CAG repeats, 
revealed that loss of MSH2 leads to increased instability towards repeat contractions, while 
these tracts are relatively stable in MSH2-proficient expression (Schweitzer and Livingston 
1997).       
Subsequently, by comparing transgenic mice carrying exon 1 of the human HD gene in the 
absence or presence of Msh2, Messer and colleagues showed that loss of Msh2 abolishes   
age-dependent CAG repeat expansions in mouse somatic tissues at 30 weeks of age (Manley 
et al. 1999). Subsequently, by using similar transgenic mouse models, Kovtun and McMurray 
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demonstrated that Msh2 can also affect germ line cells. Investigation of intergenerational 
transmission of CAG repeats in these transgenic mice demonstrated that loss of Msh2 leads to 
total abrogation of germline expansion in the progeny (Kovtun and McMurray 2001). Further 
studies of the knocked-in Hdh
Q111
 transgenic mice, containing 109 CAG repeats, showed that 
loss of Msh2 is sufficient to inhibit progression of somatic HD CAG expansion in striatum. In 
contrast, no significant changes were observed in maternal transmission of CAG repeat 
mutations (including both expansions and contractions) in the absence or presence of Msh2. 
Paternal germline transmission only showed contractions of CAG repeats in the absence of 
Msh2, suggesting that Msh2 is required for paternal CAG repeat expansions and protects 
against CAG repeat contractions (Wheeler et al. 2003).      
Similar studies have been performed for DM1, another disease caused by TNR expansion, by 
generating Msh2-KO transgenic mice carrying more than 300 CTG repeats in the non-coding 
region of the human DMPK gene. Comparison DMPK/Msh2
+/+
 and DMPK/Msh2
-/-
 results 
showed that the overall range of mutability was not changed in both female and male 
transgenic mice. In this study, loss of Msh2 caused a reduction of CTG repeat expansions and 
a shift towards contractions in somatic cells. The same situation was also observed in both 
paternal and maternal intergenerational CTG repeat expansions. To find out the timing effect 
of the Msh2 defect on intergenerational CTG repeat instability, parental gametes of different 
Msh2 genotypes were analysed. The results showed that instability of progeny could depend 
on parental germline instability. Further studies of the somatic instability of various tissues in 
newborn offspring suggested a second instability event at a very early stage of development, 
probably just after fertilisation (Savouret et al. 2003).   
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1.6.2 - MSH3 and MSH6 genes  
MutSα (MSH2-MSH6) binds to base-base mismatches. Both MutSα and MutSβ             
(MSH2-MSH3) bind to 1-2 nucleotide IDLs, while only MutSβ is able to bind to larger IDLs 
up to 16 nucleotides long (Kunkel and Erie 2005). The MutSβ complex also contributes to 
recombination by binding and stabilising nucleotide excision repair (NER) RAD1-RAD10 
endonuclease for cleavage of the 3’ non-homologous DNA. It has also been shown that 
MutSβ binds with high affinity to substrates containing double strand (ds)/ single strand (ss) 
DNA junctions and alters the conformation of such junctions, with a preference for substrates 
that contain 3’ ssDNA (Surtees and Alani 2006).  
Connection of the MutSβ complex and PCNA is mediated by the conserved PIP box                 
at the N-terminal of MSH3. Further studies have shown that mutation of the PIP box prevents 
IDL corrections, particularly IDLs with more than two nucleotides. It is also believed that 
PCNA helps MutSα to search and recognise the mismatch errors, promoting the mismatch 
binding specificity of MutSα. PIP box deletion in MSH6 may also lead to partial defects of 
MutSα activity. Analysis of the N-terminal region (NTR) of Msh6 revealed at least two 
functions for this polypeptide site, one of which involves in PCNA interaction. Studies in 
mice have shown that Msh3 and Msh6 NTRs are able to be exchanged, and that the NTR of 
Msh6 might be functional when placed on Msh2 (Jun et al. 2006; Shell et al. 2007). 
Disruption of Msh3 showed susceptibility to malignancies, such as colorectal and 
endometrial cancers, and elevation of MSI in Msh3
-/-
 mouse models. MSH6 deficiency also 
promotes tumourigenesis, but reduces MSI. It has been demonstrated that combined MSH3 
and MSH6 interruption may cause the same adverse effects as MSH2
-/- 
(Li 2008). 
Investigations of the transgenic mice carrying the human DMPK gene showed that deficiency 
of Msh3 blocks the (CTG)84 instability, whereas Msh6 deficiency leads to elevation of CTG 
expansion in somatic cells. Analysis of the CTG repeat expansion in Msh3
-/-
 transgenic mice 
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demonstrated that Msh3 may also play critical role in the expansions of this TNR over 
generations, while no similar function was observed with lack of Msh6. In other words, Msh6 
deficiency causes a decrease of CTG expansions only in maternal transmissions. In this 
study, Gourdon and colleagues demonstrated that absence of one Msh3 allele could lead to 
reduction of CTG repeat expansions (Foiry et al. 2006). Since the stability of Msh3 or Msh6 
is dependent on their opportunity for binding to Msh2, it seems that the level of Msh2-Msh3 
heterodimer in Msh6-deficient cells could be higher than in wild-type cells, resulting in 
increased TNR instability. In contrast, the presence of only the Msh2-Msh6 complex may 
result in TNR expansion blockage in somatic cells (van den Broek et al. 2002). To investigate 
the effects of Msh3 and Msh6 on intergenerational and somatic CAG repeat sizes in HD, 
Wheeler and colleagues cross-bred HD-(CAG)101 knock-in mice with Msh3-KO or Msh6-KO 
mice. No significant difference was observed in maternal transmission of CAG repeats by 
comparing Hdh
Q111
/Msh3
+/+
, Hdh
Q111
/Msh3
+/-
 and Hdh
Q111
/Msh3
-/-
 or Hdh
Q111
/Msh6
+/+
, 
Hdh
Q111
/Msh6
+/-
 and Hdh
Q111
/Msh6
-/-
 genotypes. Analysis of paternal intergenerational 
instability showed that loss of Msh3 causes a shift of mutations from expansions towards    
.no-changes or even contractions, indicating that loss of Msh3 results in reduced CAG repeat 
expansions. Msh6
+/-
 transgenic mice showed significantly greater CAG repeat contractions in 
comparison with Msh6
+/+
, suggesting the protective effect of Msh6 against CAG paternal 
contractions. However, analysing Msh6
+/+
 and Msh6
-/-
 showed no difference in the 
instabilities of paternal CAG transmission, suggesting that another mechanisms might be 
involved in promoting male intergenerational CAG contractions in the absence of Msh6 
(Dragileva et al. 2009). As with DM1, studies of HD transgenic mice carrying CAG 
expansions showed that Msh3 deficiency may lead to reduced somatic TNR instability in the 
striatum. However, no obvious effect on somatic instability was observed in the stratum of 
Hdh
Q111
 CAG knocked-in transgenic mice carrying Msh6
-/-
 (Dragileva et al. 2009). Another 
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study previously showed that absence of Msh6 moderately reduces the CAG expansions in 
brain tissues, while no effect is observed in many other tissues such as liver and spleen 
(Owen et al. 2005). In contrast to Msh2, Msh3
+/-
 showed a significant decrease in striatal 
CAG instabilities suggesting that Msh3 is a limiting factor in somatic instability of CAG, and 
that CAG striatal instability is probably mediated by Msh2-Msh3 dimers (Dragileva et al. 
2009). To investigate the potential effects of MutS complex on CAG repeat expansions and 
related mechanisms, McMurray and colleagues tested the physical and biochemical 
properties of this heterodimeric enzyme changes while bound to the CAG hairpin. The results 
showed that MutSβ can recognise the CAG expansion region, blocking the ATPase activity 
of MutSβ heterodimer proteins (Owen et al. 2005).     
1.6.3 - PMS2 gene  
Post-meiotic segregation increased 2 (PMS2) is one of the four human genes (PMS1, PMS2, 
MLH1 and MLH3) encoding proteins similar to E.coli MutL. Combination of PMS2 and 
MLH1 proteins form the MutLα heterodimer, which is the major MutL complex acting in the 
mismatch repair initiated by the MutS complexes. There are 15 human PMS2 pseudogenes, 
which is the main reason why the role of PMS2 has remained enigmatic for 10 years. This 
number of homologues may decrease the effects of PMS2 deficiency. For instance, PMS2CL 
is recognised as a PMS2 pseudogene located in chromosome 7p22-23. The similarity of 
PMS2CL and PMS2 protein structure, particularly in the site where PMS2 binds to MLH1, 
may generate a false MLH1-PMS2 heterodimer in PMS2
-/-
. Loss of PMS2 may cause a defect 
of MMR, producing somatic instability of microsatellite repeats. Studies have shown that 
mono-allelic or bi-allelic inactivation of PMS2 is required to predispose toward cancers, such 
as Lynch syndrome and Turcot syndrome, a variant of Lynch syndrome. 5% of all Lynch 
syndrome patients carry some aberration of PMS2 (Niessen et al. 2009; Silva et al. 2009). 
Mutations in PMS2 may lead to dramatic MSI in many cancers (e.g. HNPCC, and Turcot 
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syndrome). To gain better understanding of the effect of PMS2 on MSI, Monckton and 
colleagues generated transgenic mice by cross-breeding Pms2-deficient mice with mice 
carrying CTG repeat expansions in the DMPK gene. Analysis of somatic tissues showed                
a consistently lower rate of the expanded CTG repeats in the Pms2
-/-
 tissues that usually show 
high levels of expansion, namely kidney and brain. Pms2 was shown to be required to 
increase the level of CTG repeat expansions, but was not a critical factor in generating 
expansion per se. Therefore, it was suggested that the level of Pms2 might correlate with the 
level of CTG repeat expansions. However, compared to Pms2
-/-
, no significant differences in 
repeat expansion rates were observed between Pms2
+/-
 and Pms2
+/+
 transgenic mice. Thus,           
it is proposed that even single functional Pms2 allele could be sufficient to promote CAG 
repeat expansion levels (Gomes-Pereira et al. 2004). 
1.6.4 - MLH1 gene  
The human MutL homologue 1 (MLH1) is another essential MMR protein, interacting as         
MLH1-PMS2, MLH1-MLH3 or MLH1-PMS1 heterodimers with the MutS heterodimer 
complexes to continue and terminate the MMR process. The MutLα complex (MLH1-PMS2) 
is able to interact with both MutSα and MutSβ. In contrast, MutLβ (MLH1-MLH3) is only 
able to interact with MutSβ. It is believed that the presence and proper activity of MLH1 in 
the MutL heterodimer is necessary to recruit the mammalian EXO1, DNA replication protein 
A and a component of DNA polymerase δ; PCNA/POL30 (Ellison et al. 2004). Thus, lack of 
MLH1 may result in disruption of MMR complex activity, producing many cellular 
abnormalities. In addition to the occurrence of somatic point mutations, MLH1 gene silencing 
may be caused by loss of heterozygosity (LOH) and hypermethylation of the MLH1 
promoter. Studies have shown that the rate of MLH1 promoter hypermethylation (83%) is 
remarkably higher than LOH (24%) and somatic mutations (13%) (Kuismanen et al. 2000; 
Blanco et al. 2010). Similar to MSH2, defect of MLH1 often causes hereditary Lynch 
                                  
Chapter 1- Introduction: Friedreich ataxia (FRDA) and DNA mismatch repair 
  64 
 
syndrome, but it can also cause aggressive and early onset haematological, brain                         
or endometrial tumours, together with increased MSI (Abdel-Rahman et al. 2006;             
Blanco et al. 2010).  
Few studies have thus far been carried out to understand the effects of MLH1 on TNR 
instability. In 1999, Hirst and colleagues inserted the normal or pre-mutated (54-200) length 
of human FMR1 CGG repeats into the S. cerevisiae and investigated the mlh1 effect on TNR 
instabilities. The results showed no increase in CGG expansion with the mlh1 defect, while 
several repeat expansions were seen in the presence of mlh1, indicating that absence of mlh1 
reduces the CGG repeat expansion level in yeast (White et al. 1999). Later, Lin and Wilson 
inserted (CAG)95 repeats into the inactivated HPRT mini gene of the FLAH25 cell line 
(derived from the human fibrosarcoma cell line: HT1080) and treated it with two siRNAs 
against MLH1. The results showed that CAG repeat expansions are reduced and 
transcription-induced CAG contractions are increased with loss of MLH1. Further studies 
showed that simultaneous downregulation of MLH1 and DNMT1 significantly increases 
repeat instability of CAG towards contractions, suggesting that losses of MLH1 and DNMT1 
are involved in a transcription-induced pathway of TNR instability (Lin and Wilson 2009). 
 
1.7 - Aim of the study 
FRDA is a fatal neurodegenerative disorder, mainly caused by abnormal expansion of GAA 
repeats within the first intron of human FXN gene. The exact mechanisms that cause FRDA 
are not yet clear and no effective therapy currently exists. Investigations have shown that 
different DNA repair genes, including MMR genes, can contribute to many different 
disorders by destabilising TNR. Therefore, the principle objective of this research was to 
study the effects of MMR genes (MSH2, MSH3, MSH6, PMS2 or MLH1) on the instability of 
GAA repeat expansions by two major approaches. Firstly, in chapter 3, the role of each MMR 
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gene in intergenerational GAA repeat instability was investigated by comparing GAA repeat 
sizes in FXN
GAA+
/ MMR
-/-
 and FXN
GAA+
/ MMR
+/+
 transgenic mice and their offspring. 
Secondly, in chapter 4, the effect of each MMR gene in somatic GAA repeat instability was 
investigated by comparing different tissues from FXN
GAA+
/MMR
-/-
 and FXN
GAA+
/MMR
+/+
 
transgenic mice.  
Moreover, it has been demonstrated that GAA repeat expansion is associated with reduced 
FXN transcription (Greene et al. 2007; Al-Mahdawi et al. 2008). Hence, in chapter 5, to 
investigate any effect of MMR genes on FXN transcription, the FXN transcription level was 
quantified in both FXN
GAA+
/MMR
-/-
 and FXN
GAA+
/MMR
+/+
 transgenic mice in vivo and human 
cells in vitro. 
Furthermore, several investigations have reported a potential role of frataxin deficiency in 
generating malignant cells. Also, MMR gene aberrations are recognised as the source of 
various types of cancer, particularly HNPCC. Therefore, the aim of chapter 6 was to 
investigate the effect of frataxin deficiency on MMR expression levels in human cells and 
tissues, which may subsequently have an impact on potential cell malignancy.  
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2.1 - Solutions and reagents 
2.1.1 - General solutions 
- Tris/EDTA (TE) buffer: 10mM Tris-HCl (pH 7.5), 1mM EDTA. 
- Tail digestion buffer: 100mM Tris-HCl (pH 8.0), 5mM EDTA, 200mM NaCl,           
0.2% SDS.  
- DEPC-treated water (0.1%): 1ml DEPC solution (≥97%), 999ml sterilised water 
(filtered and then autoclaved twice). 
- Orange G loading dye (6x): 0.35% Orange G dye, 30% sucrose.  
- TBE (1x): 90mM Tris, 20mM Boric acid, 2mM EDTA.   
2.1.2 - Cell culture media 
- DMEM medium: 1x DMEM medium, 10% foetal calf serum (FCS),                              
2% penicillin-streptomycin (Pen-Strep; 5000U/ml penicillin and 500mg/ml of 
streptomycin, Fisher Scientific Inc.).  
- McCoy’s medium: 1x McCoy’s medium, 10% foetal calf serum (FCS),                   
2% penicillin-streptomycin (Pen-Strep; 5000U/ml penicillin and 500mg/ml of 
streptomycin, Fisher Scientific).  
2.1.3 - NucleoSpin
®
 RNA II reagents 
- Wash buffer RA3 (50 preps): 12.5ml concentrated RA3, 50ml ethanol. 
- DNase reaction mixture: 90µl reaction buffer for rDNase, 10µl reconstituted rDNase 
(used freshly).  
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2.2 - Genotyping and mRNA quantification primers  
Various primers were used for genotyping the FRDA YAC double transgenic mice 
(FXN
GAA
/MMR , Table 2.1) as well as quantification of mRNA expression of different genes 
in the human and FXN
GAA+
 double transgenic mice (Table 2.2). Primer sequences were 
obtained either from previous studies (as indicated in the Table 2.1 and Table 2.2) or were 
newly designed by using Primer 3 and BLAST software from NCBI. All primers were 
purchased from Sigma-Aldrich.   
Table 2.1 - Primers used for genotyping genetically altered mice. 
 
GAA-F
GAA-R
CGG-F
CGG-R
CAG-F
CAG-R
Msh2-P1
Msh2-P2 (KO specific)
Msh2-P3 (WT specific)
Msh3-P1 (WT specific)
Msh3-P2 (KO specific)
Msh3-P3
Msh6-P1 (WT specific)
Msh6-P2 (KO specific)
Msh6-P3
Pms2-P1
Pms2-P2 (KO specific)
Pms2-P3 (WT specific)
M001
M002 (KO specific)
M003 (WT specific)
Species Reference
Human Campuzano et al., 1996
Mouse Newly designed
Mouse Newly designed
GGTGGGATTAGATAATGCCTGCTCT
GCTGAGAATACTTAGTCTCTGGCA
Msh2  knockout             
CGGCCTTGAGCTAAGTCTATTATAAGG
GGTGGGATTAGATAATGCCTGCTCT
CCAAGATGACTGGTCGTACATAAG
Mouse Toft et al., 1999
Mouse de Wind et al., 1995
Mouse
TTTTCAGTGCAGCCTATGCTC 
Pms2  knockout     
Mlh1 knokcout
ACAGTTACATTCGGTGACAG
TTTACGGAGCCCTGGCGC
ACTAATTCCCCTACGGTTTAG
TGTCAATAGGCTGCCCTAGG 
TGGAAGGATTGGAGCTACGG 
Mouse Designed by Mark Pook
Mouse Edelmann et al., 1999
de Wind et al., 1995
GGGATTGGTTGCCAGTGCTTAAAAGTTAG
GATCTAAGGACCATCATGGCCACACTTGCC
GAA
Name of the fragment Primer ID sequence (5'-3') 
Msh3  knockout                
CAGGAAGAGGTCACTGGGAAATGG
CGG
ATGTCCTAATTCGTATGACAGCTGG
CAG
TGTCGCCTCAGCCCTTGTGG
TGCTACAGGAATCACAGGCTTCTA
CTGCTCTGCCGTTTGGGGCA
Msh6  knockout                 
CAAGTCCTAGGATTAGAGGTCTGG
CCGGTGGATGTGGAATGTGTGCG
CCATGCAAATCAGACTCGATACAA
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Table 2.2 - cDNA primers used for gene expression analysis of genetically altered mice. 
 
 
 
 
2.3 - General techniques 
2.3.1 - General preparations 
Stock solutions and dilutions were prepared in deionised water (18.2 MΩ) unless otherwise 
specified. Total RNA samples were dissolved in DEPC-treated sterile water and            
DNase-RNase free water was utilised for polymerase chain reaction (PCR) mastermix 
preparation. All necessary materials, reagents and deionised water were autoclaved at 121°C, 
100 kilo Pascal (kPa) for 20 minutes. 
Gapdh -m-F
Gapdh -m-R
GAPDH -h-F
GAPDH -h-R
FXN -h-RT-F
FXN -h-RT-R
h-RT-MSH2- F
h-RT-MSH2 -R
h-RT-MSH3- F
h-RT-MSH3 -R
h-RT-MSH6 -F
h-RT-MSH6 -R
h-RT-PMS2 -F
h-RT-PMS2 -R
h-RT-MLH1 -F
h-RT-MLH1 -R
Gapdh
GAPDH
FXN
ACCCAGAAGACTGTGGATGG
GGATGCAGGGATGATGTTCT
GAAGGTGAAGGTCGGAGT
GAAGATGGTGATGGGATTTC
CAGAGGAAACGCTGGACTCT
Name of the fragment Primer ID sequence (5'-3') Species
AGCCAGATTTGCTTGTTTGGC
Mouse
Human 
MSH2
MSH6
PMS2
MLH1
TGTGAAGACCCCAGCCAGGAGA
TTCCTCTGGGAGATTAGCAAGCCT
GGGGTCATGTGCCGGCCTTC
GGGGACAGTTCCAGGGGTGGT
TGGGACGAAGAAAAGGAATG
GGCATTTGTTTCACCTTGGACAGG
ACAGAAAGCCCTGGAACTTGAGGA
Human
GATCAGGCAGGTTAGCAAGC
Human
Human Al-Mahdawi et al., 2008
Newly designed 
Newly designed 
Newly designed 
Newly designed 
MSH3
AGGGACGAGCACTCATGATGGA
Reference
Al-Mahdawi et al., 2008
Al-Mahdawi et al., 2008
Human Newly designed 
CCTCACTGACCAAGAATCCCAT
Human
Human
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Centrifugation of samples was carried out using different equipment. Samples with large 
volumes (15-50ml) were centrifuged in a centaur 2 centrifuge (Sanyo/MSE). Depending on 
the temperature requirement, smaller samples (0.5-1.5ml) were centrifuged at room 
temperature using a standard bench top micro-centrifuge (16K, BioRad) or at 4°C using a 
refrigerator micro-centrifuge (5415R, Eppendorf). Very small volume samples (≤ 20µl) were 
briefly centrifuged by using a mini micro-centrifuge (Heathrow Scientific). 96 well plates 
were centrifuged at room temperatures using a Legend T centrifuge (Sorvall).        
Incubations at 37-60°C were performed in water baths (Grant), whereas a heating block   
(DB-2A, Techne) was utilised for higher temperatures. The pH of solutions was determined 
using a pH-meter (Delta 340, Mettler) and pH adjustments were made by adding either 
concentrated HCl or NaOH.  
Genomic DNA solutions were stored at 4°C. PCR products were stored at 4°C for short term 
or -20°C for long term. Complementary DNA (cDNA) samples were stored frozen at -20°C. 
All fresh tissues and RNA samples were snap frozen and stored at -80°C. Reagent kits were 
stored at room temperature, 4°C or -20°C according to manufacturer recommendations,         
if necessary in the dark. Frozen cells were stored overnight at -80°C in a container with 
isopropanol and then kept in liquid nitrogen for long term storage. 
2.3.2 - Agarose gel electrophoresis 
Agarose gel electrophoresis was used to detect and separate DNA, cDNA or RNA based on 
sequence size. Gels were generally prepared in a 1-2% agarose range using 1x TBE buffer. 
The agarose mixture in 1x TBE was initially boiled in a standard microwave and allowed to 
cool. Subsequently, ethidium bromide was added to the gel in a final concentration of 
0.5µg/ml and the gel was poured into a casting tray with the required well comb. After 
adding 6x orange G loading dye (5µl per 25µl of product), samples were loaded into the gels. 
The small gels were run at 70V for 25-40 minutes in mini gel tanks with the capacity volume 
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of 50ml (Flowgen Biosciences). In the case of TNR size analyses, PCR products were run 
overnight in a large volume (300ml) tank, at 60-90V. Finally the gels were visualised and 
documented using a UV transilluminator imaging system (Alpha Innotech). 
 
2.4 - Cell culture 
Two types of adherent human cell lines were used, depending on the objective of 
experiments: fibroblasts and epithelial cells. Similar procedures were carried out for both 
fibroblast and epithelial cells, but the culture media was different. To regenerate, grow and 
cryopreserve fibroblast cells, DMEM culture medium (Gibco) was applied, while McCoy’s 
culture medium (Sigma-Aldrich) was used for epithelial cell lines.   
2.4.1 - Culture media 
Aliquots of FCS (Gibco) and Pen-Strep (Gibco) were thawed at 37°C for 2 hours or 4°C 
overnight. Inside a biological safety cabinet, FCS and Pen-Strep were added to 500ml of      
1x DMEM or McCoy’s medium, which was then mixed gently. The contents were filter 
sterilised with a 0.22µM pore filter unit (Nalgene) and stored at 4°C until required to use.  
2.4.2 - Regeneration of cell lines 
Frozen cells were removed from the liquid nitrogen tank and quickly thawed by immersing 
the vial in a water bath at 37°C. To regenerate the cells, it was critical to thaw the frozen cells 
as rapidly as possible to minimise the risk of cell damage by ice crystal formation. The cells 
were then transferred into a 15ml conical tube and 10ml of pre-warmed culture medium was 
added to the cells, which were mixed gently by pipetting up and down. The cells were 
collected by centrifugation at 1500 rpm for 5 minutes, then transferred to a flask containing 
new culture medium. Cells were incubated in a 5% CO2 incubator at 37°C and 90-95% 
humidity.     
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2.4.3 - Passage of cell lines 
Both fibroblast and epithelial cells are categorised as adherent cells. Once cells attach to the 
substratum and spread, they divide, and the cell number increase. Subculture was performed 
with fresh medium and space to allow continuous growth of the cells. Culture medium, 
phosphate-buffered saline (PBS) and trypsin/EDTA solutions were pre-warmed at 37°C in 
water bath. The medium was removed by vacuum suction and cells were washed gently with 
sterile PBS. Adherent fibroblast or epithelial cells were digested with trypsin/EDTA for          
5 minutes at 37°C in the CO2 incubator to bring them into suspension. The trypsin/EDTA 
solution was neutralised by adding 10ml of the DMEM culture medium to the fibroblast cell 
lines or 10ml of the McCoy’s culture medium to the epithelial cells. The cells were collected 
by centrifugation at 1500 rpm for 5 minutes and sub-cultured in 10ml DMEM or McCoy’s 
culture medium at a 1:2 or 1:4 ratio. The cells were then incubated at 37°C, 5% CO2 with 
95% humidity. To compare the growth efficiency of different cell lines within an experiment, 
the level of population doubling (PDL) was estimated in each passage number of individual 
cell lines, using the bellow formula: 
  
    PDL =  
   
In this formula, dilution factor demonstrated fold of confluent culture cell dilutions 
(Kuranaga et al. 2001).  
2.4.4 - Cryopreservation of cell lines 
To store a back-up for future studies, 1-2 vials of the each cell line were cryopreserved. In 
contrast to thawing cells, the procedure of cooling cells was performed slowly. Thus, cells 
were digested with trypsin/EDTA and precipitated by centrifugation at 1500 rpm for                 
Log (Dilution factor) 
Log (2) 
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5 minutes. Cells were then resuspended in 1ml of appropriate culture medium (DMEM or 
McCoy) supplemented with 10% (v/v) DMSO. A good concentration of cells to freeze was 
considered to be 0.5-1.0 x 10
6
 cells/ml. Cell were initially frozen slowly to -80
o
C using a 
container containing isopropanol to avoid ice crystallisation damage of cells, then were stored 
in liquid nitrogen.      
 
2.5 - Husbandry, breeding and genotyping of mice 
Mice were housed in conventional open cages with litaspen premium 8/20 bedding, paper 
wool nesting and standard fun tunnel environmental enrichment. The animal husbandry was 
carried out at 11 hours dark versus 13 hours light, 20-23°C temperature and 45-60% 
humidity. The mice were given a diet of SDS RM3 expanded food pellets and standard 
drinking water. All procedures were performed in accordance with the UK Home Office 
“Animals (Scientific Procedures) Act 1986”.  
To yield different types of double genetically modified mice, YG8 and YG22 FXN GAA 
repeat expansion-containing transgenic mice (Al-Mahdawi et al. 2004) were cross-bred with 
each Msh2, Msh3, Msh6, Pms2 or Mlh1 heterozygous knockout mice (Baker et al. 1995;        
de Wind et al. 1995; Edelmann et al. 1996; de Wind et al. 1999). All mice were maintained 
in a predominant C57BL/6J (B6) genetic background. Each double transgenic mouse, 
containing the FXN
GAA
 transgene together with wild type (WT), heterozygous (Het) or 
homozygous MMR knockout (KO) allele, was then crossed with non-GAA transgenic mice 
to obtain the necessary offspring for subsequent analyses.     
Newborn mice were weaned between 3-4 weeks of age and were processed for initial 
genotyping of human FXN and MMR genes. The ears were clipped for identification and the 
tip of tail (<5mm) was biopsied by using local anaesthesia with ethyl chloride BP (Cryogesic, 
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Acorus Therapeutics) for DNA isolation and genotyping, including estimation of GAA repeat 
sizes and knockout genotypes for the mouse Msh2, Msh3, Msh6, Pms2 and Mlh1. To collect 
tissues, adult mice were humanely sacrificed, followed by dissection and flash freezing of 
tissues in liquid nitrogen. Each tissue was subsequently stored at -80°C. 
 
2.6 - Genomic DNA isolation 
Genomic DNA was extracted by applying the phenol/chloroform extraction method,              
to analyse GAA repeat size within different types of mouse tissue, as well as human cell 
lines. Briefly, 400µl of tail digestion buffer and 10µl of proteinase K (50mg/ml) were added 
to the collected samples in Eppendorf tubes, followed by brief vortexing and incubation 
overnight at 55°C. After digestion, 400µl of phenol was added and samples were mixed well 
by vortexing twice for 15 seconds and then centrifuged at 14000 rpm for 5 minutes at room 
temperature. Subsequently, 380µl of the supernatant was transferred to a fresh Eppendorf 
tube and 380µl of chloroform/isoamyl alcohol (24:1, v/v) was added. Samples were briefly 
vortexed and centrifuged again at 14000 rpm for 5 min at room temperature. Next, 350µl of 
the resulting supernatant was transferred to a fresh Eppendorf tube and 35µl of 3M              
Na-acetate (pH 5.2) was added. 700µl of absolute ethanol was then added to the tubes and 
samples were mixed well by inverting tubes several times. Subsequently, samples were 
incubated at -80°C for 10 minutes followed by centrifugation at 14000 rpm for 30 minutes at 
4°C. The ethanol was removed and the pellets washed with 1ml of 70% ethanol. The samples 
were again centrifuged at 14000 rpm for 20 minutes at 4°C and then ethanol were carefully 
drained off and DNA pellets were air dried by inverting the Eppendorf tubes on paper towels 
for about 10 minutes. The DNA pellets were finally resuspended in 50-100µl of TE buffer 
and stored at 4°C.         
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2.7 - Determination of genomic DNA quantity and 
purity 
Genomic DNA samples were quantified by using NanoDrop™ 2000c spectrophotometer 
(NanoDrop, Thermo Scientific). The concentration of samples was determined by detecting 
absorption (A) of ultra violet light (UV-light) at 260nm and their purity was verified by 
analysing A260/280 ratio.  
 
2.8 - Polymerase chain reaction (PCR) 
Various polymerase chain reaction (PCR) amplification systems were utilised on                  
200-500ng of bulk genomic DNA samples to identify the different TNR repeat sizes and 
genotype MMR genes.   
2.8.1 - Mycoplasma PCR screening of cell cultures 
In order to importance of regularly checking cell lines for any signs of contaminations, 
mycoplasma PCR was carried out using a Mycosensor™ PCR Assay Kit (Stratagene). 
Briefly, 100μl of medium supernatant was transferred carefully from a culture flask into a 
sterile 1.5ml Eppendorf tube and incubated for 5min at 95°C in a water bath. 10μl strataclean 
was added to the tube and mixed well by flicking the tube followed by the centrifugation. 
Then, 20-50μl of sample was taken from the supernatant (this was acted as a template) and 
placed on ice. Mycoplasma PCR mastermix was prepared by adding the following reagents in 
order: 33μl dH2O, 5μl of 10x PCR buffer (Qiagen), 1μl Q-buffer (Qiagen), 2.5μl of 10mM 
dNTP mix, 1μl primer mix, 2μl Taq DNA polymerase, 5μl internal control and 5μl test 
sample. PCR amplification was performed in 250µl tubes using a thermal cycler (PTC-225, 
MJ Research) and the cycling conditions were as described for “PCR using Taq DNA 
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polymerase” in the Table 2.3. To visualise the results, 10-15μl of PCR products were 
separated in 1-2% agarose TBE mini-gels along with a 1Kb
+
 DNA ladder (Invitrogen) at     
75V for approximately 30 minutes.     
 
Table 2.3 - Mycoplasma PCR cycling parameters (adapted from www.stratagene.com). 
Cycle(s)  Temperature 
PCR using  
Taq DNA 
polymerase  
PCR using  Taq 
DNA 
polymerase  
with 
dUTP/UNG 
decontamination  
PCR using 
the 
Brilliant   
Q-PCR 
mastermix  
PCR using the 
Brilliant Q-PCR 
mastermix with 
dUTP/UNG 
decontamination 
1x 
37°C ---------  10 minutes  ---------- 10 minutes 
94°C ---------  10 minutes 10 minutes 10 minutes 
35x 
94°C 30 seconds 30 seconds 30 seconds 30 seconds 
55°C 1 minute 1 minute 1 minute 1 minute 
72°C 1 minute 1 minute 1 minute 1 minute 
 
2.8.2 - GAA PCR 
The conventional PCR amplification of GAA repeat sequences was performed on genomic 
DNA samples using GAA-F and GAA-R primers (refer to the table 2.1). The reaction was 
performed in a volume of 25μl containing DNA template, 50μM primers, mastermix (MgCl2, 
Taq DNA polymerase, dNTPs; Qiagen), Q-buffer, and DNase-free water (Table 2.4). Positive 
and negative controls of PCR were included in each series of samples. PCR amplification 
was performed in the 250µl tube using a specific program by thermal cycler machine         
(PTC-225, MJ Research) according to the Table 2.4. PCR reaction tubes were initially heated 
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at 94°C for 2 minutes. Next, the PCR program was run for 10 cycles followed by another    
20 cycles with increment time of extension (20 seconds) per cycle. Finally, the program was 
terminated by cooling tubes at 68°C for 6 minutes.     
  
Table 2.4 - GAA PCR materials and conditions. 
 
*: time increased by 20 second increments per cycle.  
 
 
To analyse the results, a mixture of 8µl PCR product and 2µl of 6x orange G loading dye was 
run on a 1% ethidium-bromide stained agarose-TBE mini-gel along with 1Kb
+
 DNA size 
marker (Invitrogen) at 75V for approximately 30 minutes. Samples, positively identified for 
presence of the FXN
GAA
 transgene, were further analysed to better estimation of the GAA 
repeat sizes. This was achieved by loading the GAA-PCR products along with two size 
markers (1Kb
+
 and 100bp ladders; Invitrogen), then running in a 20cm-long 1.5% agarose 
TBE gel at 60-90V overnight. 
2.8.3 - Gradient-TNR-PCR 
Further to designing new primers (refer to the tTable 2.1), to investigate the size of other 
mouse TNR, two gradient-PCR (G-PCR) systems were initially performed for CAG and 
CGG repeats that are located on chromosomes 19 and 13, respectively. Reaction buffer was 
GAA PCR program Size of fragment 
                                       94°C    ------------------  2 minutes
Denaturation         94°C    ------------------  10 seconds 
Annealing              60°C    ------------------  30 seconds    10x
Extension               68°C    ------------------  45 seconds
Denaturation         94°C    ------------------  10 seconds 
Annealing              58°C    ------------------  30 seconds     20x
Extension               68°C    ------------------  1  minute*
                                68°C    ------------------  6  minutes
451bp + (GAA)n
         Materials                           PCR reaction (1x) 
-------------------------            ------------------------
  2x Qiagen master mix                       12.5µl
  Q-buffer                                            5µl
  50µM GAA-F primer                        1µl
  50µM GAA-R primer                        1µl
  dH2O                                               4.5µl
  Genomic DNA (200-500ng/µl)          1µl                           
--------------------------           ------------------------
           Total                                       25µl
Reaction materials 
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prepared in a total volume of 25μl consisting of DNA template, 50μM primers (forward and 
reverse), mastermix (MgCl2, Taq DNA polymerase, dNTPs, loading dye; Kapabiosystems) 
and DNase-free water (Table 2.5). PCR amplification was performed in the 250µl tube using 
a specific program containing 4 different annealing temperatures (58°, 60°, 62° and 64°C). 
The G-PCR was performed in a 35-cycle program by thermal cycler machine (PTC-225, MJ 
Research) according to the table 2.5. As the initial and final steps, the program was followed 
respectively by heating tubes at 94°C for 2 minutes and cooling at 72°C for 10 minutes. To 
analyse the results, 10-15µl PCR product was run in 1% ethidium bromide stained agarose 
TBE mini-gel along with 1Kb
+
 DNA size marker at 70V for approximately 30 minutes.          
 
Table 2.5 -  Mouse gradient CAG and CGG PCRs. 
 
 
 
2.8.4 - TNR-PCR 
 Following G-PCRs, the optimal annealing temperature was selected to amplify CAG or CGG 
repeats obtained from mouse genomic DNA. PCR reaction content was the same as for        
G-PCR systems, in a total volume of 25µl. Negative and positive controls were included into 
each round of samples. Each PCR reaction was performed in a 250µl tube (Fisher Scientific) 
using a thermal cycler (PTC-225, MJ Research) in 35 cycles of amplification as shown in the 
Table 2.6. 
Reaction materials Gradient PCR program Size of fragment 
        Materials                            PCR reaction (1x) 
  --------------------------              ---------------------------
  2x Kapa mastermix                             12.5µl
  50µM forward primer                          0.3µl
  50µM revrse primer                             0.3µl
  dH2O                                                10.9µl
  Genomic DNA (200-500ng/µl)             1µl
 --------------------------               --------------------------
           Total                                          25µl
                                   94°C    ------------------  2 minutes
Denaturation           94°C    ------------------  45 seconds           
Annealing        58°, 60°, 62° and 64°C -----  30 seconds      35x   
Extension                 72°C   -------------------  45 seconds                     
                                   72°C    ------------------- 10 minutes
CAG fragment size:     293+(CAG)n                                                              
CGG fragment size:      569+(CGG)n    
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Table 2.6 - Mouse CAG and CGG PCRs. 
 
 
Following on the amplifications, 10µl of PCR products along with 5µl of 1Kb
+ 
size marker 
were run on 1% ethidium-bromide stained mini-agarose-gel with 1x TBE buffer at 70V for 
30 minutes, to detect the quality of samples. Subsequently, using two types of size markers 
(1Kb
+
 and 100bp ladders), the size of relevant TNR for each sample was determined by 
running on 20cm-long 1.5% agarose gel at 60-90V, overnight.  
2.8.5 - MMR-PCRs 
A multiplex PCR was carried out on each double genetically altered mouse (FXN
GAA+
/MMR) 
genomic DNA sample to detect the MMR genotype. A total volume of 25µl reaction buffer 
was prepared for each sample containing DNA template, 3 types of the relevant MMR gene 
primers (refer to the Table 2.1) with concentration of 50µM, mastermix (including: MgCl2, 
Taq DNA polymerase, dNTPs, loading dye; Kapabiosystems) and DNase-free water (Table 
2.7). For each experiment a negative control was applied as well as 3 positive controls 
demonstrating different genotypes of the relevant MMR gene (e.g. Msh2-WT, Msh2-Het and 
Msh2-KO). PCR reactions were prepared in 250µl tubes using a thermal cycler (PTC-225, 
MJ Research) and performed in a 35 cycles of amplification, according to the Table 2.7. Each 
Reaction materials  PCR program Size of fragment 
        Materials                            PCR reaction (1x) 
  --------------------------              ---------------------------
  2x Kapa mastermix                             12.5µl
  50µM forward primer                          0.3µl
  50µM revrse primer                             0.3µl
  dH2O                                                10.9µl
  Genomic DNA (200-500ng/µl)             1µl
 --------------------------               --------------------------
           Total                                          25µl
                                   94°C    ------------------  2 minutes
Denaturation           94°C    ------------------  45 seconds           
Annealing                62°C    ------------------  30 seconds     35x   
Extension                 72°C   -------------------  45 seconds                     
                                   72°C    ------------------- 10 minutes
CAG fragment size:     293+(CAG)n                                                              
CGG fragment size:      569+(CGG)n    
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PCR program was initiated by heating tubes at 94°C for 2 minutes and terminated by cooling 
samples at 72°C for 10 minutes. Subsequently, analysis of results was carried out by 
electrophoresis of PCR products, along with a 1Kb
+
 size marker, on a 1-2% ethidium 
bromide stained agarose gel with 1x TBE buffer.      
  
Table 2.7 - Mouse MMR-PCRs. 
 
Pms2 -WT fragment size: 385bp 
Pms2 -KO fragment size: 189bp
Pms2
Mlh1
          Materials                          PCR reaction (1x) 
--------------------------              ---------------------------
2x Kapa matermix                             12.5µl
50µM primer-1                                  0.3µl
50µM primer-2                                  0.3µl                               
50µM primer-3                                  0.3µl
dH2O                                              10.9µl
Genomic DNA                                  1µl                             
--------------------------              ---------------------------
         Total                                       25µl
                                   94°C    ------------------  3 minutes
Denaturation           94°C    ------------------  45 seconds           
Annealing                55°C    ------------------  30 seconds     35x   
Extension                 72°C   -------------------  45 seconds                     
                                   72°C    ------------------- 3 minutes
Mlh1 -WT fragment size: 350bp 
Mlh1- KO fragment size: 500bp
PCR name
Msh2 /Msh3 /  
Msh6
          Materials                          PCR reaction (1x) 
--------------------------              ---------------------------
2x Kapa matermix                             12.5µl
50µM primer-1                                  0.3µl
50µM primer-2                                  0.3µl                               
50µM primer-3                                  0.3µl
dH2O                                              10.9µl
Genomic DNA                                  1µl                             
--------------------------              ---------------------------
         Total                                       25µl
                                   94°C    ------------------  2 minutes
Denaturation           94°C    ------------------  45 seconds           
Annealing                49°C    ------------------  30 seconds     35x   
Extension                 72°C   -------------------  45 seconds                     
                                   72°C    ------------------- 10 minutes
Reaction materials  PCR program Size of fragment 
          Materials                          PCR reaction (1x) 
--------------------------              ---------------------------
2x Kapa matermix                             12.5µl
50µM primer-1                                  0.3µl
50µM primer-2                                  0.3µl                               
50µM primer-3                                  0.3µl
dH2O                                              10.9µl
Genomic DNA                                  1µl                             
--------------------------              ---------------------------
         Total                                       25µl
                                   94°C    ------------------  1 minute
Denaturation           94°C    ------------------  30 seconds           
Annealing                60°C    ------------------  30 seconds     30x   
Extension                 72°C   -------------------  1 minute                     
                                   72°C    ------------------- 10 minutes
Msh2 -WT fragement size: 164bp          
Msh2 -KO fragement size:  194bp                                                                             
Msh3 -WT fragement size: 130bp           
Msh3 -KO fragement size:  250bp       
Msh6 -WT fragement size: 220bp            
Msh6 -KO fragement size:  253bp
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2.9 - Isolation of total RNA 
Isolation of total RNA was performed using two different methods: column based 
(NucloSpin
®
 RNA II) and phenol-guanidine isothiocyanate based (TRIzol
®
) techniques. The 
former method was only utilised for human cerebellum to yield a better quality of total RNA.   
2.9.1 - RNA extraction-NucloSpin
®
 RNA II 
Total RNA was extracted from human cerebellum tissues, using NucloSpin
®
 RNA II 
according to manufacturer instructions (Macherey-Nagel). In this method, 30-50mg 
cerebellum tissue samples were manually homogenised in 350µl RA1 lysis buffer and 3.5µl 
β-mercaptoethanol, by passing the lysate several times through a 0.6mm needle fitted to         
a syringe. After vigorously vortexing, the viscosity of samples was reduced and the lysate 
was cleaned by using a filter tube (NucloSpin
® 
filter) and centrifugation at 11000 rpm for                
1 minute. The NucloSpin
® 
filter tube was then discarded and 350µl ethanol (70%) was added 
to the cleaned lysate in a fresh Eppendorf tube and mixed well by vortexing. The lysate was 
loaded to a NucloSpin
®
 RNA II column, placed in a collection tube, and centrifuged at 11000 
rpm for 1 minute. The collection tube, containing the aqueous phase, was subsequently 
discarded and NucloSpin
®
 RNA II column was again placed in a fresh collection tube. Later, 
350µl membrane desalting buffer (MDB) was added to this column and the sample was 
centrifuged in 11000 rpm for 1 minute.  Once again, the tube containing aqueous phase was 
discarded. To digest DNA, 95µl DNase reaction mixture was directly added on to the centre 
of silica membrane of the column and the sample was incubated at room temperature for           
15 minutes. The NucloSpin
®
 RNA II column was then washed by 200µl buffer RA2,                 
to inactive rDNase, followed by centrifugation at 11000 rpm for 30 seconds. Next, the 
column was washed by 600µl buffer RA3 and centrifuged 11000 rpm for 30 seconds. Once 
again, the column was washed by adding 250µl buffer RA3 and centrifugation at 11000 rpm 
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for 2 minutes. Eventually, 30-50µl RNase-free water was added to the column, followed by 
centrifugation at 11000 rpm for 1 minute. The quality and quantity of RNA samples were 
determined by performing 1% agarose gel electrophoresis and NanoDrop™ 
spectrophotometer (see the section 2.7), respectively.  
2.9.2 - RNA extraction- TRIzol
®
 method 
Total RNA was extracted from human and mouse cell lines and tissues using the TRIzol
®
 
method, following supplier guidelines (Invitrogen). About 10
6
 cells or 70-100mg tissue was 
used to extract the total RNA. Each cell pellet was initially loosened by flicking the tube 
gently and resuspended in 1ml TRIzol
®
. Individual tissues were likewise homogenised 
manually in 1ml of Trizol
®
 reagent. Samples were then incubated for 10 minutes at room 
temperature. 200µl chloroform was added per 1ml TRIzol
®
 to each sample, followed by 
vigorous shaking for 15 seconds and incubation for further 15 minutes at room temperature. 
Samples were phase separated by centrifugation at 14000 rpm for 15 minutes at 4°C.              
The upper aqueous phase (about 500µl) was then transferred to a freshly labelled Eppendorf 
tube and RNA was precipitated by adding 500µl of isopropyl-alcohol. Samples were 
incubated for 10 minutes at room temperature and centrifuged at 14000 rpm for 15 minutes  
at 4°C. The supernatant was carefully removed and the RNA pellet was washed once with 
1ml of 75% ethanol (prepared with DEPC-treated water) and centrifuged again at 14000 rpm 
for 5 minutes at 4°C. The supernatant was subsequently removed carefully and the RNA 
pellet was briefly dried for a period of 5-10 minutes and resuspended in 20-50µl of double 
sterile DEPC-treated water, followed by incubation at 60°C for 10 minutes. The quality and 
quantity of RNA samples were then determined by performing 1% agarose gel 
electrophoresis and NanoDrop™ spectrophotometry (section 2.7), respectively. Total RNA 
samples were then stored at -80°C until use.   
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2.10 - DNase I treatment of RNA 
Total RNA samples were treated to prevent DNA contamination by using DNase I 
(amplification grade, Invitrogen). Essentially, 1µg RNA was added to an RNase-free 200µl 
microcentrifuge tube on ice, followed by adding 1µl DNase I reaction buffer                        
(10x concentrated) as well as 1µl DNase I (1unit/µl). The total volume of each sample was 
then made up to 10µl by adding DEPC-treated water. Samples were incubated at room 
temperature for 15 minutes. Subsequently, DNase I was inactivated by adding 1µl of 25mM 
EDTA, followed by incubation at 65°C for 10 minutes. The treated RNA samples were then 
stored at -80°C. 
 
2.11 - Complementary DNA (cDNA) synthesis 
Complementary DNA (cDNA) was synthesised by using a cloned AMV first-strand cDNA 
synthesis kit (Invitrogen). On ice, 2µl RNA (with total concentration of 1µg) was added to 
10µl primer component mastermix (7µl DEPC-treated water, 2µl of 10mM dNTP mix and 
1µl oligo(dT)20 primer). RNA and primer were denatured by keeping the samples at 65°C for 
5 minutes and immediately placing the samples on the ice. The following reagents were then 
added in order: 4µl of 5x cDNA synthesis buffer, 1µl DEPC-treated water, 1µl of              
100mM DTT, 1µl RNase-OUT™ (40 units/µl) and 1µl cloned-AMV-RT (15 units/µl).            
The 20µl reaction mixture was gently mixed by flicking the tube and briefly centrifuged to 
pull all contents to the bottom of tube. The reaction mixture was incubated at 55°C for 60 
minutes, followed by keeping the samples at 85°C for 5 minutes to terminate reverse 
transcription procedure. The cDNA samples were used immediately or stored at -20°C.   
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2.12 - Reverse transcriptase PCR (RT-PCR) 
Before performing mRNA quantification, different types of reverse transcriptase PCR         
(RT-PCR) were utilised to investigate the quality of cDNA samples.  
2.12.1 - G-RT-PCR for human MMR genes 
After designing new primers for each human MMR gene, G-RT-PCRs were performed on 
cDNA samples to optimise the amplification conditions. Each reaction mixture was prepared 
in a total volume of 25µl consisting of mastermix buffer (including: MgCl2, Taq DNA 
polymerase, dNTPs, loading dye; Kapabiosystems), 50µM primers (forward and reverse), 
DNase free water and cDNA sample with concentration of 400-500ng/µl, according to             
the table 2.8. PCR amplification was performed in 250µl tubes (Fisher Scientific) using          
a specific program for each MMR gene containing 3 different annealing temperatures         
(Table 2.8). A negative and a positive control of RT-PCR were applied for each annealing 
temperature within individual series of samples. The G-RT-PCR programs were carried out 
in a 35 cycles of amplification by using a thermal cycler machine (PCT-225, MJ Research 
Co.). As initial and final steps, the programs were followed by heating tubes at 94°C for         
2 minutes and cooling at 72°C for 10 minutes. To analyse the results, 10µl of PCR products 
along with a size marker were run in 1% ethidium bromide stained agarose gel with 1x TBE 
buffer at 60-70V for approximately 20-30 minutes.     
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Table 2.8 - G-RT-PCR for human MMR genes. 
 
Gradient   
RT-PCR 
name
MSH2
MSH3
MSH6
        Materials                                PCR reaction (1x) 
  --------------------------                   -------------------------
  2x Kapa matermix                                12.5µl
  50µM h-RT-MSH3-F primer                  0.5µl
  50µM h-RT-MSH3-R primer                 0.5µl
  dH2O                                                  10.5µl
  cDNA (400-500ng/µl)                             1µl
 --------------------------                     ------------------------
           Total                                           25µl
                          94°C    ------------------  2 minutes
Denaturation    94°C    ------------------  30 seconds           
Annealing    59°, 61° and 63°C ---------  45 seconds   35x   
Extension         72°C   -------------------  30 seconds                     
                         72°C    ------------------- 10 minutes
Fragment size: 173bp                                                                
        Materials                                PCR reaction (1x) 
  --------------------------                   -------------------------
  2x Kapa matermix                                12.5µl
  50µM h-RT-MSH6-F primer                  0.5µl
  50µM h-RT-MSH6-R primer                 0.5µl
  dH2O                                                  10.5µl
  cDNA (400-500ng/µl)                             1µl
 --------------------------                     ------------------------
           Total                                           25µl
                          94°C    ------------------  2 minutes
Denaturation    94°C    ------------------  30 seconds           
Annealing   63°, 65° and 67°C ----------  20 seconds   35x   
Extension         72°C   -------------------  35 seconds                     
                         72°C    ------------------- 10 minutes
Fragment size: 111bp                                                                
Reaction materials Gradient RT-PCR program Size of fragment 
        Materials                                PCR reaction (1x) 
  --------------------------                   -------------------------
  2x Kapa matermix                                12.5µl
  50µM h-RT-MSH2-F primer                  0.5µl
  50µM h-RT-MSH2-R primer                 0.5µl
  dH2O                                                  10.5µl
  cDNA (400-500ng/µl)                             1µl
 --------------------------                     ------------------------
           Total                                           25µl
                          94°C    ------------------  2 minutes
Denaturation    94°C    ------------------  30 seconds           
Annealing   60°, 63° and 65°C ----------  30 seconds   35x   
Extension         72°C   -------------------  45 seconds                     
                         72°C    ------------------- 10 minutes
Fragment size: 151bp                                                                
PMS2
MLH1
        Materials                                 PCR reaction (1x) 
  --------------------------                    -------------------------
  2x Kapa matermix                                    12.5µl
  50µM h-RT-PMS2-F primer                       0.3µl
  50µM h-RT-PMS2-R primer                      0.3µl
  dH2O                                                       6.9µl
  cDNA (400-500ng/µl; diluted 1:5)               5µl
 --------------------------                     -------------------------
           Total                                              25µl
                          94°C    ------------------  2 minutes
Denaturation    94°C    ------------------  30 seconds           
Annealing   60°, 63° and 65°C ----------  30 seconds   35x   
Extension         72°C   -------------------  45 seconds                     
                         72°C    ------------------- 10 minutes
Fragment size: 151bp                                                                
        Materials                                PCR reaction (1x) 
  --------------------------                   -------------------------
  2x Kapa matermix                                12.5µl
  50µM h-RT-MLH1-F primer                   0.5µl
  50µM h-RT-MLH1-R primer                  0.5µl
  dH2O                                                  10.5µl
  cDNA (400-500ng/µl)                             1µl
 --------------------------                     ------------------------
           Total                                           25µl
                          94°C    ------------------  2 minutes
Denaturation    94°C    ------------------  30 seconds           
Annealing   53°, 55° and 57°C ----------  30 seconds  35x   
Extension        72°C   -------------------  45 seconds                     
                         72°C    ------------------- 10 minutes
Fragment size: 250bp                                                                
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2.12.2 - RT-PCR 
After G-RT-PCR, the optimal annealing temperature was selected to amplify each MMR 
gene (Table 2.9). In addition, standard RT-PCR was performed for human FXN, human 
GAPDH and mouse Gapdh genes to determine the cDNA quality (Table 2.10).  
 
Table 2.9 - RT-PCR for the human MMR genes. 
 
 
 
 
 
MSH3
       Materials                            PCR reaction (1x) 
--------------------------              ---------------------------
2x Qiagen matermix                          12.5µl                                
Q-buffer                                            5µl
5µM forward primer                           1µl
5µM revrse primer                              1µl
dH2O                                                9.5µl
cDNA (300-500ng/µl)                         1µl
-------------------------               --------------------------
        Total                                        25µl
                         94°C    ------------------  2 minutes
Denaturation       94°C    ------------------  30 seconds           
Annealing            63°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  45 seconds                      
                           72°C    ------------------- 10 minutes
Fragment size: 173bp                                                        
MLH1
       Materials                            PCR reaction (1x) 
--------------------------              ---------------------------
2x Qiagen matermix                          12.5µl                                
Q-buffer                                            5µl
5µM forward primer                           1µl
5µM revrse primer                              1µl
dH2O                                                9.5µl
cDNA (300-500ng/µl)                         1µl
-------------------------               --------------------------
        Total                                        25µl
                           94°C    ------------------  2 minutes
Denaturation      94°C    ------------------  30 seconds           
Annealing            57°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  45 seconds                      
                           72°C    ------------------- 10 minutes
Fragment size: 250bp                                                        
RT-PCR 
name
Reaction materials RT-PCR program Size of fragment 
MSH2 / 
MSH6 / 
PMS2
       Materials                            PCR reaction (1x) 
--------------------------              ---------------------------
2x Qiagen matermix                          12.5µl                                
Q-buffer                                            5µl
5µM forward primer                           1µl
5µM revrse primer                              1µl
dH2O                                                9.5µl
cDNA (300-500ng/µl)                         1µl
-------------------------               --------------------------
        Total                                        25µl
                         94°C    ------------------  2 minutes
Denaturation       94°C    ------------------  30 seconds           
Annealing            65°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  1 minute                     
                           72°C    ------------------- 10 minutes
MSH2 fragment size: 151bp    
MSH6 fragment size:  111bp    
PMS2  fragment size:  151bp                                                     
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Table 2.10 - RT-PCR for FXN and GAPDH genes. 
 
 
 
As presented in the Table 2.9 and Table 2.10, a total concentration of 25µl reaction buffer 
was prepared for each sample consisted of mastermix buffer, Q-buffer (if necessary), 50µM 
primers (forward and reverse) of the relevant gene cDNA, DNase-free water and                
300-500ng/µl cDNA template. PCR amplification was performed in 250µl tube using                 
a specific RT-PCR program for each series of samples. All RT-PCR amplifications were 
carried out in a thermal cycler machine (PCT-225, MJ Research). As initial and final steps, 
the programs were followed by heating tubes at 94°C for 2 minutes and cooling at 72°C for 
10 minutes. Finally, the results were analysed by electrophoresis of 10µl RT-PCR product, 
Human 
GAPDH
        Materials                           PCR reaction (1x) 
  --------------------------              ---------------------------
  2x Kapa matermix                             12.5µl
  5µM forward primer                          1µl
  5µM revrse primer                             1µl
  dH2O                                               9.5µl
  cDNA (300-500ng/µl)                        1µl
 --------------------------               --------------------------
           Total                                       25µl
  
                           94°C    ------------------  2 minutes
Denaturation       94°C    ------------------  30 seconds           
Annealing            55°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  1 minute                     
                           72°C    ------------------- 10 minutes
Fragment size: 226bp                                                                
Human 
FXN
        Materials                           PCR reaction (1x) 
  --------------------------              ---------------------------
  2x Kapa matermix                              12.5µl
  5µM forward primer                           1µl
  5µM revrse primer                             1µl
  dH2O                                               9.5µl
  cDNA (300-500ng/µl)                        1µl
 --------------------------               --------------------------
           Total                                       25µl
                           94°C    ------------------  2 minutes
Denaturation       94°C    ------------------  30 seconds           
Annealing            55°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  1 minute                     
                           72°C    ------------------- 10 minutes
Fragment size: 172bp                                                                
Reaction materials RT-PCR program Size of fragment 
Mouse 
Gapdh
        Materials                           PCR reaction (1x) 
  --------------------------              ---------------------------
  2x Kapa matermix                             12.5µl
  5µM forward primer                          1µl
  5µM revrse primer                             1µl
  dH2O                                               9.5µl
  cDNA (300-500ng/µl)                        1µl
 --------------------------               --------------------------
           Total                                       25µl
                           94°C    ------------------  2 minutes
Denaturation       94°C    ------------------  30 seconds           
Annealing            55°C    ------------------  30 seconds      35x   
Extension            72°C   -------------------  1 minute                     
                           72°C    ------------------- 10 minutes
Fragment size: 81bp                                                                
RT-PCR 
name
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along with size marker (1Kb
+
 or 100bp), in 1% ethidium bromide stained agarose gel with  
1x TBE buffer at 60-70V, for approximately 20-30 minutes.     
 
2.13 - Quantitative real-time RT-PCR (qRT-PCR)     
Following cDNA quality analysis, quantitative real-time RT-PCR (qRT-PCR) was carried out 
using power SYBR
®
 green mastermix (Applied Biosystems) in a real time PCR machine 
(ABI prism 7900HT, Applied Biosystems). qRT-PCR reactions were performed in 96-well 
plates (Microamp, Applied Biosystems) in triplicates. A final volume of 20µl mastermix was 
prepared containing 10µl of 2x power SYBR
®
 green mastermix, 1µl of 5µM optimised 
respective forward and reverse primers (see the table 2.2 for the applied primers in different 
gene cDNAs), 5µl of (5x diluted) cDNA and distilled water. Samples were minimised to light 
exposure. Target and endogenous mastermixes were prepared separately and added to the 
plate with a repetitive electronic pipette (Rainin) followed by adding the cDNA. Then              
the plate was sealed with real time plate sealers (MicroAmp, Applied Biosystems) and           
the contents were mixed gently. The plate was then centrifuged for 1 minute at 1000 rpm to 
bring all the contents to the bottom of the wells. The cycling conditions varied according to 
the application and were optimised to amplify the different targets with similar efficiencies. 
Following qRT-PCR, a dissociation curve run was performed by increasing the temperatures 
gradually from 60°C to 95°C. Relative quantification values were identified by 2
-∆∆Ct
 method 
using SDS 2.4 and RQ manager software (Applied Biosystems).     
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2.14 - Statistical analysis 
Statistical analyses such as descriptive measurements and graphical visualisations were 
performed using Microsoft excel 2007 software. Significant differences of the frequency 
distributions of the intergenerational transmission of GAA repeat size (including three 
categories of “GAA repeat expansions”, “no changes”, and “GAA repeat contractions”) 
between groups of wild type, heterozygous or homozygous MMR knockout parental 
genotypes were determined by using 
2 
(Chi square) analyses. All other measurements, 
comparing two groups of sample, were analysed using the student’s t test to determine 
statistically significant difference of the values. A p value of 0.05 was chosen as the 
significance threshold. 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Results: The mismatch repair 
system protects against intergenerational 
GAA repeat instability in a FRDA mouse 
model 
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3.1 - Introduction 
To understand the potential effect of MMR proteins on intergenerational transmission of 
GAA repeat instability from parent to offspring, an in vivo model is considered to be the most 
useful approach. Since FRDA is a rare autosomal recessive disorder, detecting and comparing 
intergenerational GAA repeat instabilities of FRDA patients/carriers, carrying different levels 
of one particular mismatch repair protein (e.g. MSH2) is not possible. Precedents from in vivo 
model studies have confirmed the important role of transgenic mouse models to better 
understand molecular pathogenesis of FRDA disease and develop potential therapies. Thus, 
the YG8 and YG22 transgenic mice, containing 90 and 190 GAA repeats in the YG8 line and 
190 GAA repeats in the YG22 line, are the most efficient models exhibiting intergenerational 
and somatic instability of GAA repeat expansions. They also show similar molecular and 
phenotypic pathogenesis to human FRDA, including similar DNA methylation and histone 
modification epigenetic changes (Al-Mahdawi et al. 2004; Al-Mahdawi et al. 2008). These 
models are considered as good systems to test the effect of MMR proteins on the 
intergenerational instability of GAA repeat expansions, although the GAA repeat sizes are 
smaller than the average 500-600 GAA repeats found in FRDA patients. Therefore,                   
to develop improved larger GAA repeat models, breeding of transgenic mice was carried out, 
resulting in increased the number of mutational GAA repeat expansions from 90 and 190 to 
approximately 140 and 225 repeats in YG8 and from 190 to approximately 250-285 repeats 
in YG22 (Figure 3.1). 
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Figure 3.1 - Schematic representation of increasing GAA repeat expansions. 
 
 
 
 
 
The ethidium bromide-stained agarose gel image illustrates increased GAA expansions up to 
225 repeats in YG8 (blue arrow) and 285 repeats in YG22 (green arrow). Each PCR product 
contains 451bp sequences of flanking non-GAA repeat DNA within FXN intron 1. The blue 
star shows original YG9 parent (90 + 190 repeats) and the green star shows original YG22 
parent (190 repeats). YAC 1(38) is initial source of both YG8 and YG22.  
 
3.2 - Establishing genetically modified mice 
To find out the role of each MMR gene in intergenerational instability of GAA repeat 
expansions, it was initially necessary to generate human FXN transgenic mice in absence or 
presence of each MMR protein. To achieve this, Msh2, Msh3 and Msh6 heterozygous 
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knockout mice were obtained from H. Te Riele (de Wind et al. 1995; de Wind et al. 1999), 
defective Pms2 mice were obtained from D. Monckton and M. Liskay (Baker et al. 1995) and 
Mlh1 heterozygous knockout mice, established by Kucherlapati and colleagues, were 
commercially available from the Jackson laboratory (Edelmann et al. 1996).  
To generate different double genetically modified mice containing the FXN GAA repeat 
(FXN
GAA
) transgene together with wild type, heterozygous or homozygous MMR knockout 
alleles, either YG8 or YG22 FXN
GAA
 hemizygous mice (Al-Mahdawi et al. 2004) were    
cross-bred with one of Msh2, Msh3, Msh6, Pms2 or Mlh1 heterozygous knockout mice. Data 
analysis showed that almost 25% of the first generation (F1) pups simultaneously carried one 
hemizygous YG8 or YG22 FXN
GAA
 transgene as well as one MMR
+/-
 heterozygous allele. 
Later, interbreeding between FXN
GAA
/MMR
+/-
 (e.g. YG8-FXN
GAA
/Msh2
+/-
 double transgenic 
mouse) and relevant MMR
+/- 
(e.g. Msh2
+/-
)
 
transgenic mice produced different modifications 
of transgenic mice for each YG8 and YG22 lines in the second generation (F2); 
approximately 12.5% FXN
GAA
/MMR
+/+ 
or FXN
GAA
/MMR
-/-
 and 25% FXN
GAA
/MMR
+/-
. For the 
next step, each of the double genetically modified mice was bred, as either a male or a female 
parent, with non-transgenic mice to obtain the required offspring for subsequent analysis.     
 
3.3 - Mouse genotyping 
Following a small tail biopsy collection and genomic DNA isolation from the parent and 
offspring, two different PCRs were applied for genotyping of all pups in each generation:        
(i) MMR PCR in the relevant transgenic mouse model (e.g. Msh2-PCR was carried out at 
Msh2-transgenic mice) and (ii) GAA PCR. Msh2 genotyping was performed by using                
a multiplex PCR system, called Msh2-PCR, to discriminate between WT and KO alleles 
based on the size differences. Compared with a 1Kb
+
 DNA size marker (Invitrogen Inc.), the 
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length of WT and KO fragments were recognised as 164bp and 194bp, respectively. 
Therefore, a homozygous Msh2-WT genotype was revealed by the presence of only a 164bp 
fragment, a homozygous Msh2-KO genotype by the presence of only a 194bp fragment, and    
a heterozygous Msh2 genotype by the presence of both fragments. Msh2 genotyping was 
performed for each mouse within different generations of Msh2 double transgenic mouse 
model generation (Figure 3.2).  
 
 Figure 3.2 - Msh2-PCR product analysis. 
 
 
 
 
 
The image illustrates comparative standard PCR analysis of WT, Het and KO genotypes in 
Msh2 transgenic mouse samples, in 2% ethidium bromide-stained agarose gel.    
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Msh3-PCR was also a multiplex PCR system, carried out to analyse the Msh3 genotype          
in relevant transgenic mice (Msh3 double transgenic mouse line). Each specific band was 
measured against a 1Kb
+
 DNA size marker, showing a single 130bp length of fragment in 
Msh3-WT and a single 250bp length of fragment in Msh3-KO mice, while Msh3-Het mice 
showed both 130bp and 250bp fragments (Figure 3.3).     
  
 Figure 3.3 - Msh3-PCR product analysis. 
 
 
 
 
 
 
 
 
 
 
The image illustrates comparative standard PCR analysis of WT, Het and KO genotypes in 
Msh3 transgenic mouse samples in 2% ethidium bromide-stained agarose gel.    
 
By using a size marker against PCR products, in agarose gel electrophoresis, analysis of 
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WT, KO or both alleles (Heterozygous; Het) in each Msh6 double transgenic mouse. In this 
multiplex PCR analysis, the 220bp band represented WT fragment while KO fragment 
showed the length of 253bp (Figure 3.4).   
 
Figure 3.4 - Msh6-PCR product analysis. 
 
 
 
 
 
 
The image illustrates comparative standard PCR analysis of WT, Het and KO genotypes in 
Msh6 transgenic mouse samples in 2% ethidium bromide-stained agarose gel.    
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189bp and 450bp fragments represented presence of the KO allele in respectively Pms2 and 
Mlh1 (Figure 3.5). 
 
 Figure 3.5 - PCR product analysis for Pms2 and Mlh1. 
 
 
 
 
 
 
 
 
 
 
 
 
The images illustrate comparative standard PCR analysis of WT, Het and KO genotypes in 
(A) Pms2 transgenic mouse samples, (B) Mlh1 transgenic mouse samples in 2% ethidium 
bromide-stained agarose gel.    
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Further to MMR-PCR, standard GAA-PCR amplification was carried out for all different 
lines of transgenic mice. Initial analysis of the GAA-PCR products on small agarose gels 
demonstrated that some mice carried GAA repeats while the others did not carry the FXN
GAA
 
transgene. Due to the location of the GAA primers, all GAA-PCR products contain 451bp of 
DNA flanking the GAA repeat region within intron 1, together with the number of GAA 
repeats (Figure 3.6). All PCRs were confirmed using positive and negative controls, 
indicating specificity of the fragments in absence of any contamination. 
 
 Figure 3.6 - GAA-PCR product analysis. 
 
 
 
 
 
 
 
The image represents an example of the 1% ethidium bromide-stained agarose gels used to 
determine absence or presence of the FXN GAA repeat.  
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3.4 - Intergenerational GAA repeat instability 
analysis  
The effect of each MMR protein on the GAA intergenerational repeat instability was 
analysed in all GAA
+
 offspring compared to those of FXN
GAA+
 transgenic mouse parent by 
analysing GAA PCR products obtained from tail genomic DNA at almost 1 month of age. 
These studies were carried out in both male and female parents of either YG8 or YG22 
FXN
GAA+
 lines (except males in Pms2
-/-
 and both males and females in Mlh1
-/-
 which are 
sterile). In each case, three different parental genotypes were examined, including: 
FXN
GAA+
/MMR
+/+
, FXN
GAA+
/MMR
+/-
 and FXN
GAA+
/MMR
-/-
. The intergenerational transmitted 
GAA repeat size differences were classified into 3 different sub-classes for each subset: GAA 
repeat contractions, no-change and GAA repeat expansions.  
3.4.1 - Msh2 effects on transmission of GAA repeat instability  
To determine the effect of Msh2 on intergenerational transmission, GAA repeat sizes in 
parents and offspring were compared by long agarose gel electrophoresis (Figure 3.7). 
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Figure 3.7 - Representative example of intergenerational GAA repeat instability in the 
Msh2 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in a long agarose gel 
obtained from a YG22 GAA
+
/Msh2
+/-
 parent and 14 GAA
+
 offspring. M1= 100bp DNA size 
marker; M2= 1Kb
+
 DNA size marker.    
 
 
The sizes of GAA repeat fragments were analysed based on: (i) parental Msh2 genotypes: 
Msh2 homozygous wild type (Msh2-WT), Msh2 heterozygous (Msh2-Het) and Msh2 
homozygous knockout (Msh2-KO); (ii) FXN
GAA+
 transgene status (YG8 or YG22), and          
(iii) parental gender (paternal or maternal). In this study, the GAA repeat sizes were 
compared from 4 YG8 parental genotypes against their 54 YG8 offspring as well as from        
14 YG22 parental genotypes against their 107 YG22 offspring (Table 3.1).   
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Table 3.1 - FXN
GAA+
/Msh2 offspring numbers based on different characteristics. 
MMR line MMR genotype  FXN line gender 
No.            
of               
parents 
No.                     
of          
offspring  
Msh2 
WT 
YG8 
♂ 0 0 
♀ 2 26 
YG22 
♂ 2 15 
♀ 2 16 
Het 
YG8 
♂ 0 0 
♀ 1 13 
YG22 
♂ 3 42 
♀ 2 14 
KO 
YG8 
♂ 0 0 
♀ 1 15 
YG22 
♂ 3 14 
♀ 2 6 
  
 
Initial analysis of data showed a similar level of GAA repeat mutability (combined expansion 
and contraction frequencies) of 35-42% for each of YG8 or YG22 FXN
GAA+
/Msh2
+/+
 
transmission profiles. This degree of instability was raised up to almost 60% for both of 
FXN
GAA+
/Msh2
-/-
 transmission profiles (Figure 3.8). Although it was determined that the 
GAA repeat mutation level was increased by absence of Msh2 protein, it was important to 
understand whether this increase was due to increased GAA expansions or increased GAA 
contractions. Analysis of the parental YG8 FXN
GAA+
/Msh2
+/+
 transmissions revealed a similar 
frequency of expansions and contractions. In contrast, the frequency of no changes in GAA 
repeat size was notably greater than both expansions and contractions; almost 65% of all 
GAA repeat sequences. Further investigations demonstrated that loss of both Msh2 alleles 
resulted in significantly increased level of GAA contractions compared to expansions. 
Comparing GAA repeat sizes from Msh2
+/+
 intergenerational transmission with                
Msh2
-/-
 showed significantly elevated level of GAA repeat contractions and reduced level of                
no-changed GAA repeat size. The level of GAA expansions, in this analysis, is slightly 
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reduced from Msh2-WT towards Msh2-KO. These findings suggest that lack of Msh2 protein 
causes increased intergenerational GAA repeat mutability, with a significant bias towards 
contractions. However, this idea could not be expanded to the absence of Msh2 in only one 
allele, due to low levels of expansion and contraction seen in Msh2
+/-
 compared to both 
Msh2
+/+
 and Msh2
-/-
 (Figure 3.8A). In contrast to YG8 FXN
GAA+
/Msh2
+/+
, the frequency of 
GAA expansions was greater than contractions in YG22 FXN
GAA+
/Msh2
+/+
 offspring, while          
a similar level of no GAA repeat size change was observed (Figure 3.8).  
 
Figure 3.8 - The effect of Msh2 on intergerational GAA repeat sizes based upon GAA 
repeat-containing FXN transgenic. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) YG8 GAA
+
/Msh2:                
WT n=109, Het n=56, KO n=48. (B) YG22 GAA
+
/Msh2: WT n=55, Het n=142, KO n=50. 
 
 
Despite observing greater frequency of expansions than contractions from YG22 
GAA
+
/Msh2
+/+
  offspring, significantly increased level of contractions and decreased level of 
the no-changed GAA repeat size were observed from Msh2-KO offspring (Figure 3.8B). 
Interestingly, Msh2-Het showed a higher level of GAA repeat contractions compared to Msh2 
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homozygous WT and a lower level of GAA repeat contractions compared to Msh2 
homozygous KO, suggesting that by reducing the level of Msh2, the incidence of GAA 
contractions is gradually increased.   
Data was then analysed on the basis of difference in parental gender. There were 71 offspring 
from 8 paternal FXN
GAA+
/Msh2 genotypes and 90 offspring from 10 maternal FXN
GAA+
/Msh2 
genotypes (Table 3.1). Data analysis showed that 54-65% of GAA repeat sizes remained 
stable with no change and 35-46% of GAA repeat mutability was observed in each of 
paternal or maternal FXN
GAA+
/Msh2
+/+
 transmission profiles. The mutability levels were then 
increased to 56-61% for both paternal and maternal FXN
GAA+
/Msh2
-/-
 transmission profiles 
(Figure 3.9). 
 In paternal Msh2
+/+
 offspring the frequency of intergenerational expansions was significantly 
greater than contractions. However, more than 50% of offspring did not show any GAA 
repeat size change (Figure 3.9A). In absence of both Msh2 alleles, the level of no-changed 
GAA repeats and expansions were reduced, whilst the frequency of GAA repeat contractions 
was raised up to the same level of expansions: almost 28%. In comparison with Msh2
+/+
,        
the range of contractions was notably increased from Msh2
-/-
 mice transmission profiles, 
while the frequency of expansions was reduced. These results suggest that Msh2 disruption 
increases mutability level with a trend towards contractions.  Further analyses showed that 
even absence of a single Msh2 allele slightly increased the level of GAA contractions, 
implying that progressive reduction of the Msh2 expression level causes a gradually increased 
level of GAA repeat contractions.     
Maternal Msh2
+/+
 offspring showed less GAA repeat expansion frequency than paternal 
Msh2
+/+
 offspring. However, this was still greater than frequency of GAA repeat contraction 
in maternal transmission profiles. Analysing maternal Msh2
-/-
 GAA repeat transmissions 
showed that the level of contractions was remarkably increased, while the frequency of        
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no-changed GAA repeat size was remarkably reduced. However, the level of GAA repeat 
expansions remained almost stable in contrast to maternal Msh2
+/+
, indicating that loss of 
Msh2 protein leads to an increased frequency of transmitting GAA repeat contractions to 
offspring (Figure 3.9B).  
 
Figure 3.9 - The effect of Msh2 on intergerational GAA repeat sizes based upon perental 
genotypes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) Paternal GAA
+
/Msh2:                
WT n=32, Het n=114, KO n=32. (B) Maternal GAA
+
/Msh2: WT n=132, Het n=84, KO n=66. 
 
 
 
Ultimately, the combined results of GAA repeat transmission were analysed from                     
18 FXN
GAA+
 parents and 161 offspring based only on Msh2 genotypes (Table 3.1). Taken 
together, analysis of the data based only on Msh2 genotypes showed 38% mutability GAA 
repeats transmitted from Msh2 homozygous WT mice, while this level significantly increased 
to 59% for Msh2 homozygous KO mice (Figure 3.10, Table 3.2). These findings reveal that 
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fully disruption of Msh2 causes increased frequency of intergenerational GAA repeat 
mutability, although a notable frequency of the GAA repeat transmissions remained stable. 
To further understand the cause of increased mutability with depletion of Msh2,                       
the frequency of each expansion, contraction and no-changed level was analysed in different 
Msh2 genotypes. Comparing Msh2
+/+
 with Msh2
-/- 
GAA repeat sizes showed that the level of 
expansions remained stable, while GAA repeat contraction frequency was significantly 
increased in Msh2
-/-
 (Figure 3.10, Table 3.2). Moreover, the mean GAA repeat size variations 
for Msh2
-/-
 showed a bias towards contractions, compared with both the Msh2
+/+ 
and Msh2
+/-
 
(Table 3.3). Thus, it is proposed that Msh2 is not the principal cause of intergenerational 
GAA mutability (both expansions and contractions), but it is involved to some extent in 
mismatch repair process to protect the expanded GAA repeat from any more instability.  
 
Figure 3.10 - The effect of Msh2 on the intergerational GAA repeat sizes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission: WT n=164, Het n=198,          
KO n=98.  
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Table 3.2 - χ2 analysis of GAA repeat transmissions in Msh2 transgenic mice. 
Msh2 parental 
genotype 1  
Msh2 parental 
genotype 2  
χ2 value df P value 
Msh2
+/+
 Msh2
+/-
 4.04 2 0.132 
Msh2
+/+
 Msh2
-/-
 18.17 2 <0.001 
Msh2
+/-
 Msh2
-/-
 38.63 2 <0.001 
 
 
Table 3.3 - Mean transmitted GAA repeat size variations in Msh2 transgenic mice.  
Parent genotype  
Mean GAA repeat 
size increase of 
expansions  
Mean GAA repeat 
size increase of 
contractions 
Mean GAA repeat size 
variation of all 
transmissions  
Msh2
+/+
 + 2.6 -3.3 + 0.19 
Msh2
+/-
 + 2.6 -17.9 + 0.42 
Msh2
-/-
 + 2.6 -9.1 -2.54 
 
 
3.4.2 - Msh3 effects on transmission of GAA repeat instability  
To find out the effect of Msh3 protein on intergenerational transmissions, GAA repeat sizes 
were initially analysed in agarose gel electrophoresis by comparing FXN
GAA+
 offspring with 
those of the
 
parents (Figure 3.11).  
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Figure 3.11 - Representative example of intergenerational GAA repeat instability in 
Msh3 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in a long agarose gel 
obtained from a YG22 GAA
+
/Msh3
-/-
 parent and 12 GAA
+
 offspring. M= 100bp DNA size 
marker.    
 
To distinguish any GAA repeat size difference between parent and offspring, based on two 
different GAA repeat expansion-containing FXN transgenes with different Msh3 genotypes, 
data from 5 YG8 parents against 43 YG8 offspring and from 15 YG22 parents compared with 
129 YG22 offspring were analysed separately (Table 3.4).   
 
Table 3.4 - FXN
GAA+
/Msh3 offspring numbers based on different characteristics. 
MMR line 
MMR 
genotype  
FXN line gender 
No.            
of     
parents 
No.                 
of         
offspring  
Msh3 
WT 
YG8 
♂ 1 5 
♀ 1 12 
YG22 
♂ 1 8 
♀ 2 23 
Het 
YG8 
♂ 1 11 
♀ 0 0 
YG22 
♂ 3 21 
♀ 2 16 
KO 
YG8 
♂ 1 4 
♀ 1 11 
YG22 
♂ 4 44 
♀ 3 17 
P
a
re
n
t 
 
Offspring 
M 
800 bp 
1000 bp 
1200 bp 
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Initial analysis based on different transgene type showed that more than 60% of each YG8 or 
YG22 FXN
GAA+
/Msh3
+/+
 GAA repeat size transmissions remained with no GAA size change. 
However, this level significantly decreased in both of YG8 and YG22 FXN
GAA+
/Msh3
-/-
 
transmission profiles to less than 30% (Figure 3.12). In parallel the range of mutability level 
was raised to more than 70% in GAA repeat transmitted from Msh3
-/-
 offspring mice, 
suggesting that presence of Msh3 protein is necessary to protect GAA repeat size against 
mutability (Figure 3.12).   
 
Figure 3.12 - The effect of Msh3 on intergerational GAA repeat sizes based upon GAA 
repeat-containing FXN transgenic. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) YG8 GAA
+
/Msh3:                
WT n=36, Het n=33, KO n=15. (B) YG22 GAA
+
/Msh3: WT n=73, Het n=99, KO n=168. 
 
 
 
 
 
Analysis of the parental YG8 GAA
+
/Msh3
+/+
 transmissions showed a similar 8-12% 
frequency of expansions and contractions, while more than 80% of GAA repeat sizes did not 
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change. A similar profile was observed in Msh3 heterozygous transgenic mouse offspring 
GAA repeat sizes. In contrast, YG8 GAA
+
/Msh3
-/- 
analysis showed a sharply increased level 
of GAA repeat contractions and a reduced level of no-changed GAA repeat size from 80% to 
27% (Figure 3.12A). These observations reveal that absence of Msh3 in YG8 transgenic 
remarkably increases the GAA repeat instability errors towards contractions.  
In the case of YG22 GAA
+
/Msh3
+/+
, the frequency of expansions was almost 3 times more 
than contractions. However, similar to YG8, the combined level of expansions and 
contractions was still much less than the no-change GAA repeat size group (Figure 3.12). 
Compared with YG22 GAA
+
/Msh3
+/+
, Msh3
+/-
 transmission did not show any prominent 
difference in the level of no-change GAA repeat size, while this level was dramatically 
decreased in YG22 GAA
+
/Msh3
-/-
. Further analysis for Msh3
-/-
 transmissions showed a 
significant trend of mutations towards an increased level of GAA repeat contractions (more 
than 50%; Figure 3.12), suggesting that fully absence of Msh3 induces contractions of GAA 
repeat size. However, even the presence of one Msh3 allele might be enough to preserve the 
majority of the YG22 GAA repeat stability.  
Further analysis was carried out based on different parental genders, comprising 79 offspring 
from 11 paternal GAA
+
 genotypes and 129 offspring from 9 maternal GAA
+
 genotypes 
(Table 3.4). Data analysis showed that the range of mutability in each paternal or maternal 
FXN
GAA
/Msh3
+/+
 transmission profile was less than 50%. The level of mutability then showed 
a dramatic increase for both Msh2
-/-
 parental genders, compared with both wild type and 
heterozygous states (Figure 3.13). Analysing paternal Msh3
+/+
 GAA repeat sizes revealed 
similar levels of contractions and expansions, with twice as many stable GAA repeat 
transmissions (Figure 3.13A). In contrast, paternal Msh3
-/-
 transmission profiles showed              
a remarkable increased frequency of contractions, while the level of unchanged GAA repeat 
sizes significantly decreased and the frequency of GAA expansions remained similar                 
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to Msh3
+/+
 (Figure 3.13A). These findings suggest that the absence of Msh3 protein notably 
increases the intergenerational transmission of GAA repeat contractions. High levels of GAA 
repeat stability were observed from Msh3
+/- 
transmitting mice, indicating that even the 
presence of one Msh3 allele could be sufficient to protect GAA repeat against instability.           
In other words, even expression from a single allele is sufficient to produce adequate 
functional Msh3 protein to protect against increased levels of GAA repeat mutability.  
 
Figure 3.13 - The effect of Msh3 on intergerational GAA repeat sizes based upon 
perental genotypes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) Paternal GAA
+
/Msh3:                
WT n=23, Het n=94, KO n=130. (B) Maternal GAA
+
/Msh3: WT n=91, Het n=43, KO n=56. 
 
 
Maternal Msh3
+/+
 transmission profiles showed that 80% of GAA repeat sizes did not change 
and the low levels of contractions and expansions were similar. Heterozygous transmission 
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profiles demonstrated that the frequency of both GAA expansions and contractions were 
increased with a slight bias towards GAA repeat expansions. In contrast, loss of both Msh3 
alleles led to a dramatically increased level of contractions (Figure 3.13B). These findings 
suggest that absence of Msh3 protein leads to increase GAA repeat mutability with a notable 
bias towards greater frequency of GAA repeat contractions.       
Overall, analysis based only upon Msh3 genotype demonstrated that there is no difference 
between Msh3
+/+
 and Msh3
+/-
 transmission profiles. The level of mutability in both of these 
profile offspring was almost 25% with similar level of expansions and contractions, while the 
level of no-changed GAA repeat size was approximately 3 fold higher (Figure 3.14,             
Table 3.5).  
      
 
Figure 3.14 - The effect of Msh3 on the intergerational GAA repeat sizes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission: WT n=114, Het n=137,             
KO n=186.  
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Table 3.5 - χ2 analysis of GAA repeat transmissions in Msh3 transgenic mice. 
Msh3 parental 
genotype 1  
Msh3 parental 
genotype 2  
χ2 value df P value 
Msh3
+/+
 Msh3
+/-
 0.39 2 0.822 
Msh3
+/+
 Msh3
-/-
 64.4 2 <0.001 
Msh3
+/-
 Msh3
-/-
 67.5 2 <0.001 
 
 
In contrast, absence of both Msh3 alleles caused a significantly increased level of GAA 
repeat mutability, with a bias towards contractions (54%) rather than expansions (18%) 
expansions (Figure 3.14, Table 3.5). Furthermore, the mean GAA repeat size variations for 
Msh3
-/-
 showed a bias towards greater contraction size compared with both the Msh3
+/+ 
and 
Msh3
+/-
 (Table 3.6). These findings indicate that when Msh3 is fully disrupted, the GAA 
repeat mutability level is increased with a notable trend towards contractions, while presence 
of a single Msh3 allele can produce sufficient Msh3 protein to preserve GAA repeat stability. 
Since GAA instability persists in the absence of Msh3, it can be concluded that Msh3 protein 
is not the cause of intergenerational GAA repeat instability, but is involved in MMR 
processes to protect against intergenerational GAA repeat instability. 
 
 
Table 3.6 - Mean transmitted GAA repeat size variations in Msh3 transgenic mice. 
Parent genotype  
Mean GAA repeat 
size increase of 
expansions  
Mean GAA repeat 
size increase of 
contractions 
Mean GAA repeat size 
variation of all 
transmissions  
Msh3
+/+
 +2.2 -3.5 -0.19 
Msh3
+/-
 +2.7 -2.9 +0.03 
Msh3
-/-
 +3.7 -4.7 -1.88 
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3.4.3 - Msh6 effects on transmission of GAA repeat instability         
To investigate the effect of Msh6 protein on intergenerational transmission of GAA repeat 
instability, the GAA PCR products obtained from offspring were initially compared with 
those of the parent by long agarose gel electrophoresis (Figure 3.15).  
 
Figure 3.15 - Representative example of intergenerational GAA repeat instability in 
Msh6 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in a long agarose gel 
obtained from a YG22 GAA
+
/Msh6
+/-
 parent and 15 GAA
+
 offspring. M= 100bp DNA size 
marker.    
 
 
 
 
To determine intergenerational GAA repeat size differences between parent and offspring 
based upon Msh6 genotypes, 39 YG8 offspring were compared with 3 YG8 parents and 137 
YG22 offspring were compared with 13 YG22 parents (Table 3.7).  
800 bp 
1000 bp 
1200 bp 
Offspring 
M 
P
a
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n
t 
 Chapter 3 – The MMR system and intergenerational instability  
 
  114 
 
Table 3.7 - FXN
GAA+
/Msh6 offspring numbers based on different characteristics. 
MMR line 
MMR 
genotype  
FXN line gender 
No.             
of    
parents 
No.                 
of         
offspring  
Msh6 
WT 
YG8 
♂ 1 9 
♀ 0 0 
YG22 
♂ 1 17 
♀ 1 7 
Het 
YG8 
♂ 1 15 
♀ 0 0 
YG22 
♂ 5 55 
♀ 2 14 
KO 
YG8 
♂ 0 0 
♀ 1 15 
YG22 
♂ 3 29 
♀ 1 15 
 
 
Similar to Msh3, data analysis of the parental YG8 GAA
+
/Msh6
+/+
 transgenic mice 
transmission showed that more than 80% of GAA repeat sizes did not change (Figure 3.16A). 
In contrast, analyses of YG8 GAA
+
/Msh6
-/-
 transmission profiles showed that the frequency 
of no-changed GAA repeat size was reduced to almost half fold (about 44% of no-changed 
GAA repeat size), indicating a sharply increased level of GAA repeat mutability. The levels 
of transmitted contractions for Msh6-KO were similar to those of Msh6-WT and Msh6-Het, 
whilst the level of expansions was dramatically raised to 47%: almost 4 times more than 
Msh6-WT and Msh6-Het (Figure 3.16A). These findings suggest that a single Msh6 allele 
could be sufficient to the produce sufficient functional Msh6 protein to protect an expanded 
GAA repeat against further instability. In contrast, complete absence of Msh6 protein 
dramatically increases the frequency of YG8 GAA repeat instabilities towards expansions. 
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Figure 3.16 - The effect of Msh6 on intergerational GAA repeat sizes based upon GAA 
repeat-containing FXN transgenic. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) YG8 GAA
+
/Msh6:                
WT n=27, Het n=45, KO n=43. (B) YG22 GAA
+
/Msh6: WT n=38, Het n=196, KO n=138. 
 
 
 
Compared to YG8, the level of mutability was significantly greater in YG22 GAA
+
/Msh6
+/+
. 
However, the frequency of both expansions and contractions were still remarkably lower than 
no-changed GAA repeat size. Loss of one Msh6 allele produced a trend towards a reduced 
level of no-changed GAA repeat sizes and increased mutability, with equal levels of 
expansions and contractions. Similar to YG8, loss of both Msh6 alleles in YG22 transmission 
profiles showed increased mutability level with a greater bias towards expansions               
(Figure 3.16B). Although loss of one Msh6 allele showed remarkable difference between 
YG8 and YG22 mutability, absence of Msh6 consistently increased the size of expanded 
GAA repeat in both YG8 and YG22.  
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Further analysis was carried out based on different parental genders, comprising 125 
offspring from 11 paternal GAA
+
 genotypes and 51 offspring from 5 maternal GAA
+
 
genotypes (Table 3.7). Analysing paternal Msh6
+/+
 transmission of GAA repeats showed that 
the level of GAA repeat expansions is slightly higher than contractions, while the range of 
mutability overall was dramatically less than no-changed GAA repeat size (Figure 3.17A). 
Loss of only one Msh6 allele resulted in a promoted level of GAA repeat mutability. This 
trend was towards an increased frequency of GAA repeat expansions, however a slight 
increase was also observed in contraction frequencies. Loss of both Msh6 alleles resulted            
in even greater increases of mutability, with a notable bias towards GAA repeat expansions. 
 
Figure 3.17 - The effect of Msh6 on intergerational GAA repeat sizes based upon 
parental genotypes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) Paternal GAA
+
/Msh6:                
WT n=44, Het n=194, KO n=93. (B) Maternal GAA
+
/Msh6: WT n=21, Het n=47, KO n=88. 
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Analysing the maternal Msh6
+/+
 transmission profiles demonstrated that most GAA repeats 
were stable, but a greater level of mutability was observed in these offspring compared with 
paternal Msh6
+/+
. Analysis of maternal Msh6
-/-
 transmission profiles showed that the 
frequency of both contractions and expansions were increased. Interestingly, paternal and 
maternal Msh6
-/-
 transmission mutability levels showed contrasting results. Thus, paternal 
Msh6 deficiency produced an increased frequency of GAA repeat expansions, while maternal 
Msh6 deficiency produced increases of both GAA repeat expansions and contractions with          
a slight bias towards contractions (Figure 3.17B). Although the overall level of mutability 
was increased in both paternal and maternal GAA repeat transmissions, these results suggest 
that the trend of GAA repeat mutability frequencies differ towards either contractions or 
expansions based on the parental gender.  
Finally, intergenerational GAA repeat size transmissions were analysed from 16 parents and 
176 offspring based only upon Msh6 genotypes (Table 3.7). This revealed 37% GAA repeat 
mutability of Msh6-WT (FXN
GAA+
/Msh6
+/+
) transmission profiles, comprising 20% 
expansions and 17% contractions (Figure 3.18, Table 3.8). In contrast to Msh2 and Msh3, the 
level of GAA repeat stability was then significantly reduced with loss of only one Msh6 
allele. Mutability frequencies were increased to 54%, with a similar level of expansions and 
contractions. Loss of both Msh6 alleles caused further increases in GAA repeat instability. 
Compared with Msh6
+/-
, the level of expansions showed notable increase from Msh6
-/-
, while 
contraction level did not show any prominent change (Figure 3.18, Table 3.8). These findings 
suggest that a single allele of Msh6 can partially afford some protection, but both alleles of 
Msh6 are required for full protection, against GAA repeat instability. 
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Figure 3.18 - The effect of Msh6 on the intergerational GAA repeat sizes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission: WT n=65, Het n=241,                
KO n=181.  
 
 
Further, to investigate the dynamics of intergenerational GAA repeat transmissions, analysis 
of the mean GAA repeat size variations for Msh6
+/-
 and Msh6
-/-
 mice demonstrated a bias 
towards an increased mean GAA repeat size (Table 3.9). 
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Table 3.8 - χ2 analysis of GAA repeat transmissions in Msh6 transgenic mice. 
Msh6 parental 
genotype 1  
Msh6 parental 
genotype 2  
χ2 value df P value 
Msh6
+/+
 Msh6
+/-
 6.26 2 0.044 
Msh6
+/+
 Msh6
-/-
 23.25 2 <0.001 
Msh6
+/-
 Msh6
-/-
 12.87 2 <0.01 
 
 
 
Table 3.9 - Mean transmitted GAA repeat size variations in Msh6 transgenic mice. 
Parent 
genotype  
Mean GAA repeat 
size increase of 
expansions  
Mean GAA repeat 
size increase of 
contractions 
Mean GAA repeat 
size variation of all 
transmissions  
Msh6
+/+
 + 1.8 -3.6 -0.24 
Msh6
+/-
 + 6.2 -5.5 + 0.31 
Msh6
-/-
 + 3.7 -3.5 + 0.53 
 
 
3.4.4 - Pms2 effects on transmission of GAA repeat instability 
To determine the effect of Pms2 protein on intergenerational transmission of GAA repeats, 
the GAA PCR products obtained from offspring were compared with those of parents by long 
agarose gel electrophoresis (Figure 3.19). Analysis of paternal Pms2
-/-
 GAA repeat 
frequencies was not feasible, because Pms2 
-/-
 males are sterile.   
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Figure 3.19 - Representative example of intergenerational GAA repeat instability in 
Pms2 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in a long agarose gel 
obtained from a YG8 GAA
+
/Pms2
+/+
 parent and 5 offspring, and from a YG8 GAA
+
/Pms2
+/- 
parent  and 6 GAA
+
 offspring. M= 100bp DNA size marker.    
 
To determine intergenerational GAA repeat size differences between parent and offspring, 
data were analysed separately from 3 YG8 parental genotypes with 39 offspring and from         
13 YG22 parental genotypes with 137 YG22 offspring (Table 3.10). 
 
Table 3.10 - FXN
GAA+
/Pms2 offspring numbers based on different characteristics. 
MMR line 
MMR 
genotype  
FXN line gender 
No.                   
of              
parents 
No.                     
of         
offspring  
Pms2 
WT 
YG8 
♂ 3 21 
♀ 2 18 
YG22 
♂ 2 22 
♀ 0 0 
Het 
YG8 
♂ 1 23 
♀ 2 37 
YG22 
♂ 3 69 
♀ 0 0 
KO 
YG8 
♂ Sterile 0 
♀ 1 6 
YG22 
♂ Sterile 0 
♀ 1 14 
M
 
Offspring Offspring 
P
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n
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P
a
re
n
t 
 
1000 bp 
800 bp 
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YG8 GAA
+
/Pms2
+/+
 intergenerational transmission was stable for approximately 68% of 
GAA repeats, while mutability levels showed a bias towards expansions, with approximately 
24% expansions and 9% contractions (Figure 3.20A). Loss of one Pms2 allele increased the 
mutability level to 75%. Although the level of contraction was slightly increased, the 
majority of GAA repeat instability was towards expansions in Pms2 heterozygous 
transmission profiles. Transmission of GAA repeat sizes from YG8 Pms2
-/-
 showed a similar 
overall level of mutability to Pms2
+/-
, while the frequency of expansions was greater and the 
level of contraction was notably less than Pms2
+/-
 transmission profiles (Figure 3.20A). 
These findings indicate that similar to Msh6, lack of even one Pms2 allele results in greater 
instability levels with a bias towards expansions. Curiously, full absence of Pms2 protein not 
only causes further elevation of GAA repeat expansion, but also reduces the GAA contraction 
level. 
Similar to YG8, the majority (60%) of YG22 GAA
+
/Pms2
+/+
 intergenerational transmission 
profiles showed no change with GAA repeat size and similar levels of GAA contractions 
(22%) and expansions (18%) (Figure 3.20). YG22 GAA
+
/Pms2
+/-
 showed a degree of 
increased mutability level mainly towards expansions, although the frequency of contractions 
was also slightly increased. Loss of both Pms2 alleles caused a dramatic increase in 
mutability level, with expansions up to 99% and contractions down to zero. These findings 
confirmed the results from YG8, suggesting that absence of Pms2 protein prohibits 
intergenerational GAA repeat contractions and causes dramatically increased levels of 
expansions.    
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Figure 3.20 - The effect of Pms2 on intergerational GAA repeat sizes based upon 
transgene 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) YG8 GAA
+
/Pms2:                
WT n=102, Het n=256, KO n=18. (B) YG22 GAA
+
/Pms2: WT n=54, Het n=201, KO n=70. 
 
 
Further analysis was carried out based on different parental genders, comprising                       
135 offspring from 9 paternal GAA
+ 
genotypes and 75 offspring from 6 maternal GAA
+ 
genotypes (Table 3.10). Investigations of GAA repeat transmission profiles showed that the 
range of mutability was less than 50% in both paternal and maternal FXN
GAA+
/Pms2
+/+
 
genotypes. This instability level then dramatically increased in parental Pms2
+/-
 and Pms2
-/-
 
genotypes. Analysis of paternal Pms2
+/+ 
GAA repeat size transmissions showed slightly 
greater frequency of expansions than contractions, while more than 50% of GAA repeat size 
transmissions were stable (Figure 3.21A). Since Pms2 homozygous KO males are sterile, 
investigation of the paternal Pms2
-/-
 GAA repeat size transmission was not possible. 
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However, Pms2
+/-
 transmissions showed greater levels of GAA expansions and contractions 
compared to paternal Pms2
+/+
 values (Figure 3.21A).   
 
Figure 3.21 - The effect of Pms2 on intergerational GAA repeat sizes based upon 
perental genotypes. 
 
A                                                           B 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission. (A) Paternal GAA
+
/Pms2:                
WT n=102, Het n=296, KO parents are sterile. (B) Maternal GAA
+
/Pms2: WT n=54, Het 
n=161, KO n=88. 
 
 
 
 
 
Analysing the results of intergenerational transmissions obtained from maternal Pms2
+/+
 
mice showed that more than 75% of GAA repeats size did not change. Similar to paternal 
transmissions, the majority of maternal Pms2
+/+
 mutability was due to the GAA repeat 
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expansions (Figure 3.21B). The level of mutability from maternal Pms2
+/- 
transmission was 
significantly increased, showing a strong bias towards GAA repeat expansions. The level of 
mutability was increased in Pms2
-/-
 compared with Pms2
+/-
, although the frequency of 
contractions was reduced to almost 1% (Figure 3.21B). Overall, these findings suggest that 
loss of a single allele of Pms2 is similar to lack of both Pms2 alleles, with insufficient 
mismatch repair protein being produced to protect against maternal transmission of GAA 
repeat expansions. 
Ultimately, the intergenerational GAA repeat size transmissions were evaluated from                 
15 parents and 210 offspring, based only upon Pms2 genotypic states (Table 3.10). Data 
analysis revealed that almost 35% of all parental Pms2-WT transmissions presented GAA 
repeat mutability, including 22% expansions and 13% contractions (Figure 3.22, Table 3.11). 
Similar to Msh6, with the loss of one Pms2 allele the level of mutability was significantly 
increased with a notable bias towards expansions. Interestingly, further analysis showed that 
lack of both Pms2 alleles culminated in a sharply increased level of GAA repeat expansions 
up to 92%, while only 1% GAA repeat contraction was observed in these transmission 
profiles (Figure 3.22, Table 3.11). These findings suggest that, while one Pms2 allele exerts 
some protective effect against GAA repeat expansions, both Pms2 alleles are required to fully 
activate mismatch repair protection against GAA repeat expansions and perhaps promote 
contractions.       
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Figure 3.22 - The effect of Pms2 on the intergerational GAA repeat sizes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission: WT n=156, Het n=457,              
KO n=88. 
 
    
 
 
Table 3.11 - χ2 analysis of GAA repeat transmissions in Pms2 transgenic mice. 
Pms2 parental 
genotype 1  
Pms2 parental 
genotype 2  
χ2 value df P value 
Pms2
+/+
 Pms2
+/-
 66.63 2 <0.001 
Pms2
+/+
 Pms2
-/-
 111 2 <0.001 
Pms2
+/-
 Pms2
-/-
 57 2 <0.001 
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Further to analysing frequencies of intergenerational GAA repeat transmission, both Pms2
+/-
 
and Pms2
-/-
 transmissions also showed elevated mean GAA repeat size variations within their 
offspring in an allele-dose dependent manner (Table 3.12). 
 
Table 3.12 - Mean transmitted GAA repeat size variations in Pms2 transgenic mice. 
Parent 
genotype  
Mean GAA repeat 
size increase of 
expansions  
Mean GAA repeat 
size increase of 
contractions 
Mean GAA repeat 
size variation of all 
transmissions  
Pms2
+/+
 + 6.4 -8.2 +0.28 
Pms2
+/-
 + 5.7 -4.00 +1.93 
Pms2
-/-
 + 7.6 -1.00 +7.00 
  
 
 
3.4.5 - Mlh1 effects on transmission of GAA repeat instability 
To assess the effect of Mlh1 protein on intergenerational transmission of GAA repeat size 
instability, FXN
GAA+
 and Mlh1 Het mice were developed. Since both male and female      
Mlh1-KO transgenic mice are sterile (Edelmann et al. 1996), investigating the 
intergenerational GAA repeat transmission of these mice could only be done at the 
heterozygous level. Furthermore, only YG22 mice have thus far been investigated         
(Figure 3.23, Table 3.13).     
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Figure 3.23 - Representative example of intergenerational GAA repeat instability in 
transgenic Mlh1 model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in a long agarose gel 
obtained from a YG22 GAA
+
/Mlh1
+/+
 parent and 10 GAA
+
 offspring. M= 100bp DNA size 
marker.     
 
 
 
 Table 3.13 - FXN
GAA+
/Mlh1 offspring numbers based on different characteristics. 
MMR line 
MMR 
genotype  
FXN 
line 
gender 
No.             
of      
parents 
No.                 
of         
offspring  
Mlh1 
WT YG22 
♂ 2 10 
♀ 0 0 
Het YG22 
♂ 1 4 
♀ 3 17 
KO YG22 
♂ Sterile 0 
♀ Sterile 0 
 
 
 
Data analysis revealed that more than 85% of parental Mlh1-WT transmission profiles 
showed mutability with GAA repeat size, including 70% expansion and 17% contractions. 
This result is contrary to the previous intergenerational transmission results obtained from all 
Msh2
+/+
, Msh3
+/+
, Msh6
+/+
 and Pms2
+/+
 mice, which showed significantly greater levels              
Offspring 
P
a
re
n
t 
 
M
 
800 bp 
1000 bp 
1200 bp 
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of  no-changed GAA repeat sizes (Figure 3.24, Table 3.14). With loss of one Mlh1 allele, the 
frequency of contractions sharply increased to almost 75% while the level of expansions 
decreased to 19%. This was completely opposite to the observed levels of contractions and 
expansions from Mlh1-WT transmission profiles (Figure 3.24, Table 3.14). This suggests that 
Mlh1 protein could protect against intergenerational GAA repeat contractions and perhaps 
also promote expansions. However, to clarify this situation, more studies are required on 
further offspring.   
 
 
Figure 3.24 - The effect of Mlh1 on the intergerational GAA repeat sizes. 
 
Frequencies of GAA expansions, no chages and GAA contractions transmitted to offspring 
are presented as percentages of total GAA repat transmission: WT n=30, Het n=63. 
 
 
Table 3.14 - χ2 analysis of GAA repeat transmissions in Mlh1 transgenic mice. 
Mlh1 parental 
genotype 1  
Mlh1 parental 
genotype 2  
χ2 value df P value 
Mlh1
+/+
 Mlh1
+/-
 28.2 2 <0.001 
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3.5 - Potential effect of the MMR proteins on other 
TNR instability 
To find out whether the increased instability levels induced by defect of MMR proteins are 
specific for the expanded GAA repeat transgene or a more general effect for the other in vivo 
TNR sequences, transmission of a 12 repeat CGG sequence and a 21 repeat CAG sequences, 
located on mouse chromosome 19 and 13, respectively, were similarly analysed. After 
designing PCR primers, the optimal annealing temperature was detected by gradient PCR    
(G-PCR) for each CAG or CGG fragments, called G-CAG PCR and G-CGG PCR, 
respectively (Figure 3.25). Based on the PCR product quality, standard PCR systems were 
then designed with optimal annealing temperatures of 58°C for CAG PCR and 64°C for CGG 
PCR.    
 
 Figure 3.25 - Gradient PCR for CAG and CGG repeats. 
 
The images show the ethidium bromide-stained agarose gels used to determine             
gradient mouse (A) CGG-PCR and (B) CAG-PCR. M: 1Kb
+
 size marker. A.T: Annealing 
temperature.   
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Investigating the Msh2 effect on CGG repeat instabilities showed that lack of this protein 
increased mutability only towards CGG repeat expansions (Figure 3.26A, Table 3.15). 
However, Msh2 deficits increased both CAG repeat expansion and CAG repeat contraction 
frequencies (Figure 3.26B, Table 3.16).   
 
Figure 3.26 - Intergenerational CGG and CAG repeat instabilities in Msh2 transgenic 
mice. 
 
The image illustrates unstable transmission of (A) CGG tandem repeat (B) CAG tandem 
repeat from Msh2-WT compared with Msh2-KO. M: 100bp size marker, P: Parent.  
 
        
 
 
 
 Table 3.15 - Intergenerational CGG repeat instability frequencies in Msh2 mice. 
   CGG repeats Expansions (%) No change (%)  Contractions (%) 
Msh2 
WT 0 100 0 
KO  33.3 66.7 0 
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Table 3.16 - Intergenerational CAG repeat instability frequencies in Msh2 mice.   
   CAG repeats Expansions (%) No change (%)  Contractions (%) 
Msh2 
WT 0 100 0 
KO  10 75 15 
 
 
Compared with Msh2, lack of Msh3 resulted in reduced mutability level of the CGG repeat 
observed in Msh3
+/+
 mice offspring (Figure 3.27A, Table 3.17). Further analysis showed that 
Msh3 deficits did not change the mutability level of CAG repeat compared with Msh3
+/+
 mice 
offspring (Figure 3.27B, Table 3.18).   
 
   
Figure 3.27 - Intergenerational CGG and CAG repeat instabilities in Msh3 transgenic 
mice. 
 
The image illustrates unstable transmission of (A) CGG tandem repeat (B) CAG tandem 
repeat from Msh2-WT compared with Msh2-KO. M: 100bp size marker, P: Parent.  
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Table 3.17 - Intergenerational CGG repeat instability frequencies in Msh3 mice. 
   CGG repeats Expansions (%) No change (%)  Contractions (%) 
Msh3 
WT 50 28.6 21.4 
KO  0 100 0 
 
 
 
 
Table 3.18 - Intergenerational CAG repeat instability frequencies in Msh3 mice.   
   CAG repeats Expansions (%) No change (%)  Contractions (%) 
Msh3 
WT 16.7 62.5 20.8 
KO  33.3 66.7 0 
 
 
 
Similar to Msh3, the level of CGG repeat mutability was decreased with fully disruption of 
Msh6 compared to Msh6
+/+
 mice transmission (Figure 3.28A, Table 3.19). No CAG repeat 
mutability was observed neither with Msh6
+/+
 nor with Msh6
-/- 
transgenic mice. In other 
words, loss of Msh6 did not effect on the mutability level of CAG repeats (Figure 3.28B, 
Table 3.20).      
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Figure 3.28 - Intergenerational CGG and CAG repeat instabilities in Msh6 transgenic 
mice. 
 
 
The image illustrates unstable transmission of (A) CGG tandem repeat (B) CAG tandem 
repeat from Msh6-WT compared with Msh2-KO. M: 100bp size marker, P: Parent. 
 
 
Table 3.19 - Intergenerational CGG repeat instability frequencies in Msh6 mice. 
   CGG repeats Expansions (%) No change (%)  Contractions (%) 
Msh6 
WT 27.3 63.7 9 
KO  0 100 0 
 
 
Table 3.20 - Intergenerational CAG repeat instability frequencies in Msh6 mice.   
   CAG repeats Expansions (%) No change (%)  Contractions (%) 
Msh6 
WT 0 100 0 
KO  0 100 0 
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Analysing CGG repeat sizes showed greater mutability level with Pms2
-/-
 than Pms2
+/+
             
(Figure 3.29A, Table 3.21), while, similar to Msh3 and Msh6, no CAG repeat mutability was 
observed with both Pms2
+/+
 and Pms2
-/-
 states (Figure 3.29B, Table 3.22). No study has been 
carried out yet to determine the role of Mlh1 on CAG and CGG repeat instabilities.  
 
Figure 3.29 - Intergenerational CGG and CAG repeat instabilities in Msh6 transgenic 
mice. 
 
The image illustrates unstable transmission of (A) CGG tandem repeat (B) CAG tandem 
repeat from Msh2-WT compared with Msh2-KO. M= 100bp size marker, P= Parent. 
 
 
 
 
Table 3.21 - Intergenerational CGG repeat instability frequencies in Pms2 mice. 
   CGG repeats Expansions (%) No change (%)  Contractions (%) 
Pms2 
WT 0 100 0 
KO  25 50 25 
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Table 3.22 - Intergenerational CAG repeat instability frequencies in Pms2 mice.   
   CAG repeats Expansions (%) No change (%)  Contractions (%) 
Pms2 
WT 0 100 0 
KO  0 100 0 
 
 
 
Taken together, data analysis revealed minor effects of MMR protein deficits on                      
the mutability level of intergenerational CGG or CAG repeat, which are distinguishable from 
the effects of MMR proteins on intergenerational transmission of the expanded GAA repeat 
instabilities. Therefore, these findings confirm that is plausible to propose a specific influence 
of MMR proteins on intergenerational transmission of the expanded GAA repeat within the 
context of the FXN transgene sequence, rather than a general effect on any TNR. In future,         
it will similarly be necessary to investigate the effect of Mlh1 on CGG and CAG parental 
transmissions.  
  
3.6 - Discussion 
To investigate potential molecular mechanisms of intergenerational GAA repeat instability in 
FRDA, the effects of MMR proteins Msh2, Msh3, Msh6, Pms2 and Mlh1 were investigated 
during parent to offspring transmission of GAA repeats from YG8 and YG22 transgenic 
mice. Data analysis based upon parental MMR genotypes showed a similar mutability level 
of 25-37% for each of the Msh2-WT, Msh3-WT, Msh6-WT and Pms2-WT transmission 
profiles. This is consistent with previous findings for YG8 and YG22 transgenic mouse 
intergenerational instability (Al-Mahdawi et al., 2004). However, the data obtained from 
YG22 GAA
+
/Mlh1
+/+
 transmissions was not similar to the previous findings. The reason for 
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this finding is not clear yet. It is possible that there could be a genetic background difference 
in the YG22 GAA
+
/Mlh1
+/+
 mice. There may also be some effect due to the comparatively 
small number of Mlh1-WT intergenerational transmissions analysed compared with the other 
MMR-WT analyses. Further investigations are required to explain the disparity of these 
results. 
In this chapter, it has been shown that loss of MMR genes results in continued transmission 
of GAA repeat contractions and expansions over generations, but with a bias towards 
increased mutability. Thus, it is concluded that, during intergenerational GAA repeat 
transmissions, Msh2, Msh3, Msh6, Pms2 and Mlh1 are not the main cause of GAA 
mutability, neither contractions nor expansions, but they rather function in a repair capacity 
to protect against negative effects of GAA repeat instability. This would agree with the 
generally accepted functions of the mismatch repair system: (i) to identify and start the repair 
of small IDLs by Msh2-Msh3 heterodimers, (ii) to identify and start the repair of single base 
pair mismatches and single base IDLs by Msh2-Msh6 heterodimers, and (iii) the interaction 
of Mlh1-Pms2 heterodimers with one of Msh2-Msh3 or Msh2-Msh6 heterodimers to 
continue the repair process during replication and recombination. Despite their similarities, 
distinct differences were also detected between the effects of Msh2 and Msh3 compared with 
Msh6, Pms2 and Mlh1. Thus, Msh2 and Msh3 were found to protect against intergenerational 
GAA repeat contractions, whilst Msh6 was shown to have a minor protective effect against 
both contractions and expansions. Pms2 was found to significantly protect against expansions 
but also contribute to the promotion of contractions, whereas Mlh1 protects against 
intergenerational GAA repeat contractions and promotes expansions. To further investigate 
the role of MMR proteins on GAA repeats, the occupancy of each MMR protein (except 
Mlh1) around the expanded GAA repeats was compared with the normal GAA repeats by my 
colleague, Dr Sahar Al-Mahdawi, who performed ChIP assays at five regions of the YG8 and 
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YG22 FXN
GAA+
 transgenic mice (-1254, promoter, upstream GAA, downstream GAA and 
intron 2), compared with stable normal-sized GAA repeat-containing Y47 FXN transgenic 
mice. Consistent enrichment of Msh2 occupancy was observed at all 5 regions of the FXN 
locus in both YG8 and YG22 compared with Y47 mice. Although, the most significant level 
of Msh2 occupancy was detected at downstream GAA and the intron 2 regions. Similarly, 
Msh3 enrichment was found at downstream GAA and intron 2 regions (Figure 3.30).                  
In contrast, no difference of occupancy was observed at any region of the FXN locus for each 
of Msh6 and Pms2, with one exception of Msh6 enrichment at the downstream GAA region 
in YG22 mice (Ezzatizadeh et al. 2012). These findings suggest that rather than there being           
a single MMR mechanism in operation, at least two different MMR systems may be involved 
to identify and start intergenerational FRDA GAA mutability. One mechanism predominantly 
involves Msh2-Msh3 heterodimers, which play a role in limiting GAA repeat contractions.  
 
Figure 3.30 - MMR occupancy at 5 regions of the FXN locus (Ezzatizadeh et al. 2012). 
 
ChIP data showing Msh2, Msh3, Msh6 and Pms2 occupancy at 5 regions of the FXN locus: 
1254bp upstream of the transcription start site (−1254), promoter (Pro), upstream GAA (Up), 
downstream GAA (Down) and 11482bp downstream of the transcription start site (intron 2). 
Columns represent quantitative PCR data from IP samples relative to input. YG8 and YG22 
values are shown as fold changes relative to Y47 set at 1.0. * = P<0.05, ** = P<0.01. Error 
bars=s.e.m. of independent experiments, n=4. 
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The second mechanism predominantly involves Msh2-Msh6 heterodimers acting to limit 
GAA repeat expansions and/or contractions. Loss of Msh3 or Msh6 might cause an 
alternative MMR system to identify and start repairing expanded GAA repeat mutations. 
Depending on the loss of either Msh2 or Msh6 protein, GAA repeats might undergo a greater 
frequency of contractions or both expansions and contractions, respectively.  
The results from this study indicate that Pms2 is involved in the continuation of the MMR 
process to limit GAA repeat expansions. Therefore, Pms2 may be one protein of a MutLα 
heterodimer that mainly contributes to protecting expanded GAA repeats against further 
expansion by continuing the MMR processes initiated by MutSα heterodimers. However,           
the combination of the MutLα with MutSβ may also protect GAA repeats against both 
expansions and contractions. To find out the exact role of each MMR protein in the repair of 
GAA repeat expansions, it would be useful to establish triple genetically altered mice, 
simultaneously having defect of two co-operating heterodimers. Indeed, by generating double 
KO FXN
GAA+
 transgenic mice for both Msh2 and Msh3 genes, it may be possible to 
investigate the role and occupancy of the other MutS protein, Msh6, within expanded GAA 
repeat region.   
The findings of increased frequencies of GAA repeat contractions in the Msh2
-/-
 and Msh3
-/-
 
mice offspring, and to a lesser extent of Msh6
-/-
 mice, are in agreement to previous studies of 
HD and DM1 transgenic mice in which a similar effect of Msh2
-/-
 and Msh3
-/-
 and Msh6
-/-
 
deficits on CAG and CTG repeats was respectively observed (Foiry et al. 2006; Dragileva et 
al. 2009). This suggests a common MMR system by which all expanded TNR sequences are 
protected against intergenerational repeat contractions. However, there may be a difference in 
the way that the MMR system acts on expanded GAA versus CAG or CTG repeats, since 
there is no GAA repeat expansion loss in FXN transgenic mice as observed with CAG and 
CTG repeat expansions in HD and DM1 transgenic mice, respectively. Therefore, it is 
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proposed that, unlike MMR effects on CAG and CTG repeat expansions in HD and DM1 
disorders, Msh2 and Msh3 proteins are not considered to be essential for intergenerational 
GAA repeat expansions in FRDA (Savouret et al. 2003; Wheeler et al. 2003; Foiry et al. 
2006; Dragileva et al. 2009). This is probably due to differences in the secondary structure of 
GAA repeat expansions compared with CAG and CTG repeat expansions. For example, it is 
proposed that expanded CAG repeats form hairpin structures, which are recognised by MutSβ 
heterodimers, but they do not elicit a normal MMR repair function. In this hypothesis, known 
as “hijacking” of the MMR system, it is believed that instead there may be a non-canonical 
MutSβ binding DNA segment preventing repair and preserving repeat expansions 
(McMurray 2008). Another proposal suggests that there might be an alternative, as yet 
unknown, Msh2-dependent mechanism which induces CAG repeat expansions, independent 
of Msh3 and Msh6 proteins (Dragileva et al. 2009).  
Loss of Msh6 or Pms2 was shown to cause an increased frequency and size of GAA repeat 
expansions in an allele dose dependent condition. Thus, intergenerational GAA repeat 
expansions may occur when there is insufficient expression of Msh6 or Pms2 protein to 
produce a normally functioning MMR system. It has previously been observed that defect of 
Msh6 did not increase intergenerational CAG or CTG repeat expansion frequency in HD or 
DM1 transgenic mice. These findings are contrary to the increased GAA repeat expansions 
detected in Msh6-deficient FXN mice. However, increased somatic CTG repeat expansion 
sizes were observed in some tissues from Msh6-deficient DM1 transgenic mice (van den 
Broek et al. 2002). Thus far, our study is the only one to investigate the effect of Pms2 on 
intergenerational TNR instability. Therefore, it would be interesting to investigate the 
potential effect of Pms2 on the intergenerational instability of other TNR disorders             
(Gomes-Pereira and Monckton 2004). Overall, the MMR system would appear to have shown 
more differences than similarities when comparing its effects on GAA repeat expansions 
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versus CAG/CTG repeat expansions. This is likely to be due to the different ways that the 
MMR system recognises and acts upon the secondary structures of different TNRs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 - Results: The mismatch repair 
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4.1 - Introduction 
In addition to effects on intergenerational GAA repeat transmission, it is also essential to 
understand the potential effects of MMR proteins on somatic GAA repeat instability. Since 
FRDA is a tissue-selective disorder, investigation of an in vivo model is considered a more 
useful approach than an in vitro model to simultaneously study the effect of these proteins on 
GAA repeat instability within different tissues. However, this is not possible in humans, 
because FRDA affects critical organs, such as brain and cerebellum. Precedents from 
previous in vivo studies have shown transgenic mice to be useful models to investigate 
molecular mechanisms involved in FRDA and subsequently develop potential therapies.     
Of the currently available FRDA mouse models, YG8 and YG22 transgenic mice are 
recognised as good models since they exhibit similar somatic GAA instability to FRDA 
patients (Al-Mahdawi et al. 2004). Therefore, these mice were considered as good in vivo 
systems to determine the effect of MMR protein deficits on the somatic instability of GAA 
repeat expansions.  
 
4.2 - MMR effects on somatic GAA repeat instability 
To understand the role of each MMR gene in somatic GAA repeat instability, it was initially 
important to establish human GAA repeat-containing FXN transgenic mice with the presence 
or absence of each MMR protein. Thus, the same double genetically modified mouse models, 
as described in chapter 3, were generated by cross-breeding FXN
GAA+
 hemizygous mice 
together with MMR heterozygous knockout mice. Following a small tail biopsy collection, 
genomic DNA was isolated and two different PCRs were performed (including GAA-PCR 
and MMR-PCR; refer to the section 3.3), to genotype the mice.  
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4.2.1 - Msh2 effects on somatic instability of GAA repeat 
expansions   
Subsequent to initial genotyping, FXN
GAA+
/Msh2
+/+
 and FXN
GAA+
/Msh2
-/-
 transgenic mice 
were selected for both YG8 and YG22 lines and grown to at least 6 months of age. The 
objective of this study was to understand the dynamics of somatic GAA repeat instability by 
comparing multiple tissues of Msh2 proficient and deficient mice. Thus, somatic GAA repeat 
instability was analysed in two neural tissues (brain and cerebellum) and two non-neural 
tissues (liver and kidney) from Msh2 proficient and deficient mice of comparable age and 
gender, after confirming the genotypes. Analysis of tissues from Msh2-WT mice showed 
somatic GAA repeat instability for both YG8 and YG22 lines, with some expansion in the 
brain and the greatest expansion in the cerebellum. However, liver and kidney tissues showed 
stable GAA repeats. This result is consistent with previous observations indicating neural 
somatic tissue selectivity of progressive GAA repeat instability (Al-Mahdawi et al. 2004).    
In contrast, analysis of multiple tissues from Msh2-KO FXN transgenic mice demonstrated no 
significant difference in the size of GAA repeats in any tissues (Figure 4.1). Thus,                   
a comparison of Msh2-WT mice with Msh2-KO showed that progressive somatic GAA 
repeat expansions were lost in all tissues with the absence of Msh2, even in the cerebellum, 
which is the most unstable tissue for GAA repeat instability. This finding suggests that lack 
of Msh2 stabilises expanded GAA repeats and prevents further somatic GAA repeat 
expansion instability. In other words, the presence of Msh2 is one of the factors necessary for              
tissue-selective progressive somatic GAA repeat expansion instability in FRDA.        
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Figure 4.1 - Somatic GAA repeat instability in the Msh2 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in 1.5% long agarose gel 
obtained from YG8 and YG22 multiple tissues in absence or presence of Msh2 protein.      
M= 100bp size marker, B= brain, C= cerebellum, L= liver, K= kidney. 
 
 
4.2.2 - Msh3 effects on somatic instability of GAA repeat 
expansions   
Following initial genotyping, FXN
GAA+
/Msh3
+/+
 and FXN
GAA+
/Msh3
-/-
 transgenic mice were 
selected for YG22 lines and grown to 6 month of age. To investigate the dynamics of somatic 
GAA repeat instability, multiple tissues of Msh3-WT and Msh3-KO mice were compared. 
Somatic GAA repeat instability was analysed in two neural tissues (brain and cerebellum) 
and two non-neural tissues (heart and liver) from Msh3 proficient and deficient mice. As with 
the Msh2 mouse model, analysis of FXN GAA repeats within different tissues from       
Msh3-WT mice identified somatic GAA repeat instability, with greater expansions 
particularly in cerebellum, as previously described (Al-Mahdawi et al. 2004). Analysis of 
multiple tissues from Msh3-KO mice showed no significant difference in the size of GAA 
repeats in any tissue (Figure 4.2). This observation suggests that, as with Msh2, loss of Msh3 
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protects against somatic GAA repeat expansions. Therefore, it is tempting to speculate that 
Msh3 might be a factor causing tissue selectivity of somatic GAA repeat expansions in 
FRDA.    
 
 
 Figure 4.2 - Somatic GAA repeat instability in the Msh3 transgenic model. 
 
The image illustrates PCR products to determine GAA repeat sizes in 1.5% long agarose gel 
obtained from YG22 multiple tissues in absence or presence of Msh3 protein. M= 100bp size 
marker, B= brain, C= cerebellum, L= liver, H= heart. 
 
 
4.2.3 - Msh6 effects on somatic instability of GAA repeat 
expansions   
Subsequent to initial genotyping, FXN
GAA+
/Msh6
+/+
 and FXN
GAA+
/Msh6
-/-
 transgenic mice 
were selected for YG22 lines and grown to 4 month of age. The aim of this study was to 
determine the dynamics of somatic GAA repeat instability by comparing multiple tissues of 
Msh6 proficient and deficient mice. Thus, somatic GAA repeat instability was assessed in 
two neural tissues (brain and cerebellum) and two non-neural tissues (heart and liver) from    
Msh6-WT and Msh6-KO mice of comparable age and gender. Comparing FXN GAA repeats 
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within different tissues of Msh6-WT mice showed somatic GAA repeat instability in the 
YG22 line, with greater expansions particularly in cerebellum (Figure 4.3), as previously 
described (Al-Mahdawi et al. 2004). Investigations showed no difference in the size of the 
expanded GAA repeats in heart and brain tissues from both Msh6-WT and Msh6-KO mice. 
However, the results demonstrated changes in the cerebellum and to a lesser extent in the 
liver. Analysis of these tissues showed that there is still some residual GAA repeat expansion, 
but the extent of the expansion is not as great as in the WT mouse (Figure 4.3). Thus, it is 
proposed that Msh6 promotes further expansions of GAA repeats, while absence of this 
protein leads to reduced size of expanded GAA repeats, particularly in cerebellum tissue. 
Therefore, most likely Msh6 promotes somatic GAA repeat expansion to a lesser degree than 
Msh2 and Msh3. 
 
Figure 4.3 - Somatic GAA repeat instability in the Msh6 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in 1.5% long agarose gel 
obtained from YG22 multiple tissues in absence or presence of Msh6 protein. M= 100bp size 
marker, B= brain, C= cerebellum, H= heart, L= liver. 
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4.2.4 - Pms2 effects on somatic instability of GAA repeat 
expansions   
Following initial genotyping, FXN
GAA+
/Pms2
+/+
 and FXN
GAA+
/Pms2
-/-
 transgenic mice were 
selected for YG8 lines and grown to at least 5 month of age. The objective of this experiment 
was to understand the dynamics of somatic GAA repeat instability by comparing multiple 
tissues of Pms2 proficient and deficient mice. Thus, somatic GAA repeat instability was 
analysed in two neural tissues (brain and cerebellum) and two non-neural tissues (heart and 
liver) from Pms2-WT and Pms2-KO mice. 
Previously Al-Mahdawi and colleagues reported tissue selectivity of somatic GAA repeat 
expansions, indicating most instability with cerebellum tissue (Al-Mahdawi et al. 2004). 
Similarly, analysing multiple tissues of the Pms2-WT mouse showed that the frequency of 
expanded GAA repeats were increased in brain and particularly cerebellum compared with 
heart and liver tissues (Figure 4.4). This condition was also observed with Pms2-KO mouse. 
In other words, the tissue-selective progressive GAA repeat expansion was still observed 
even with the loss of Pms2. In fact, an even greater degree of GAA repeat expansions was 
observed in brain, and particularly cerebellum, with loss of Pms2 (Figure 4.4). Subsequently, 
Bourn and colleagues have confirmed these observations by performing small-pool GAA 
PCR of the same mouse tissues. They have confirmed that loss of Pms2 actually increases the 
GAA repeat instability towards expansions particularly in cerebellum and DRG tissues 
(Bourn et al 2012). This finding is contrary to the other mismatch repair observations (Msh2, 
Msh3 or Msh6), suggesting that Pms2 plays a different role in the tissue selectivity of GAA 
repeat expansions in FRDA. Thus, it is proposed that the presence of Pms2 might protect 
against further expansion of somatic GAA repeats, particularly in tissues that are highly 
sensitive to reduced levels of frataxin.        
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 Figure 4.4 - Somatic GAA repeat instability in the Pms2 transgenic model. 
 
The image illustrates PCR products to determine GAA repeat sizes in 1.5% long agarose gel 
obtained from YG8 multiple tissues in absence or presence of Pms2 protein. M= 100bp size 
marker, B= brain, C= cerebellum, H= heart, L= liver. 
 
 
 
4.2.5 - Mlh1 effects on somatic instability of GAA repeat 
expansions   
Subsequent to initial genotyping, FXN
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/Mlh1
+/+
 and FXN
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/Mlh1
-/-
 transgenic mice 
were selected for YG22 lines and grown to 3 months of age. Due to the tumour-forming 
effects caused by disruption of Mlh1 protein, the Mlh1-KO transgenic mice did not survive 
for more than 3 months. After confirming genotypes, to find out the dynamics of somatic 
GAA repeat instability, multiple tissues of Mlh1-WT and Mlh1-KO mice were compared 
together. In this study, somatic GAA repeat instability was analysed in two neural tissues 
(brain and cerebellum) and two non-neural tissues (heart and liver) from Mlh1 proficient and 
deficient mice.    
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Comparing multiple tissues from Mlh1-WT mice showed somatic GAA repeat instability, 
with greater expansions particularly in the cerebellum (Figure 4.5), as previously described 
(Al-Mahdawi et al. 2004). In contrast, tissues from Mlh1-KO mice showed no difference in 
the size of the GAA repeats. Thus, it was determined that the presence of Mlh1 caused 
somatic GAA repeat expansions, particularly in the cerebellum, while the absence of Mlh1 
caused stabilisation of GAA repeats (Figure 4.5). These findings suggest that, as with Msh2 
and Msh3, loss of Mlh1 results in stabilisation of GAA repeats. Therefore, it is proposed that 
Mlh1 protein is a necessary factor for tissue-selective somatic GAA repeat expansion in 
FRDA.   
 
 
 Figure 4.5 - Somatic GAA repeat instability in the Mlh1 transgenic model. 
 
 
The image illustrates PCR products to determine GAA repeat sizes in 1.5% long agarose gel 
obtained from YG22 multiple tissues in absence or presence of Pms2 protein. M= 100bp size 
marker, B= brain, C= cerebellum, H= heart, L= liver. 
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4.3 - Discussion 
To understand the potential molecular mechanisms of somatic GAA repeat expansion 
instability in FRDA, the role of MMR proteins Msh2, Msh3, Msh6, Pms2 and Mlh1 were 
investigated in multiple tissues from YG8 and YG22 transgenic mice. In this chapter, the 
results first revealed GAA repeat instability towards further expansion within neural tissues 
for each of the Msh2-WT, Msh3-WT, Msh6-WT, Pms2-WT and Mlh1-WT mice, confirming 
previously reported tissue selectivity of somatic GAA repeat expansions (Al-Mahdawi et al. 
2004). The results further showed that deficiency of each of the individual MMR genes could 
affect somatic GAA repeat expansions within different tissues. However, it seems that the 
MMR proteins do not all play the same functional role. Lack of Msh2, Msh3, Msh6 or Mlh1 
proteins resulted in stabilisation of the expanded GAA repeats in somatic cells. This might be 
due to either MMR protection against further GAA repeat expansions or induction of GAA 
repeat contractions in neural tissues, which appear to be the most sensitive tissues to frataxin 
deficiency. These findings also highlight two points. Firstly, the similar effect of these 
proteins on somatic GAA repeat expansions suggests that they may cooperate functionally. 
This would agree with the generally accepted role of the MutS MMR system, which acts as 
MutS  (Msh2/Msh6) and MutS  (Msh2/Msh3) heterodimers. Thus, disruption of Msh2, 
Msh3 or Msh6 proteins may cause dysfunction of one (Msh3 or Msh6) or both (Msh2) MutS 
heterodimers and subsequently have an effect on the frequency of somatic GAA repeat 
expansions. However, it is possible that the MutSα and MutSβ complexes interact differently 
with GAA loops. Provided they have similar functions, then MutSβ (Msh2/Msh3) could 
compensate for the absence of Msh6 deficits and subsequently cause GAA repeat expansions, 
and vice versa. However, if the MutS complexes do not act similarly, then each of the Msh3 
or Msh6 protein deficits could result in loss of a MutS complex function that prevents further 
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GAA repeat expansion, which agrees with the results in this thesis. Dysfunction of each MutS 
complex may prevent binding between the Msh2-ATPase domains of relevant MutS 
heterodimers to expanded GAA repeat loops. The absence of MutS proteins at the GAA 
repeat could consequently lead to efficient repair of the expanded GAA repeats by other 
DNA repair systems. Secondly, the effects of each of the Msh2, Msh3 or Msh6 proteins on 
GAA repeat stability promotes the idea that, not only are these proteins unable to repair 
mutations as MutSα or MutSβ heterodimers, leading to further GAA repeat expansions in 
neural tissues, but also that they may themselves cause increased frequency of the expanded 
GAA repeats by as yet unknown mechanisms.  
The findings of reduced somatic GAA repeat expansions in the Msh2
-/-
 and Msh3
-/-
 mice are 
in agreement with recent investigations of GAA repeat-containing human cellular systems 
(Halabi et al. 2012). Previous studies of HD and DM1 transgenic mice also showed similar 
effects of Msh2
 
and Msh3 deficits on CAG and CTG repeat expansions (van den Broek et al. 
2002; Savouret et al. 2003; Wheeler et al. 2003; Tome et al. 2009). This suggests a common 
MMR mechanism by which all expanded TNR sequences undergo further expansions 
through MutSβ heterodimers function. Therefore, aberration of Msh2 and/or Msh3 could 
protect TNR against expansions. Moreover, the results also show that Msh6 protein can 
increase the level of GAA repeat expansions. This finding has been confirmed by small-pool 
PCR studies carried out by Bidichandani and colleagues, showing a quantitatively significant 
effect of Msh6 on the expanded GAA repeats in FXN transgenic mice (Bourn et al. 2012). 
These findings suggest that interaction of Msh2-Msh6, as MutSα heterodimers, could also 
affect GAA repeat instability. In contrast, there might be a notable difference in the way that 
MutSα heterodimers act on the expanded GAA versus CAG or CTG repeats, since the loss of 
GAA repeat expansions in FXN
GAA+
/Msh6
-/-
 mice has not been observed with CAG and CTG 
repeat expansions in HD and DM1, respectively (van den Broek et al. 2002; Savouret et al. 
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2003; Wheeler et al. 2003; Tome et al. 2009). The mechanisms by which MutS complexes 
affect the GAA repeat expansions are not clear yet. However, it is proposed that non-
canonical looped-DNA structures may be a potential mutagenic cause of TNR expansions by 
binding with the MutS heterodimers and blocking the related ATPase activity. For example, 
it has been reported that the ATPase domain is a critical part of MSH2, playing a role in the 
full function of MSH2 protein within MutSβ complexes of MMR system. Thus, absence of 
this domain might lead to a condition similar to total lack of MSH2, particularly in some 
TNR diseases (Tome et al. 2009). Binding of the MSH2 ATPase domain with a TNR         
non-canonical loop structure may lead to error-prone instability within expanded TNR 
sequences, although the exact mechanism of this event are yet to be determined. 
Investigations have shown that reduced ATPase activity of the MutSβ complex upon binding 
to CAG hairpins causes blockage of ATPase activity and impaired repair of CAG hairpins, 
leading to further CAG repeat expansion (Owen et al. 2005). Other studies have shown that 
lack of ATPase activity causes reduced levels of somatic and intergenerational expansions in 
DM1 CTG repeats, demonstrating the necessity of functional MSH2-ATPase activity within a 
functional MMR system for TNR expansion (Tome et al. 2009).  
In the case of somatic GAA repeat expansions, it is proposed that loss of Msh2, Msh3 or 
Msh6 could result in dysfunction of MutSα and/or MutSβ heterodimers and most likely 
prevent unusual binding of MutS heterodimers to GAA loops. This event may consequently 
cause a reduced level of error-prone expansion-biased instability within expanded TNR 
sequences. On the other hand, recent investigations suggest that MutS complexes might act 
upon secondary structures caused by GAA repeat expansions via R-loops and DNA-DSBs. 
Different studies have shown that R-loops can cause further expansions in GAA repeats 
(Soragni et al. 2008; Ditch et al. 2009; Rindler and Bidichandani 2011). R-loops could be 
caused by binding of a nascent mRNA with the transcriptional template strand. However, this 
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is not a normal event during transcription. Nonetheless, it has been reported that R-loops can 
occur during transcription of GAA repeats. Several factors may contribute to R-loop 
formation, such as defective biogenesis of messenger ribonucleoprotein (mRNP) or lack of 
splicing factors (Aguilera and Gomez-Gonzalez 2008; Bourn et al. 2012). It is plausible that 
GAA repeat expansion sequences may themselves induce abnormal splicing. Furthermore, it 
is recognised that lack of some splicing factors, such as ASF (also called SF2), can lead to 
DSB formations (Aguilera and Gomez-Gonzalez 2008). In addition, it is believed that DSBs 
could occur in neuronal tissues through each of the HR or NHEJ pathways (Merlo et al. 
2005; Fishel et al. 2007; Aguilera and Gomez-Gonzalez 2008). MMR proteins are also 
involved in DSB repair via the DNA damage response, HR and NEHJ (Zhang et al. 2009; 
Shahi et al. 2011). Investigations have shown that a highly error-prone DSB repair system 
across the GAA repeat sequences that may lead to dramatically increased instability of the 
repeats (Pollard et al. 2008). In summary, it is proposed that the MMR system may be 
recruited to repair DSBs within GAA repeat R-loops, leading to further GAA expansions. 
This hypothesis is consistent with the results obtained in this thesis, not only from Msh2, 
Msh3 and Msh6, but also from Mlh1 proteins.  
It has also been shown in this chapter that Pms2 can protect against progressive somatic GAA 
repeat expansions. Small-pool PCR investigations, carried out by Bidichandani and 
colleagues, have also confirmed this Pms2 effect (Bourn et al. 2012). Curiously, this finding 
is contrary to the results observed with the other MMR proteins. It is also contrary to the 
investigations of DM1 transgenic mice, which show depletion Pms2 protein to cause               
a reduced CTG repeat expansions (Gomes-Pereira et al. 2004). The reasons for these 
differences are not clear. However, it is proposed that Pms2 may not be acting in the usual 
MMR mechanism to protect GAA repeats against expansions, but may be acting through an 
Msh2-independent manner (Siehler et al. 2009). For instance, it has been reported that Pms2 
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is able to protect other microsatellites, such as tetramer repeats, against expansions in 
conditions of non-hairpin-formation (Bourn et al. 2012).      
As with the intergenerational studies, analysis of somatic tissues has shown that Mlh1 
promotes GAA repeat expansions, while Pms2 was found to protect against GAA repeat 
expansions. To my knowledge, these data are the first to identify a potential role for Mlh1 in 
somatic TNR instability. The mechanism by which Mlh1 causes greater GAA repeat 
expansions is unknown. Nonetheless, similar to MutS-complex proteins, it is proposed that 
Mlh1 causes error-prone instability within expanded GAA repeat sequences either by binding 
of the ATPase domain with a GAA hairpin or by repairing DSBs caused by R-loops. Mlh1 is 
an important ATPase member of the MMR system and it is recognised as a regulator of DSB 
formation. Therefore, Mlh1 could bind via its ATPase domain with secondary structures of 
GAA repeats, most probably R-loops, and repair DSBs in an error-prone expansion-oriented 
manner. This hypothesis is consistent with recent investigations that show Mlh1 to play an 
important role, through its ATPase activity, in DNA end processing and NHEJ error-prone 
DSB repair (Chahwan et al. 2012). 
In conclusion, somatic GAA repeat expansions appear to arise from the complex interplay of 
several different molecular mechanisms, one of which is the MMR system. Further 
investigations are required to determine the precise mechanisms by which MMR proteins and 
the other molecular mechanisms are involved in somatic GAA repeat expansions, and thereby 
to identify potential targets for FRDA therapy. 
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5.1 - Introduction 
Frataxin is a fundamental mitochondrial protein expressed in all cells.  Previous studies have 
shown that there is a link between the greater size of expanded GAA repeats and lower FXN 
transcription level in FRDA human (Greene et al. 2007; Al-Mahdawi et al. 2008). Further 
studies have shown similar effects by investigating YG8 FXN
GAA+
 and YG22 FXN
GAA+
 
transgenic mice (Figure 5.1). 
 
Figure 5.1 - Analysis of FXN
GAA+ 
mouse transcription levels (Al-Mahdawi et al. 2008). 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from Y47           
(9 GAA repeats), YG8 (190+90 GAA repeats) and YG22 (190 GAA repeats) mouse brain 
and heart tissues, normalised to the mean Y47 FXN mRNA level taken as 100%.   
 
 
In the previous chapter, I showed that defects of MMR genes influence somatic GAA repeat 
expansion instability in different tissues, particularly the cerebellum. However, it is not yet 
clear whether such instability caused by MMR gene deficits is linked to changes in FXN 
transcriptional levels. To investigate this, YG8 FXN
GAA+
 and YG22 FXN
GAA+
 transgenic mice 
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were used as in vivo systems to determine the effect of MMR protein deficiencies on FXN 
transcription levels. Since prior analysis of FXN
GAA+
/MMR models had shown brain and 
cerebellum to be the most sensitive tissues to GAA repeat instability (refer to the chapter 4), 
the levels of FXN transcription were measured in these tissues from different MMR-modified 
mice by qRT-PCR analysis. The effects of MMR deficiencies on FXN transcription were also 
analysed in vitro, using two human epithelial cell lines: HCT-116 (a MMR deficient 
epithelial cell line causing HNPCC) and NCM-460 (an epithelial unaffected MMR cell line). 
The use of an in vitro model could lead to further understanding of mechanisms by which 
MMR proteins affect the FXN transcription level, in addition to investigating potential 
differences between the in vitro and in vivo models.   
 
5.2 - Analysis of cDNA quality 
By using the Trizol
®
 method, total RNA was isolated from brain and cerebellum tissues of 
those YG22 FXN
GAA+
/MMR transgenic mice which were previously used to study the 
correlation of MMR proteins with GAA repeat instability (refer to the chapter 4). Similarly, 
in the case of in vitro models, total RNA was isolated from about one million human 
epithelial cells. Total RNA samples were treated with DNase I enzyme to prevent potential 
genomic DNA contamination. Following analysis of total RNA quality and quantity, the 
concentrations were adjusted to 400-500ng/µl and the RNA was converted to cDNA. The 
quality of cDNA was initially confirmed by performing standard FXN RT-PCR and GAPDH 
endogenous control RT-PCR experiments. Analysis of the standard FXN RT-PCR products 
on agarose gels showed a specific FXN product of 172bp for all transgenic mice and human 
epithelial cell line samples (Figure 5.2A). In the case of mouse tissues, analysis of             
Gapdh-RT-PCR products on agarose gels showed a specific 81bp fragment (Figure 5.2B). In 
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contrast, analysis of human GAPDH-RT-PCR products revealed a specific band with length 
of 226bp in human epithelial samples (Figure 5.2C). In all cases, observation of a specific 
fragment and no primer-dimer confirmed the adequate quality and quantity of cDNA samples 
to subsequently use for qRT-PCR.  
 
 
Figure 5.2 - Standard RT-PCR analysis. 
 
 
 
 
The images show PCR products from (A) human FXN-RT-PCR, (B) mouse Gapdh-RT-PCR, 
and (C) human GAPDH-RT-PCR run in ethidium bromide-stained 1% agarose gels, together 
with 1Kb
+ 
size markers. P= positive control, N= negative control.  
   
 
 
 
 
5.3 - Quantification of FXN mRNA in mouse tissues 
To determine the level of FXN transcription, tissues from YG22 FXN
GAA+
 transgenic mice 
with different MMR genotypes (MMR-WT and MMR-KO) were analysed by qRT-PCR.       
In as much as some transgenic mice also carried a normal mouse Fxn gene, in this 
experiment, it was essential to use two human FXN-transgene specific primers to enable 
FXN-transgene specific qRT-PCR. To quantify the FXN expression levels, the Ct values 
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obtained for FXN mRNA were normalised to those for mouse Gapdh mRNA, as the 
endogenous control. Each sample was run in triplicate (Figure 5.3A) and each experiment 
was performed at least twice. The mean value of each individual triplicate sample was 
applied for further calculations using the 2
-ΔΔCt
 method to find relative quantification (RQ) 
values. Later, relative transcription levels of FXN from both MMR-WT and MMR-KO mouse 
tissues were calibrated by calculating the RQ mean values, followed by setting the MMR-WT 
group arbitrarily as 100%. The mean age of each group of mice was matched throughout all 
mRNA quantification experiments to prevent any age dependent variability. Following the 
qRT-PCR amplification program, the quality of the target and endogenous (FXN and Gapdh) 
cDNA products, with no primer-dimer formation, were confirmed by performing dissociation 
curve analysis (Figure 5.3B, Figure 5.3C).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5 – The MMR system affects FXN transcription   
 
  160 
 
 Figure 5.3 - qRT-PCR analysis. 
 
 
 
The images show (A) Ct of each individual triplicate sample for FXN and Gapdh cDNAs,   
(B) dissociation curve for RT-Gapdh primers, and (C) dissociation curve for RT-FXN 
primers. 
B) C) 
A) 
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5.3.1 - Effect of Msh2 on human transgenic FXN transcription 
To investigate the effects of Msh2 on FXN transcription, 22 Msh2-WT with 18 Msh2-KO 
genotypes were analysed. The mean age of each group was approximately 7.5 months. The 
mRNA level of FXN was analysed in brain and cerebellum tissues based on: (i) Msh2 
genotypes: Msh2-WT and Msh2-KO; (ii) age of genetically modified Msh2 mice: 6-7 months 
and 8-9 months; (iii) gender of genetically modified Msh2 mice: male and female. 
- Brain tissue: To assess any possible age effect on FXN transcription in brain tissue in the 
absence or presence of the Msh2 protein, transgenic mice aged 6-7 months (WT n=10,              
KO n=6) were compared with mice aged 8-9 months (WT n=12, KO n=12). Data analysis 
showed no statistically significant difference of the FXN transcription level between higher 
age (8-9 months) and lower age (6-7 months) for both Msh2-WT and Msh2-KO (Figure 5.4).  
 
Figure 5.4 - Effect of Msh2 on the FXN
 
transcription level of brain tissues in different 
age groups. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of 6-7 months (WT n=10, KO n=6) and 8-9 months (WT n=12, KO n=12) mice with 
different modifications of Msh2, normalised to the mean FXN mRNA level found in the        
8-9 months of age Msh2-WT control samples and taken as 100%.  Error bars= S.E.M. 
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To investigate whether the FXN transcription level of brain tissue is affected by sex in the 
absence or presence of Msh2, female samples (WT n=6, KO n=8) were compared with male 
samples (WT n=16, KO n=10). Curiously, the data showed contrary results in male mice 
compared with female mice. Thus, the mRNA level of FXN was significantly increased with 
Msh2
-/-
 in the male, compared with Msh2
+/+
 (Figure 5.5). In contrast, there was a significantly 
reduced level of FXN transcription with Msh2
-/-
 in female brain tissue. Comparing Msh2-WT 
brain tissues showed that the FXN mRNA level was increased in female (119.5%) compared 
with male mice (normalised as 100%; p<0.05); while analysing Msh2-KO mice revealed that 
the level of FXN transcription was increased in male (about 1.5 fold) compared with female 
mice (86%; p<0.001). These findings indicate a modification due to sex of the Msh2 effect on 
FXN transcription in brain tissue, suggesting that absence of Msh2 could increase FXN 
transcription in males, while it decreases FXN transcription in females.     
 
Figure 5.5 - Effect of Msh2 on the FXN
 
transcription level of brain tissues in different 
genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of female (WT n=6, KO n=8) and male (WT n=16, KO n=10) mice with different 
modifications of Msh2, normalised to the mean FXN mRNA level found in the male           
Msh2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05, ***= p<0.001  
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Subsequently, the relative quantification of FXN transcription in brain tissues, based only 
upon Msh2 modifications, was identified by qRT-PCR. Analysing the data showed no 
difference in the FXN transcription with loss of Msh2 protein (Figure 5.6), possibly due to the 
contrary effects of Msh2 of the different genders cancelling each other out.  
 
 Figure 5.6 - Effect of Msh2 on the FXN
 
transcription in brain tissue. 
 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of Msh2-WT and Msh2-KO mice, normalised to the mean FXN mRNA level found in 
the Msh2-WT control samples and taken as 100%.  Error bars= S.E.M. 
 
 
- Cerebellum tissue: Age effects on the FXN transcription level from cerebellum tissues, in 
the absence or presence of the Msh2 protein, were investigated by comparing samples of                 
8-9 month-old mice (WT n=10, KO n=12) with 6-7 month-old mice (WT n=12, KO n=6). 
Data analysis showed that the transcription level of FXN was increased in the absence of 
Msh2 protein with both age groups (Figure 5.7). With regards to previous reports indicating 
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that larger GAA repeat expansions cause reduced level of FXN transcription (Greene et al. 
2007; Al-Mahdawi et al. 2008), the finding here is consistent with my previous results 
showing that lack of Msh2 reduced somatic GAA repeat expansions (refer to the chapter 4). 
Further analysis revealed that FXN transcription was increased in older Msh2
-/-
 (151%) 
compared with younger Msh2
-/- 
mice (128%; p=0.08), while in the presence of Msh2 similar 
levels of FXN transcription were observed. Therefore, comparing brain and cerebellum 
tissues, it is suggested that any age dependent effect of Msh2 on FXN transcription levels is 
also dependent on the tissue type.    
          
Figure 5.7 - Effect of Msh2 on the FXN
 
transcription level of cerebellum tissues in 
different age groups. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of 6-7 months (WT n=12, KO n=6) and 8-9 months (WT n=10, KO n=12) mice with 
different modifications of Msh2, normalised to the mean FXN mRNA level found in the 6-7 
months of age Msh2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05, 
***= p<0.001     
 
 
 
To study whether the FXN transcription level of cerebellum tissue is modified by sex in the 
absence or presence of Msh2, female (WT n=6, KO n=8) were compared with male samples 
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(WT n=16, KO n=10). Analysing Msh2
+/+
 mice showed significantly higher FXN 
transcription in female (161%) compared with male (normalised as 100%, P<0.01) 
cerebellum tissues (Figure 5.8). As with brain, data analysis showed contrary results in male 
compared with female mice. Thus, FXN transcription was significantly upregulated with lack 
of Msh2 in males, compared with Msh2-WT (P<0.001). In contrast, FXN transcription was 
downregulated with loss of Msh2 in female cerebellum tissue from 161% to 134%         
(Figure 5.8). Taken together, observations represented similar findings in both brain and 
cerebellum tissues. These findings indicate a sex-related effect of Msh2 on FXN transcription 
in tissues that are sensitive to the FRDA abnormality, whereby absence of Msh2 increases 
FXN transcription in males, but decreases it in females. 
 
Figure 5.8 - Effect of Msh2 on the FXN
 
transcription level of cerebellum tissues in 
different genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of female (WT n=6, KO n=8) and male (WT n=16, KO n=10) mice with different 
modifications of Msh2, normalised to the mean mRNA level of FXN found in the male   
Msh2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05, **= p<0.01, 
***= p<0.001 
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Finally, the relative quantification of FXN transcription in cerebellum tissues, based only 
upon Msh2 modifications, was measured by qRT-PCR. A statistically significant increased 
level of FXN transcription was detected with loss of Msh2 protein (Figure 5.9). Comparing 
these cerebellar findings with the brain tissue results suggest that the overall effect of Msh2 
on FXN transcription is tissue selective.   
 
 Figure 5.9 - Effect of Msh2 on the FXN
 
transcription level in cerebellum tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of Msh2-WT and Msh2-KO mice, normalised to the mean FXN mRNA level found in 
the Msh2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05   
 
 
 
Taken together, these findings indicate that lack of Msh2 produces increased transcription of 
FXN, particularly in cerebellum tissue. This may possibly be due to comparatively decreased 
sizes of GAA repeat expansion mutation. However, the Msh2 deficiency effects on FXN 
transcription are modified by the gender of the mice.    
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5.3.2 - Effect of Msh3 on human transgenic FXN transcription 
To examine the effect of Msh3 protein on FXN transcription, qRT-PCR was performed on 
groups of 20 Msh3
+/+
 and 13 Msh3
-/-
 mice. The FXN transcription levels were analysed in 
either brain or cerebellum tissues based on: (i) Msh3 genotypes: Msh3-WT and Msh3-KO; 
(ii) age of genetically modified Msh3 mice: 5-7 months and 9-12 months; (iii) gender of 
genetically modified Msh3 mice: male and female. 
- Brain tissue: To investigate the age effect on FXN transcription in brain tissues, in the 
absence or presence of Msh3 protein, transgenic mice aged 5-7 months (WT n=8, KO n=3) 
were compared with mice aged 9-12 months (WT n=12, KO n=8). Data analysis showed no 
statistically significant difference in the FXN transcription level between older (9-12 months) 
and younger (5-7 months) mice for both Msh3-WT and Msh3-KO (Figure 5.10).  
  
Figure 5.10 - Effect of Msh3 on the FXN
 
transcription level of brain tissues in different 
age groups. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of 5-7 months (WT n=8, KO n=3) and 9-12 months (WT n=12, KO n=8) mice with 
different modifications of Msh3, normalised to the mean FXN mRNA level found in the          
9-12 months of age Msh3-WT control samples and taken as 100%. Error bars= S.E.M.    
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To find out whether the FXN transcription level of brain tissue was modified by sex in the 
absence or presence of Msh3, 18 female samples (WT n=10, KO n=8) were compared with 
15 male samples (WT n=10, KO n=5). The data analysis demonstrated similar levels of FXN 
transcription in Msh3-WT for both males and females, while in Msh3
-/-
 mice, FXN 
transcription was significantly higher in males (117%, p<0.001) compared with females 
(Figure 5.11). Further analysis showed a reduced level of FXN transcription in Msh3-KO 
female mice (88%) compared with Msh3-WT mice (normalised as 100%).    
  
 Figure 5.11 - Effect of Msh3 on the FXN
 
transcription level of brain tissues in different 
genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of female (WT n=10, KO n=8) and male (WT n=10, KO n=5) mice with different 
modifications of Msh3, normalised to the mean FXN mRNA level found in the female    
Msh3-WT control samples and taken as 100%. Error bars= S.E.M, **= P<0.01,                 
***= p<0.001 
 
 
Subsequently, relative quantification of FXN transcription in brain tissues was performed 
based on Msh3 modification only. Analysis of data did not reveal any notable difference due 
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to the loss of Msh3 protein (Figure 5.12). This result suggests that lack of Msh3 does not 
affect the transcription level of FXN in brain tissue.  
 
 Figure 5.12 - Effect of Msh3 on the FXN
 
transcription level in brain tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of Msh3-WT and Msh3-KO mice, normalised to the mean FXN mRNA level found in 
the Msh3-WT control samples and taken as 100%. Error bars= S.E.M. 
 
 
- Cerebellum tissue: The potential age-modifying effect of Msh3 on FXN transcription was 
assessed in cerebellum tissue samples of the mice aged 5-7 months (WT n=13, KO n=4) and 
the mice aged 9-12 months (WT n=10, KO n=5). Data analysis did not show any significant 
difference between FXN transcription levels of these differently aged groups (Figure 5.13).  
In addition, no difference was observed by comparing Msh3-WT with Msh3-KO in each 
group. These findings were similar to the results obtained from brain tissue. Thus, it is 
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proposed that levels of FXN transcription in cerebellum are not affected by the absence of 
Msh3 or modified by different ages of mice. 
      
 Figure 5.13 - Effect of Msh3 on the FXN
 
transcription level of cerebellum tissues in 
different age groups. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of 5-7 months (WT n=13, KO n=4) and 9-12 months (WT n= 10, KO n=5) mice with 
different modifications of Msh3, normalised to the mean FXN mRNA level found in the           
5-7 months of age Msh3-WT control samples and taken as 100%. Error bars= S.E.M.   
 
   
 
To study whether the FXN transcription level of cerebellum tissue is related to the gender in 
absence or presence of Msh3, female samples (WT n=13, KO n=3) were compared with male 
samples (WT n=10, KO n=6). Analysis of Msh3-WT and Msh3-KO males, like in brain 
tissues, did not show any significant difference in FXN transcription (Figure 5.14). 
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 Figure 5.14 - Effect of Msh3 on the FXN
 
transcription level of cerebellum tissues in 
different genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of female (WT n=13, KO n=3) and male (WT n=10, KO n=6) mice with different 
modifications of Msh3, normalised to the mean FXN mRNA level found in the female     
Msh3-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05, ***= p<0.001   
 
 
However, the level of FXN transcription was significantly increased in cerebellum tissue of 
female mice with lack of Msh3 (approximately 1.5 fold, P<0.05). This is consistent with 
observations obtained from brain tissue showing a significant difference of FXN transcription 
levels in females, and not males, when comparing Msh3-WT and Msh3-KO mice. 
Nonetheless, it is important to say that level of FXN transcription in the brain tissue of       
Msh3-KO was reduced compared with Msh3-WT (refer to the figure 5.11), while this 
situation was reversed in cerebellum tissues. These findings indicate that FXN transcription 
exhibits a degree of tissue selectivity in Msh3-female transgenic mice. Finally, the levels of 
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FXN transcription in cerebellum tissues were analysed based only upon Msh3 genotype. 
Analysis of data did not show any notable difference in Msh3-KO compared with Msh3-WT 
(Figure 5.15). This result suggests that lack of Msh3 does not affect the FXN transcription 
level in cerebellum tissue. Taken together, the findings obtained from this study indicate that 
Msh3 defect does not have any significant influence on the FXN transcription, other than 
female mice showing a tissue selective effect.  
 
 Figure 5.15 - Effect of Msh3 on the FXN
 
transcription level in cerebellum tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of Msh3-WT and Msh3-KO mice, normalised to the mean FXN mRNA level found in 
the Msh3-WT control samples and taken as 100%. Error bars= S.E.M. 
 
 
 
5.3.3 - Effect of Msh6 on human transgenic FXN transcription 
To understand the effect of Msh6 on FXN transcription, qRT-PCR was utilised to compare 
the FXN transcription levels of 12 Msh6-WT (both male and female mice) with 3 Msh6-KO 
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samples (female mice only). In this experiment, the age of each individual mouse was               
9 months. The FXN transcription level in both brain and cerebellum tissues was analysed 
based on: (i) Msh6 genotypes: Msh6-WT and MSh6-KO; (ii) gender of genetically modified 
mice: female.   
- Brain tissue: To understand whether the FXN transcription level of brain tissue is modified 
by sex in the absence or presence of Msh6, 9 samples from Msh6
+/+
 females were compared 
with 3 samples from Msh6
-/-
 females. Since no Msh6-KO male sample was available, FXN 
transcriptional analysis in males was not feasible. Data analysis from brain tissues of female 
mice showed that the level of FXN transcription was significantly reduced (1.8 fold; p<0.001) 
in the absence of Msh6 compared with the presence of Msh6 (Figure 5.16). 
 
 Figure 5.16 - Effect of Msh6 on the FXN
 
transcription level of brain tissues in different 
genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of female mice with different modifications of Msh6 (WT n=9; KO n=3), normalised 
to the mean FXN mRNA level found in the male Msh6-WT control samples and taken as 
100%. Error bars= S.E.M, ***= p<0.001   
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Moreover, relative quantification of the transcription level of FXN in brain tissues was 
performed only based upon Msh6 genotype only. The data analysis showed remarkably 
reduced levels of FXN transcription (less than 56%; p<0.01) with loss of Msh6 (Figure 5.17), 
suggesting that lack of Msh6 causes downregulation of FXN transcription. Although this 
latter finding was based on analysis of both male and female samples, it showed similar effect 
to those findings of only based on female mice. This comparison suggests that the effect of 
Msh6 deficiency on FXN transcription level would not be modified by gender in brain tissue.   
  
 Figure 5.17 - Effect of Msh6 on the FXN
 
transcription level in brain tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of Msh6-WT and Msh6-KO mice, normalised to the mean FXN mRNA level found in 
the Msh6-WT control samples and taken as 100%. Error bars= S.E.M, **= p<0.01  
 
  
 
- Cerebellum tissue: To investigate whether FXN transcription of cerebellum tissue was 
related to the gender of mice in the absence or presence of Msh6, nine samples from female 
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Msh6
+/+
 genotype were compared with three samples from Msh6
-/-
. Since Msh6-KO male 
mice were not available, FXN transcriptional analysis in males was not feasible. Analysing 
the data from cerebellum tissues of female mice showed that the level of FXN transcription 
was significantly reduced (1.6 fold; p<0.001) in the absence of Msh6 compared with the 
presence of Msh6 (Figure 5.18). 
 
Figure 5.18 - Effect of Msh6 on the FXN
 
transcription level of cerebellum tissues in 
different genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of female mice with different modifications of Msh6 (WT n=9, KO n=3), normalised 
to the mean FXN mRNA level found in the male Msh6-WT control samples and taken as 
100%. Error bars= S.E.M, ***= p<0.001   
 
 
 
Furthermore, relative quantification of the FXN transcription in cerebellum tissues was 
performed based only upon Msh6 genotype. The data analysis showed remarkably reduced 
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levels of FXN transcription (60%; p<0.001) in the absence of Msh6 compared with the 
presence of Msh6 (Figure 5.19), indicating that, similar to brain tissue, lack of Msh6 causes 
downregulation of FXN transcription in cerebellum tissue, which again is unmodified by 
gender. 
 
 Figure 5.19 - Effect of Msh6 on the FXN
 
transcription level in cerebellum tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of Msh6-WT and Msh6-KO mice, normalised to the mean FXN mRNA level found in 
the Msh6-WT control samples and taken as 100%. Error bars= S.E.M, ***= p<0.001   
 
 
 
Taken together, these findings reveal that Msh6 deficits result in a general downregulation of 
FXN transcription. 
5.3.4 - Effect of Pms2 on human transgenic FXN transcription 
To understand the effect of Pms2 protein on FXN transcription, qRT-PCR was performed to 
compare the FXN transcription level of 9 Pms2-WT samples with that of 17 Pms2-KO 
 Chapter 5 – The MMR system affects FXN transcription   
 
  177 
 
samples (from both male and female mice). In this study, FXN transcription was analysed in 
both brain and cerebellum tissues based on: (i) Pms2 genotypes: Pms2-WT and Pms2-KO; 
(ii) gender of genetically modified mice: male and female.  
- Brain tissue: To find out whether the FXN transcription levels of brain tissue were 
modified by sex in the absence or presence of Pms2, samples from female mice (WT n=3, 
KO n=6) were compared with those of male mice (WT n=6, KO n=11). The data analysis 
demonstrated that the FXN transcription level was reduced from 128% in Pms2-WT females 
to less than 91% in Pms2-KO females. A similar trend, although not statistically significant, 
was also observed between Pms2-WT and Pms2-KO males (Figure 5.20).  
 
Figure 5.20 - Effect of Pms2 on the FXN
 
transcription level of brain tissues in different 
genders. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of female (WT n=3, KO n=6)  and male (WT n=6, KO n=11) mice with different 
modifications of Pms2, normalised to the mean FXN mRNA level found in the male       
Pms2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05   
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Subsequently, relative quantification of FXN transcription in brain tissues was performed 
based upon Pms2 genotype only. Data analysis showed that the level of FXN transcription 
was significantly reduced with loss of Pms2 (Figure 5.21; p<0.05).  
 
 
Figure 5.21 - Effect of Pms2 on FXN
 
transcription level in brain tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of Pms2-WT and Pms2-KO mice, normalised to the mean FXN mRNA level found in 
the Pms2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05   
 
 
- Cerebellum tissue: To study whether FXN transcription in cerebellum was modified by 
gender in the absence or presence of Pms2, female samples (WT n=8, KO n=5) were 
compared with male samples (WT n=6, KO n=5). Analysis of data from male cerebellum 
tissue demonstrated that loss of Pms2 culminated in reduced FXN transcription compared 
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with Pms2-WT (Figure 5.22). A similar trend, but not statistically significant, was observed 
by comparing Pms2-KO and Pms2-WT females. 
 
 
 
 
Figure 5.22 - Effect of Pms2 on the FXN
 
transcription level of cerebellum tissues in 
different genders.  
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of female (WT n=8, KO n=5) and male (WT n=6, KO n=5) mice with different 
modifications of Pms2, normalised to the mean FXN mRNA level found in the male       
Pms2-WT control samples and taken as 100%. Error bars= S.E.M, **= p<0.01 
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Finally, the relative quantification of FXN transcription in cerebellum tissues was measured 
based on Pms2 genotype only. As with brain, data analysis showed that the FXN mRNA level 
of cerebellum tissues was significantly reduced with loss of Pms2 (Figure 5.23; p<0.05).  
 
 Figure 5.23 - Effect of Pms2 on FXN
 
transcription level in cerebellum tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of Pms2-WT and Pms2-KO mice, normalised to the mean FXN mRNA level found in 
the Pms2-WT control samples and taken as 100%. Error bars= S.E.M, **= p<0.01   
 
 
Taken together, these findings indicate that loss of Pms2 causes reduced levels of FXN 
transcription, which might be due to comparatively increased sizes of GAA repeat expansion, 
as described in the chapter 4.  
      
 Chapter 5 – The MMR system affects FXN transcription   
 
  181 
 
5.3.5 - Effect of Mlh1 on human transgenic FXN transcription 
To assess the effect of Mlh1 protein on FXN transcription, qRT-PCR analysis was performed 
for brain and cerebellum tissues based only upon Mlh1 genotypes in male transgenic mice. 
Since Mlh1-KO mice did not survive beyond more than 3 months, data analysis based on age 
was not feasible. Analysing data from brain tissues of 2 samples of Mlh1-WT mice compared 
with 3 samples of Mlh1-KO revealed that, with loss of Mlh1, the level of FXN transcription 
was decreased to approximately half that of Mlh1-WT (Figure 5.24).  
 
 Figure 5.24 - Effect of Mlh1 on the FXN
 
transcription level in brain tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from brain 
tissues of Mlh1-WT and Mlh1-KO mice, normalised to the mean FXN mRNA level found in 
the Pms2-WT control samples and taken as 100%. Error bars= S.E.M, *= p<0.05   
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Data analysis of cerebellum tissue from 4 Mlh1-WT mice compared with 12 Mlh1-KO mice 
demonstrated that, as with brain tissue, the level of FXN transcription decreased dramatically 
with loss of Mlh1 (about 5.5 fold, Figure 5.25). 
 
 
Figure 5.25 - Effect of Mlh1 on the FXN
 
transcription level in cerebellum tissue. 
 
The image represents qRT-PCR analysis of transgenic FXN mRNA isolated from cerebellum 
tissues of Mlh1-WT and Mlh1-KO mice, normalised to the mean FXN mRNA level found in 
the Mlh1-WT control samples and taken as 100%. Error bars= S.E.M, **= p<0.01  
 
 
Taken together, these findings indicate that deficits of Mlh1 lead to remarkable                    
downregulation of FXN transcription in both brain and cerebellum tissues. 
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5.4 - Quantification of FXN mRNA in human cell 
lines 
Following on from the previous section, the effects of MMR genes on FXN transcription 
were also investigated in human epithelial cell lines. This strategy was designed to establish 
whether a human in vitro cell model could be considered as a valid system to study the 
effects of MMR proteins on FXN transcription, compared with the mouse in vivo model 
system. Hence, the aim of this experiment was to investigate the effect of MMR proteins on 
FXN transcription in vitro. Since MMR deficiencies are particularly observed in HNPCC 
malignancy, a human epithelial colorectal cell line was considered as the most efficient cell 
type to use. In this study, a human MMR-proficient epithelial cell line, named NCM-460, was 
selected as the control (Moyer et al. 1996), and this was compared with a human                 
MMR-deficient epithelial colorectal adenocarcinoma cell line, HCT-116. Observations have 
shown that HCT-116 contains a mutation within MLH1 causing dysfunction of the related 
protein (Davis et al. 1998). This mutation could prevent binding of MLH1 to PMS2 in vitro 
subsequently causing MutLα heterodimer dysfunction (Belvederesi et al. 2006). Further 
studies have shown that PMS2 protein function is also disrupted in HCT-116 cells 
(Shimodaira et al. 2003), due to degradation of PMS2 in the absence of MLH1 (Chang et al. 
2000). Thus, it is proposed that HCT-116 cell lines could be an efficient model to investigate 
the effect of dysfunction of MutLα, the critical secondary complex that continues and 
completes the MMR process.    
To investigate the effect of MLH1 and PMS2 on FXN transcription in unaffected human 
MMR epithelial colorectal cells and HNPCC cells, the cells were initially sub-cultured for 10 
passages (from passage 30 to 40). In addition to comparing NCM-460 with HCT-116 from 
compatible passages, to further understand the potential variability of FXN transcription 
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within different cell passages, FXN expression levels were analysed at three passage 
numbers: 30, 35 and 40. Briefly, total RNA was extracted from about one million cells by the 
Trizol
®
 method and was converted into cDNA, followed by relative quantification of FXN 
transcription using qRT-PCR. To assess differences in gene expression efficiency, the               
Ct values from FXN cDNA were normalised to human GAPDH, as an endogenous control. 
Each sample was run in triplicate and each experiment was carried out at least two times. The 
mean value of each sample was applied for further calculations to obtain RQ values by using 
the 2
-ΔΔCt
 formula. Later, relative levels of FXN transcription from multiple passages of both 
NCM-460 and HCT-116 cell lines were determined by calculating the RQ mean values, 
followed by designating the value from passage number 30 of the NCM-460 cell line 
arbitrarily as 100%.   
5.4.1 - The effects of PMS2 and MLH1 on FXN transcription 
Analysis of data showed that the mean value of FXN transcription was significantly higher in 
the MMR-proficient NCM-460 control cells compared with the lack of MLH1 and PMS2 
proteins in HCT-116 cell lines (Figure 5.26), indicating that lack of MLH1 and/or PMS2 
protein(s) cause(s) reduced FXN transcription. This result is consistent with previous finding 
in mouse models with lack of each individual Pms2 (refer to the figure 5.22) or Mlh1 (refer to 
the figure 5.23) protein, suggesting the same mechanism of action for PMS2 and MLH1 in 
both in vivo mouse cells and in vitro human cells. 
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 Figure 5.26 - FXN
 
transcription level analysis in human epithelial cell lines. 
 
The image represents qRT-PCR analysis of the mean FXN transcription level (passage 
numbers 30, 35 and 40) isolated from MMR proficient cell line, NCM-460, and MutLα 
heterodimers deficient cell line, HCT-116, normalised to the mean FXN mRNA level found 
in the NCM-460 control sample and taken as 100%. Error bars= S.E.M, **= p<0.01  
 
 
Further data, based on the number of passages, likewise showed less FXN transcription in 
HCT-116 cells compared with NCM-460 cells. Curiously, analysis showed that the trend of 
FXN mRNA expression was downwards in HCT-116 passage number 30 to 40, indicating 
that FXN transcription was gradually reducing with increasing passage number (Figure 5.27). 
The principle cause of FXN transcription level variation within different passages of          
HCT-116 cells was not clear.  
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 Figure 5.27 - FXN
 
transcription analysis in different passages of human epithelial cell 
lines. 
 
The image represents qRT-PCR analysis of the FXN transcription level with different passage 
numbers (30, 35 and 40) of MMR proficient cell line, NCM-460, and MutLα heterodimers 
deficient cell line, HCT-116, normalised to the mean FXN mRNA level found in the passage 
number 30 of NCM-460 control sample and taken as 100%. Error bars= S.E.M, *= p<0.05, 
***=p<0.001.  
 
 
 
To determine whether or not GAA repeat instability could be the cause of progressive FXN 
transcription reduction in HCT-116 cells, GAA repeat sizes were assessed in different 
passages of HCT-116 and NCM-460 cells. However, all passages of both cell types gave 
GAA PCR products of about 485bp, indicating approximately 11 GAA repeats, and no 
instability was observed (Figure 5.28). This shows that PMS2 and MLH1 deficiencies caused 
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reduced FXN transcription without affecting the size of normal GAA repeats, suggesting         
a different mechanism of action. 
 
 Figure 5.28 - GAA-PCR in human epithelial cell lines.      
 
  
   
 
            
The image illustrates GAA-PCR analysis of samples serial-passages of HCT-116 and 
NCM460 cell lines in 1.5% ethidium bromide-stained agarose gel electrophoresis.                
P= Passage, M1= 100bp ladder, M2= 1Kb
+ 
ladder. 
 
 
 
 
5.5 - Discussion 
The aim of this chapter was to investigate the effect of MMR proteins on FXN transcription 
in vivo and in vitro. Analysis of the in vivo results, taken together with the somatic GAA 
repeat instability findings of the chapter 4, addresses the relationships between MMR 
proteins, GAA repeat expansions and FXN transcription. In addition, categorisation of the 
data based on age and gender, helps to further understand potential modifier effects.  
Analysis of the data from FXN
GAA+ 
MMR-WT mice based on age did not reveal any 
significant difference between the FXN transcription levels of older versus younger mice. 
Likewise, findings indicated no age-related effect on FXN transcription in Msh3
-/-
 transgenic 
mice. In contrast, a higher level of FXN transcription was identified in older Msh2
-/-
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transgenic mice, compared with younger mice, suggesting an age-related effect. Further 
investigations are required to understand how age could affect FXN transcription in the 
absence of Msh2. No study has yet been carried out on Msh6, Pms2 and Mlh1 deficient mice 
in terms of age modification. Therefore, it would be noteworthy to investigate the effect of 
these proteins on FXN transcription based on age.   
In the case of gender, the data revealed that the level of FXN transcription is generally 
modified by sex in FXN
GAA+ 
MMR-WT mice. Thus, the FXN mRNA levels in female brain 
and cerebellum tissues were shown to be higher than those in males. In contrast, loss of Msh2 
or Msh3 resulted in upregulation of FXN transcription in males compared with females. 
Curiously, no significant difference was observed between males and females with loss of 
Pms2. Further studies are required to determine how sex could modify the MMR-affected 
changes of FXN transcription. In addition, the investigation of any sex-modifying effects of 
Msh6 and Mlh1 proteins on FXN transcription levels would be useful future studies. 
Data analysis based only upon MMR genotypes showed no significant difference in FXN 
transcription levels by comparing Msh3-KO with Msh3-WT mice, while loss of Msh2 
resulted in increased FXN transcription in the cerebellum. The latter finding was consistent 
with previous observations of somatic GAA repeat instability (refer to the chapter 4), 
whereby a loss of GAA repeat expansion, and hence likely increased FXN expression, was 
demonstrated in Msh2-KO cerebellar tissues. In contrast, loss of Pms2 causes further 
increased somatic GAA repeat expansions (refer to the chapter 4) and a corresponding 
reduction in the level of FXN transcription. A similar decrease in FXN expression was seen in 
the PMS2-deficient human cell models, but without any accompanying GAA repeat 
expansion. This suggests a comparable non-GAA repeat-related mechanism of PMS2/Pms2 
action, not only within in vitro and in vivo models, but also within mice and humans.                  
In addition, loss of Msh6 or Mlh1 proteins led to reduced levels of FXN transcription, despite 
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corresponding losses of somatic GAA repeat expansions. The reasons for these conflicting 
results are not known. However, it is proposed that another mechanism, which does not 
involve GAA repeat expansions, may cause reduced levels of FXN transcription in Msh6 or 
Mlh1 deficient cells. In addition to repairing base mismatches or short IDLs resulting from 
replication errors, MMR proteins are also able to cooperate with the nucleotide excision 
repair (NER) system to amend genomic errors with bulky helix loops (Kobayashi et al. 2005; 
Denver et al. 2006). Generally, the NER system contributes to DNA repair through two        
sub-pathways; global genome NER (GG-NER) and transcription-coupled NER (TC-NER). 
Within TC-NER, the NER system is recruited to repair genomic errors, caused by 
preferentially binding transcription and RNA polymerase II to the transcribed DNA strand in 
expressed genes (Mellon and Hanawalt 1989; Kobayashi et al. 2005). Several investigations 
of different organisms have implicated MMR proteins in TC-NER. Thus, studies of E.coli 
have shown that lack of MutS and MutL proteins leads to dysfunction of TC-NER in the Lac 
operon (Mellon and Champe 1996). Moreover, it is reported that all yeast MMR proteins are 
involved in TC-NER of oxidative damage, while no effect was observed on TC-NER of 
ultraviolet (UV) light damage (Sweder et al. 1996; Leadon and Avrutskaya 1997; Kathe et al. 
2004). In comparison with lower organisms, the role of MMR on mammalian TC-NER is still 
controversial. Nonetheless, several studies have indicated involvement of MMR proteins in 
TC-NER within particular expressed genes. Interestingly, defect of MSH2/MSH6 
heterodimers in LOVO cells (a human colon defected MMR adenocarcinoma cell line) 
resulted in hypersensitivity of this epithelial cell type to UV due to loss of TC-NER function 
(Mellon et al. 1996; Kobayashi et al. 2005). Since MMR-defective mouse fibroblasts showed 
no effect of Msh2 loss on sensitivity of UV damage (Sonneveld et al. 2001), it is proposed 
that MSH6 is the principal MMR protein contributing to TC-NER in LOVO cells. Studies of 
HCT-116 human epithelial MLH1-defective cells have also shown hypersensitivity to UV 
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light, due to the lack of TC-NER, while artificially introducing MLH1 gene to this cell line 
culminated in TC-NER and a reduced sensitivity to UV light (Mellon et al. 1996; Kobayashi 
et al. 2005). These studies have all implicated MSH6 and MLH1 in TC-NER. Interestingly, 
this is consistent with the findings described in this chapter, regarding the effect of Msh6 or 
Mlh1 on transcription level of FXN. However, it has also been reported that defects of             
TC-NER result in reduced levels of transcription of particular genes (Michalowski et al. 
2001). Taken together, these observations suggest a similar mechanism of action of Msh6 and 
Mlh1 on FXN transcription. Thus, it is proposed that transcribed FXN mRNA sequences and 
RNA polymerase II perhaps bind to an opened GAA/TTC repeat expansion within the first 
intron of the FXN gene to form an R-loop. In this case, the presence of Msh6 and Mlh1 may 
recruit the TC-NER system to correct the blockage and allow transcription to proceed. 
However, with a loss of Msh6 or Mlh1, TC-NER cannot proceed appropriately, the FXN 
mRNA fragment and RNA polymerase II are not released and FXN transcription is reduced. 
In summary, this thesis has identified an important role of the MMR system in FXN 
transcription. Comparing individual MMR genes suggests that they have similar effects on 
FXN transcription, except for Msh2. Thus, analysis of Msh6, Pms2 and Mlh1 deficient mice 
demonstrated lower FXN transcription compared with FXN
GAA+
/MMR
+/+
 transgenic mice, 
while Msh2 deficient mice showed increased FXN transcription. Taken together, the findings 
obtained from chapters 4 and 5 suggest that there might be a direct link between GAA repeat 
expansions and FXN transcription with loss of Msh2 or Pms2. In contrast, no direct link was 
determined between GAA repeat expansions and FXN transcription level with lack of Msh6 
or Mlh1. Loss of Msh6 or Mlh1 protein caused reduced levels of GAA repeat expansions, 
while the levels of FXN transcription were also reduced. The mechanisms by which Msh6 
and Mlh1 proteins are involved in FXN transcription are not clear yet. Nevertheless, it is 
proposed these MMR proteins may be able to increase the levels of FXN transcription by 
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activating the TC-NER system. However, further investigations are now required to confirm 
this hypothesis. 
  
 
 
 
 
 
 
 
 
 
 
Chapter 6 - Results: The effects of frataxin 
deficiency on MMR gene expression and 
potential malignant cell transformation 
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6.1 - Introduction 
Various types of cancer have been detected in the FRDA patients (Barr et al. 1986; Ackroyd 
et al. 1996; De Pas et al. 1999; Kidd et al. 2001), although, the prevalence of the 
simultaneous occurrence of both FRDA and cancer is very low. It has been proposed that due 
to the cardiomyopathy at the early onset of the disease, FRDA patients do not generally live 
long enough to develop cancers, such as breast cancers (Kidd et al. 2001). Further 
investigations have also revealed that deficiency of frataxin is associated with multiple types 
of cell malignancy (Schulz et al. 2006; Guccini et al. 2011; Kirches et al. 2011).  
Dysfunction of DNA repair genes might cause gene aberrations, resulting in disorders such as 
FRDA and cancer. An investigation of cultured FRDA cells has shown increased MSH2 
mRNA levels and increased GAA repeat expansions in induced pluripotent stem cells 
(iPSCs) compared to the donor FRDA fibroblasts. In contrast, no significant difference was 
observed in the MSH3 mRNA expression level by comparing FRDA iPSC with donor 
fibroblasts (Ku et al. 2010). These findings suggested that expansion of GAA repeats, and 
subsequently FXN deficits, are associated with increased MMR gene expression in iPSCs. 
Considering the involvement of frataxin in cell malignancy and the relationship between 
GAA repeat expansions and MMR expression levels, it was considered relevant to investigate 
the potential role of frataxin deficiency in the formation of malignant cells via the MMR 
pathway. Therefore, the aim of this study was to understand whether a reduced level of 
frataxin could affect the mRNA expression level of different MMR genes. To reach this 
objective, the transcription levels of MMR genes were quantified both in vitro, using FRDA 
and unaffected human fibroblast cells, and in vivo, using FRDA and unaffected human 
autopsy tissues. 
 Chapter 6 – The effect of frataxin deficiency on MMR gene expression    
 
  194 
 
6.2 - Analysis of cDNA quality 
To investigate the effect of FXN on the mRNA expression levels of MMR genes in vitro, 
total RNA was isolated using Trizol
®
 from about 1 million human FRDA and human 
unaffected primary fibroblast cells. For the human in vivo study, total RNA was isolated from 
cerebellar tissue of FRDA patients and unaffected individuals using a NucloSpin
®
 RNA II 
column based method. All RNA samples were treated with DNase I enzyme to prevent 
potential false positive results caused by MMR pseudogenes in contaminating DNA. 
Following quantity and quality analysis, 300-400ng/µl RNA was converted into cDNA. Then 
PCR primers were designed and reactions were optimised for each MMR gene by performing 
G-RT-PCR (Figure 6.1).  
 
Figure 6.1 - Analysis of G-RT-PCR for MMR genes. 
 
 
An example of G-RT-PCR for human MMR genes showing MLH1 PCR products obtained 
by using different annealing temperatures run in ethidium bromide-stained 1% agarose gels, 
together with 1Kb
+ 
size markers. P= positive control, N= negative control.  
 
 
Subsequently, the quality of cDNA samples was confirmed by performing standard RT-PCR 
of the relevant MMR genes or human GAPDH endogenous control (refer to the figure 5.2C). 
In all cases, no primer-dimers were observed and only the specific PCR products were 
obtained, confirming a suitable quality of cDNA samples to use for qRT-PCR.   
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6.3 - Quantification of human MMR gene 
transcription in vitro 
In this study, three different FRDA patient primary fibroblast cell cultures, containing 
different sizes of GAA repeat expansion, were compared with two to three control fibroblast 
cell cultures containing normal-sized GAA repeat sequences. These fibroblast cell lines 
originated from skin biopsies of FRDA and unaffected individuals (Table 6.1). 
 
Table 6.1 - Details of the human primary fibroblasts.  
  ID Sex 
Age 
(Yrs) 
Number of GAA 
repeats  
References 
Control 
H. Normal Male 27 Normal Kindly provided by Ian Kill 
GM07492 Male 17 Normal  Coriell cell repositories Inc. 
GM04503 Female 31 Normal Coriell cell repositories Inc. 
FRDA 
GM03816 Female 36 330/380  Coriell cell repositories Inc. 
GM04078 Male 30 420/541  Coriell cell repositories Inc. 
GM03665 Female 13 445/740  Coriell cell repositories Inc. 
 
Despite previous observations showing that the level of FXN transcription is reduced                   
in expanded GAA repeats of FRDA patients (Greene et al. 2007; Al-Mahdawi et al. 2008),  
in this study, quantifying FXN transcription was considered to be useful to investigate the 
potential link between GAA repeat size, FXN transcription and MMR gene transcription. 
Therefore, FXN and MMR transcription levels were determined in each fibroblast cell line by 
qRT-PCR. 
To analyse mRNA expression levels of MMR and FXN genes, the Ct value for each gene was 
normalised to human endogenous GAPDH. Each sample was run in triplicate and each 
experiment was carried out at least twice. The mean value of each individual triplicate sample 
was applied for further calculations using the 2
-ΔΔCt
 method to find RQ values. Next, the 
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relative transcription level of each gene, from both FRDA and unaffected cell lines, was 
calibrated against one of the unaffected FXN controls, ‘H.Normal’, which was arbitrarily 
assigned as 100%. All cell lines were matched in terms of passage number to prevent any 
potential passage-based variability. Analysis of the dissociation curve showed specificity of 
each set of primers (GAPDH and each MMR gene) without any non-specific PCR products, 
in the condition of optimised primer concentration (Figure 6.2). 
 
 Figure 6.2 - qRT-PCR analysis. 
 
 
 
 
The images show schematic example of (A) Ct of each individual triplicate sample for target 
gene and GAPDH cDNAs, (B) dissociation curve for RT-GAPDH primers, and                      
(C) dissociation curve for RT-FXN primers. 
A) 
B) C) 
 Chapter 6 – The effect of frataxin deficiency on MMR gene expression    
 
  197 
 
Quantification of the unaffected primary fibroblast cells demonstrated comparable levels             
of FXN transcription, while the sizes of GAA sequences were 9 to 16 repeats (Table 6.1, 
Figure 6.3).  
 
Figure 6.3 - Quantification of FXN mRNA in human primary fibroblasts.  
 
 
qRT-PCR measurement of FXN mRNA expression in A-B) individual fibroblast cell lines, 
and C) average expression between the unaffected and FRDA primary fibroblasts.                 
FXN expression values were first normalised to GAPDH and then calibrated to unaffected 
fibroblasts expression. Each result is the mean of two independent experiments.                 
Error bars = S.E.M, *= p<0.05, **= p<0.01, ***= p<0.001 (Chiranjeevi Sandi, personal 
discussions).  
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In contrast, comparing different FRDA fibroblast cell lines presented statistically significant 
differences in FXN transcription between the cells with greatest and least GAA repeat 
expansions. Thus, FRDA cells with less GAA repeat expansions (GM03816) showed a higher 
level of FXN transcription. Moreover, further analyses showed reduced levels of FXN 
transcription in all three FRDA fibroblast cells, GM04078, GM03816 and GM03665, 
compared with the unaffected fibroblast cell lines (Figure 6.3). The mean level of FXN 
transcription in FRDA cells was confirmed as 40% that of unaffected fibroblasts (p<0.001). 
This finding would agree with generally accepted view of the effect of GAA repeat expansion 
on the FXN transcription (Pianese et al. 2004; Greene et al. 2007; Al-Mahdawi et al. 2008). 
6.3.1 - The effect of reduced FXN on MSH2 transcription 
The effect of frataxin deficiency on MSH2 transcription was analysed by comparing MSH2 
mRNA expression in two unaffected FXN primary fibroblasts with three FRDA primary 
fibroblast lines. qRT-PCR results clearly showed an increased value of MSH2 mRNA 
expression in human FRDA fibroblasts (more than 2.5 fold; p<0.001), suggesting               
upregulation of the mRNA expression level of this MMR gene with defects of frataxin         
(Figure 6.4A). This finding suggests that MSH2 is not likely to play a role in tumourigenesis 
of defective FXN fibroblast cells, since MSH2 upregulation is a natural intrinsic response to 
mutations, while downregulation of MSH2 has been recognised to cause various types of cell 
malignancy, such as HNPCC. I propose that upregulation of MSH2 transcription leads to the 
increased level of MSH2 protein, which is consequently recruited to repair the GAA repeat 
expansion mutations and other DNA damage in FRDA fibroblast cells.  
Since different sizes of GAA repeat expansions were observed in the three FRDA fibroblast 
cell lines, to study whether the increased MSH2 mRNA expression level was directly related 
to GAA repeat expansions, MSH2 transcription levels were determined individually in each 
cell line and statistical differences were assessed by the student t-test (Figure 6.4B-C).  
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Figure 6.4 - Analysis of MSH2 mRNA expression level in fibroblast cells. 
 
 
 
The graphs represent MSH2 mRNA level in (A) average expression between unaffected and 
FRDA primary fibroblasts, (B) individual fibroblast cells, and (C) comparison with GAA 
repeat sizes. Error bars = S.E.M, *=P<0.05, **= P<0.01, ***= P<0.001 
 
 
Table 6.2 - Student t-test p-values of frataxin deficiency effect on the MSH2 mRNA 
expression level during individual cell line analyses. 
  
Control FRDA 
H. Normal GM07492 GM03816 GM04078 GM03665 
Control 
H. Normal   0.12 0.11 0.007 0.05 
GM07492 0.12   0.12 0.019 0.015 
FRDA 
GM03816 0.11 0.12   0.83 0.221 
GM04078 0.007 0.019 0.83   0.064 
GM03665 0.05 0.015 0.221 0.064   
B) C) 
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Although increased mRNA levels of MSH2 were observed in the GM03816 and GM04078 
FRDA cell lines compared with GM03665, the differences were not statistically significant 
(Figure 6.4B-C, Table 6.2). This finding suggests that there is no obvious relationship 
between sizes of expanded GAA repeats and levels of MSH2 mRNA. Thus, GAA repeat 
expansion is not the principle cause of MSH2 upregulation in FRDA fibroblasts. Therefore, 
other mechanisms that result from frataxin deficiency are more likely to be involved in the 
upregulation of MSH2. In other words, these findings suggest a mechanistic pathway between 
upregulation of MSH2 transcription, GAA repeat expansions and decreased frataxin levels in 
FRDA fibroblasts. 
6.3.2 - The effect of reduced FXN on MSH3 transcription 
To investigate the effect of frataxin deficiency on MSH3 expression, MSH3 mRNA was 
analysed in two cell lines of primary fibroblasts compared with three FRDA primary 
fibroblast cells. qRT-PCR data analysis demonstrated upregulation of MSH3 mRNA 
expression in FRDA cell lines compared with controls (Figure 6.5A). This is in contrast with 
the hypothesis that frataxin deficiency may form malignant cells by reducing MSH3 
expression. Therefore, I suggest that, as with MSH2, upregulation of MSH3 results in 
increased level of MSH3 protein to repair expanded GAA repeat mutations and other DNA 
damage in FRDA fibroblast cells.   
With regards to the different sizes of GAA repeat expansions in FRDA fibroblasts, analysis 
of data showed slight fluctuations in the MSH3 mRNA expression level within the three 
individual FRDA fibroblast cells; however, no statistically significant differences were 
observed (Figure 6.5B-C, Table 6.3). This observation indicates that there is not any direct 
link between GAA repeat expansion sizes and levels of MSH3 mRNA expression. Therefore, 
other mechanism(s) are likely to be involved in upregulation of MSH3 transcription within 
FRDA fibroblasts.  
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Figure 6.5 - Analysis of MSH3 mRNA expression level in fibroblast cells. 
 
 
 
 
The graphs represent MSH3 mRNA level in (A) average expression between unaffected and 
FRDA primary fibroblasts, (B) individual fibroblast cells, and (C) comparison with GAA 
repeat sizes. Error bars = S.E.M, *=P<0.05 
 
 
Table 6.3 - Student t-test p-values of frataxin deficiency effect on the MSH3 mRNA 
expression level during individual cell line analyses. 
  
Control FRDA 
H. Normal GM07492 GM03816 GM04078 GM03665 
Control 
H. Normal   0.54 0.44 0.17 0.95 
GM07492 0.54   0.27 0.1 0.52 
FRDA 
GM03816 0.44 0.27   0.92 0.475 
GM04078 0.17 0.1 0.92   0.12 
GM03665 0.95 0.52 0.475 0.12   
A) 
B) C) 
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6.3.3 - The effect of reduced FXN on MSH6 transcription 
To examine the effect of frataxin deficiency on MSH6 expression, MSH6 mRNA expression 
was analysed in three FRDA primary fibroblast cell lines compared with two unaffected FXN 
fibroblasts. qRT-PCR analysis clearly demonstrated an increase of MSH6 mRNA expression 
in FRDA cells, approximately 1.5-fold that of control cells (p<0.001; Figure 6.6A), indicating 
that frataxin deficiency results in upregulation of MSH6 mRNA expression. Therefore, it is 
proposed that defects of frataxin do not lead to cell malignant transformation through 
affecting the level of MSH6 expression. Rather, it is proposed that, as with MSH2 and MSH3, 
upregulation of MSH6 mRNA expression causes an increased level of MSH6 protein required 
to repair expanded GAA repeat mutations and general DNA damage in FRDA fibroblast 
cells. Analysing individual cell lines demonstrated no significant difference of the MSH6 
mRNA expression level in the unaffected FXN primary fibroblasts. Likewise, by comparing 
the MSH6 transcription level in each FRDA cell line, no statistically significant variability 
was observed, while they showed different sizes of GAA repeat expansion (Figure 6.6B-C, 
Table 6.4). This finding suggests no direct link between sizes of expended GAA repeats and 
mRNA levels of MSH6. Thus, GAA repeat expansion is not the main cause of MSH6 
upregulation in FRDA fibroblasts. Therefore, it is proposed that other mechanisms might also 
be involved in this upregulation.  
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 Figure 6.6 - Analysis of MSH6 mRNA expression level in fibroblast cells. 
 
 
 
The graphs represent MSH6 mRNA level in (A) average expression between unaffected and 
FRDA primary fibroblasts, (B) individual fibroblast cells, and (C) comparison with GAA 
repeat sizes. Error bars = S.E.M, ***=P<0.001 
 
 
Table 6.4 - Student t-test p-values of frataxin deficiency effect on the MSH6 mRNA 
expression level during individual cell line analyses. 
  
Control FRDA 
H. Normal GM07492 GM03816 GM04078 GM03665 
Control 
H. Normal   0.12 0.24 0.06 0.075 
GM07492 0.12   0.33 0.08 0.11 
FRDA 
GM03816 0.24 0.33   0.33 0.74 
GM04078 0.06 0.08 0.33   0.12 
GM03665 0.075 0.11 0.74 0.12   
A) 
B) C) 
 Chapter 6 – The effect of frataxin deficiency on MMR gene expression    
 
  204 
 
6.3.4 - The effect of reduced FXN on PMS2 transcription   
To determine if PMS2 expression was affected by frataxin deficiency, PMS2 mRNA 
transcription was quantified in three primary FRDA fibroblast cell lines compared with two 
unaffected fibroblast cell lines. Analysis of the results showed increased PMS2 mRNA 
expression in FRDA cell lines (127%) compared with controls (normalised as 100%); 
however, the results were not statistically significant (p=0.14, Figure 6.7). To accurately 
quantify the PMS2 mRNA levels individually in each cell line, further experiments would be 
needed. 
 
Figure 6.7 - Analysis of PMS2 mRNA expression level in fibroblast cells. 
 
 
The graph illustrates mean value of the PMS2 mRNA level in unaffected and FRDA primary 
fibroblasts. Error bars =S.E.M. 
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6.3.5 - The effect of reduced FXN on MLH1 transcription  
In this experiment, the MLH1 mRNA level was quantified by qRT-PCR to examine the effect 
of frataxin deficiency. Data obtained from three FRDA and two unaffected primary fibroblast 
cell lines demonstrated that the value of MLH1 mRNA was significantly higher in FRDA 
cells (approximately 1.5-fold; p<0.05), suggesting that the MLH1 mRNA level is                       
upregulated as a result of defects of FXN in human fibroblasts (Figure 6.8A). Considering 
that downregulation of MLH1 has been reported to cause various types of cell malignancies, 
this result indicates that MLH1 expression level is not involved in tumourigenesis in defective 
FXN fibroblast cells. It is proposed that, as with the other MMR proteins, upregulation of the 
MLH1 mRNA expression level might be a natural cellular mechanism to repair GAA repeat 
expansion mutations and other general DNA damage in FRDA fibroblasts. To determine if 
sizes of GAA repeat expansions are directly linked to MLH1, the mRNA level of this MMR 
gene was analysed within individual FRDA primary fibroblasts. Although, the data analysis 
showed fluctuations in the level of MLH1 transcription within these three cell lines, no 
statistically significant difference was observed (Figure 6.8B-C, Table 6.5). This finding 
suggests that expanded GAA repeat sizes do not directly affect the transcription level of 
MLH1 gene. In other words, expansion of GAA repeats is not the direct cause of MLH1 
mRNA upregulation in FRDA fibroblasts. Therefore, it is also proposed that other 
mechanism(s) might also be involved in this upregulation. Further investigations are required 
to clarify the exact mechanism(s) involved in this event. 
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Figure 6.8 - Analysis of MLH1 mRNA expression level in fibroblast cells. 
 
 
 
 
The graphs represent MLH1 mRNA level in (A) average expression between unaffected and 
FRDA primary fibroblasts, (B) individual fibroblast cells, and (C) comparison with GAA 
repeat sizes. Error bars =S.E.M, *=P<0.05 
 
Table 6.5 - Student t-test p-values of frataxin deficiency effect on the MLH1 mRNA 
expression level during individual cell line analyses. 
  
Control FRDA 
H. Normal GM07492 GM03816 GM04078 GM03665 
Control 
H. Normal   0.31 0.26 0.03 0.8 
GM07492 0.31   0.015 0.03 0.04 
FRDA 
GM03816 0.26 0.015   0.09 0.06 
GM04078 0.03 0.03 0.09   0.051 
GM03665 0.8 0.04 0.06 0.051   
A) 
B) C) 
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6.4 - Quantification of MMR transcription in human 
FRDA tissues 
 
Following on from the FRDA cell culture studies, the effects of frataxin deficiency on MMR 
mRNA expression levels (excluding MSH3 mRNA expression level) were investigated in 
human FRDA tissues.  In this study, cerebellum tissues were obtained from 4 FRDA patients 
compared with 4 unaffected individuals. Initial analysis of FRDA patient blood DNA 
samples showed different sizes of GAA repeat expansions (Table 6.6), while analysis of 
unaffected individuals showed normal-sized (<16) GAA repeats within brain and cerebellum 
tissues (Figure 6.9) 
 
 
Table 6.6 - Details of the human cerebellum tissues.  
  ID Sex Age (Yrs) 
Number of GAA 
repeats 
FRDA patients  
22/CA M 24 550/750 
44/HK M 17 630/750 
58/CR M 40 570/930 
80/JT M 25 780/780 
unaffected 
individuals  
3/HN M 80 <16 
8/HN F 82 <16 
13/HN M 81 <16 
16/HN M 64 <16 
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Figure 6.9 - Analyses of GAA repeat size in the unaffected individuals. 
 
 
 
The image represents example of the ethidium bromide-stained agarose gel used to determine 
GAA repeat sizes, showing an inverted image of PCR products obtained from two tissues of 
three unaffected individuals (controls 1-3). B= brain tissue, C= cerebellum tissue,                     
M= 1Kb
+ 
size marker.     
 
 
 
 
Prior to quantifying MMR gene transcription, the quality of cDNA samples was analysed by 
performing a standard RT-PCR for the human GAPDH gene (Figure 6.10). The results 
demonstrated a specific PCR product for all FRDA and control samples, with an absence of           
any non-specific products, indicating a good enough quality of samples to perform qRT-PCR.  
To verify the specificity of MMR gene PCR products, conventional RT-PCRs were also 
performed for each MMR gene. The results confirmed the specificity of all MMR genes, with 
the exception of MSH3, which showed only a non-specific PCR product. Therefore, MSH3 
RT-PCR was not performed as part of this study, but will require further optimisation in it is 
to be performed in the future.  
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 Figure 6.10 - GAPDH-RT-PCR analysis. 
 
 
The image represents quality of cDNA obtained from human cerebellum tissues of four 
FRDA patients compared with four unaffected individuals by analysing human                    
GAPDH-RT-PCR products in 1% ethidium bromide-stained agarose gel electrophoresis.     
M= 1kb size marker.   
 
 
To quantify the mRNA expression, the Ct value for each target gene was normalised to the 
human endogenous GAPDH. In this study, each sample was run in triplicate and each 
experiment was performed at least twice. The mean value of each individual triplicate sample 
was calculated for further analysis using the 2
-ΔΔCt
 formula to find the RQ value. 
Subsequently, the relative level of transcription of each gene was determined for all FRDA 
and unaffected samples by calculating the RQ mean values, followed by setting one of the 
human unaffected cerebellum samples arbitrarily as 100%. 
To understand the potential link between FXN deficiency and transcription levels of MMR 
genes, FXN mRNA expression levels were first verified. Standard FXN RT-PCR did not 
produce any products in any of the FRDA patients, whilst the control samples obtained from 
human unaffected cerebellum tissues gave specific RT-PCR products (Figure 6.11).  
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Figure 6.11 - Human FXN-RT-PCR analysis. 
 
 
 
 
 
The image illustrates human FXN-RT-PCR analyses of samples in 1% ethidium          
bromide-stained agarose gel electrophoresis. M= 1Kb
+ 
size marker, P= positive control,        
N= negative control. n.b. this was a preliminary result to confirm the quality of cDNAs, 
before optimising primers for qRT-PCR.  
 
 
As shown earlier (Figure 6.10), analysing RT-PCR products for GAPDH confirmed the 
quality of cDNA in all FRDA and unaffected individuals. Since the FRDA patients had very 
large GAA repeat expansions, and since frataxin is poorly expressed in cerebellum, I would 
propose that not observing a FXN RT-PCR product in the FRDA samples indicates very low 
levels of FXN expression in these samples. 
 
6.4.1 - The effect of FXN deficiency on MSH2 transcription 
To understand the effect of FXN on MSH2 transcription, the MSH2 mRNA expression level 
was analysed by comparing cerebellum tissues of four FRDA patients with four unaffected 
individuals. Analysis of mean values demonstrated a remarkably reduced level of the MSH2 
mRNA in FRDA patients (approximately 23%) in comparison with unaffected individuals 
(Figure 6.12A), indicating that MSH2 mRNA expression is downregulated in FRDA 
cerebellum tissue.           
Since the GAA repeat expansion sizes were variable within the four different FRDA patients, 
a comparison was made between GAA repeat expansions and MSH2 cerebellum mRNA 
expression levels. Quantification of the individual tissue samples by qRT-PCR clearly 
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showed reduced levels of MSH2 mRNA expression in all four FRDA patients: 22/CA, 
44/HK, 58/CR and 80/JT showed levels of 25%, 23%, 23% and 10%, respectively, compared 
to the reference unaffected control, 8/HN. Further analyses did not show any significant 
differences in the level of MSH2 transcription with increasing magnitude of GAA repeat 
expansions in FRDA samples, except in the 80/JT (Figure 6.12B-C, Table 6.7). In this 
experiment, quantification of unaffected tissues showed slight fluctuation in MSH2 mRNA 
expression levels; however, no statistically significant differences were observed.  
Taken together, findings obtained from this experiment demonstrated that defects of FXN 
expression, most likely caused by GAA repeat expansions, led to downregulation of MSH2 
transcription in FRDA cerebellum tissues. That means frataxin deficiency might be able to 
contribute to cell malignancies by reducing MSH2 expression in the cerebellum. However, 
finding no direct link between expanded GAA repeat size and levels of MSH2 expression 
indicates that GAA repeat expansions do not by themselves downregulate MSH2 mRNA 
expression in the human cerebellum tissue. It is proposed that other mechanisms, such as 
epigenetic modifications, might be involved in this downregulation. In other words, these 
findings suggest an interactive pathway between GAA repeat expansion, frataxin deficiency 
and downregulation of MSH2 transcription in FRDA cerebellum. 
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Figure 6.12 - Analysis of MSH2 mRNA expression levels in human cerebellum tissues. 
 
 
 
The graphs represent MSH2 mRNA level in (A) average expression between unaffected and 
FRDA cerebellum tissues, (B) individual cerebellum tissues, and (C) comparison with GAA 
repeat sizes. Error bars= S.E.M, *=P<0.05, **= P<0.01, ***= P<0.001 
 
 
 
Table 6.7 - Student t-test p-values of frataxin deficiency effect on the MSH2 mRNA 
expression level during individual cerebellum tissue analyses. 
  44/HK 58/CR 80/JT 8/HN 3/HN 13/HN 16/HN 
44/HK   0.97 0.0009 0.003 0.195 0.08 0.06 
58/CR 0.97   0.22 0.04 0.17 0.06 0.014 
80/JT 0.0009 0.22   0.0001 0.09 0.07 0.053 
8/HN 0.003 0.04 0.0001   0.29 0.27 0.15 
3/HN 0.105 0.17 0.09 0.29   0.46 0.43 
13/HN 0.08 0.06 0.07 0.27 0.46   0.9 
16/HN 0.06 0.014 0.053 0.15 0.43 0.9   
 
A) 
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6.4.2 - The effect of FXN deficiency on MSH6 transcription 
To investigate effects of frataxin deficiency on MSH6 transcription, the level of MSH6 
mRNA was quantified in cerebellum tissue of three different FRDA patients and three 
unaffected individuals. Analysis of mean values demonstrated a 46% level of MSH6 mRNA 
in FRDA patient cerebellum tissues compared with unaffected controls (p<0.001; Figure 
6.13A). This finding suggests that deficit of frataxin in cerebellum tissue causes 
downregulation of MSH6 mRNA expression level. Individual sample analysis demonstrated a 
reduced level of MSH6 mRNA expression in all FRDA samples compared with unaffected 
controls, but a statically significant difference was only observed with one of the FRDA 
samples (80/JT) (Figure 6.13B, Table 6.8). Further analyses showed that, while there were 
fluctuations in the mRNA expression levels of MSH6, no statistically significant differences 
were observed within all three FRDA cerebellum tissues (Figure 6.13B-C, Table 6.8).  
Taken together, these findings reveal that frataxin deficiency caused downregulation of 
MSH6 transcription in cerebellum tissue, suggesting a possible effect of frataxin defects on 
cerebellum tissue tumourigenesis through MSH6 aberrations. Moreover, finding no direct 
link between expanded GAA repeat size and levels of MSH6 mRNA indicates that GAA 
repeat expansions are sufficient, but not necessary to downregulate MSH6 expression. 
Therefore, it is proposed that there is interplay of GAA repeat expansion, frataxin deficiency 
and reduced expression of both MSH6 and MSH2 in FRDA cerebellum tissues.  
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Figure 6.13 - Analysis of MSH6 mRNA expression levels in human cerebellum tissues. 
 
 
 
The graphs represent MSH6 mRNA level in (A) average expression between unaffected and 
FRDA cerebellum tissues, (B) individual cerebellum tissues, and (C) comparison with GAA 
repeat sizes. Error bars= S.E.M, *=P<0.05, ***= P<0.001 
 
 
Table 6.8 - Student t-test p-values of frataxin deficiency effect on the MSH6 mRNA 
expression level during individual cerebellum tissue analyses. 
  8/HN 13/HN 16/HN 22/CA 44/HK 80/JT 
8/HN   0.32 0.47 0.11 0.08 0.021 
13/HN 0.32   0.18 0.13 0.069 0.092 
16/HN 0.47 0.18   0.053 0.035 0.08 
22/CA 0.11 0.13 0.053   0.36 0.15 
44/HK 0.08 0.069 0.035 0.36   0.22 
80/JT 0.021 0.092 0.08 0.15 0.22   
A) 
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6.4.3 - The effect of FXN deficiency on PMS2 transcription 
The PMS2 mRNA expression levels were quantified in cerebellum tissues of four FRDA 
patients and four unaffected individuals. Analysis of mean values demonstrated                   
significant downregulation of the PMS2 mRNA in FRDA patients compared with unaffected 
individuals (p<0.05: Figure 6.14A), indicating that the level of PMS2 expression is 
remarkably reduced in FRDA cerebellum tissues. Analysis of individual samples revealed 
fluctuation of PMS2 mRNA expression levels, although no statistically difference was 
observed (Figure 6.14B-C, Table 6.9). 
Taken together, these observations showed that frataxin deficiency resulted in                 
downregulation of PMS2 transcription in FRDA cerebellum tissues, but in a manner that was 
not related to GAA repeat size. Therefore, it is proposed that there may be interplay between 
GAA repeat expansion, frataxin deficiency and downregulation of MSH2, MSH6 and PMS2 
in FRDA cerebellum tissue. 
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Figure 6.14 - Analysis of PMS2 mRNA expression levels in human cerebellum tissues. 
 
 
 
The graphs represent PMS2 mRNA level in (A) average expression between unaffected and 
FRDA cerebellum tissues, (B) individual cerebellum tissues, and (C) comparison with GAA 
repeat sizes. Error bars= S.E.M, *=P<0.05 
 
Table 6.9 - Student t-test p-values of frataxin deficiency effect on the PMS2 mRNA 
expression level during individual cerebellum tissue analyses. 
  22/CA 58/CR 8/HN 3/HN 13/HN 16/HN 
8/HN 0.14 0.96   0.06 0.14 0.009 
3/HN 0.07 0.14 0.06   0.02 0.24 
13/HN 0.11 0.44 0.14 0.02   0.07 
16/HN 0.07 0.16 0.009 0.24 0.07   
22/CA   0.09 0.14 0.07 0.11 0.07 
58/CR 0.09   0.96 0.14 0.44 0.16 
A) 
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6.4.4 - The effect of FXN deficiency on MLH1 transcription 
To determine if MLH1 expression was affected by frataxin deficiency, the MLH1 mRNA 
levels were quantified in cerebellum tissues of four FRDA patients and four unaffected 
individuals. Analysis of mean values demonstrated a remarkably reduced level of MLH1 
mRNA expression in FRDA patients, at approximately 20% of the level in unaffected 
cerebellum tissues (p<0.001; Figure 6.15A). This finding indicates that defects of frataxin 
caused by GAA repeat expansions induce downregulation of MLH1 expression in 
cerebellum. Quantification of individual samples by qRT-PCR clearly demonstrated reduced 
levels of MLH1 mRNA expression in all four FRDA patients: 22/CA (38%), 44/HK (32%), 
58/CR (29%), and 80/JT (29%), compared with controls (Figure 6.15B). The data showed no 
statistically significant differences between MLH1 expression in the four FRDA cerebellum 
tissues (Figure 6.15B-C, Table 6.10). Further analyses did not suggest any direct link 
between the level of MLH1 transcription and size of expanded GAA repeats in the FRDA 
cerebellum tissues.  
Taken together, the observations obtained from this experiment demonstrated that frataxin 
deficiency downregulates the MLH1 transcription level in cerebellum tissue, suggesting a 
possible effect of frataxin defects on cerebellum tissue tumourigenesis through MLH1 
aberrations.  Furthermore, finding no direct link between sizes of expanded GAA repeats and 
levels of MLH1 mRNA indicates that GAA repeat expansions are sufficient, but not 
necessary, to downregulate MLH1 expression. Therefore, other mechanisms might be 
involved in this downregulation. Further investigations are required to clarify the exact 
mechanisms involved in this interaction, which now appears to involve GAA repeat 
expansion, frataxin deficiency and downregulation of all four MMR genes so far investigated, 
namely MSH2, MSH6, PMS2 and MLH1. 
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Figure 6.15 - Analysis of MLH1 mRNA expression levels in human cerebellum tissues. 
 
 
 
The graphs represent MLH1 mRNA level in (A) average expression between unaffected and 
FRDA cerebellum tissues, (B) individual cerebellum tissues, and (C) comparison with GAA 
repeat sizes. Error bars= S.E.M,*=P<0.05, **= P<0.01, ***= P<0.001 
 
Table 6.10 - Student t-test p-values of frataxin deficiency effect on the PMS2 mRNA 
expression level during individual cerebellum tissue analyses. 
  22/CA 44/HK 58/CR 80/JT 8/HN 3/HN 16/HN 
22/CA   0.27 0.34 0.1 0.02 0.1 0.03 
44/HK 0.27   0.64 0.55 0.03 0.09 0.03 
58/CR 0.34 0.64   0.93 0.04 0.09 0.002 
80/JT 0.1 0.55 0.93   0.93 0.09 0.025 
8/HN 0.02 0.03 0.04 0.93   0.18 0.043 
3/HN 0.1 0.09 0.09 0.09 0.18   0.51 
16/HN 0.03 0.03 0.002 0.025 0.43 0.51   
 
A) 
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6.5 - Discussion 
To understand the molecular mechanisms that could potentially contribute to malignant cell 
transformation of frataxin-deficient cells, the mRNA expression levels of human MMR genes 
were investigated using in vitro and in vivo FRDA model systems. In vitro analysis 
demonstrated upregulation of MSH2, MSH3, MSH6 and MLH1 gene expression in FRDA 
fibroblasts compared to unaffected fibroblasts. PMS2 also showed a non-statistically 
significant trend towards upregulation in FRDA fibroblasts. Therefore, it is proposed that 
MMR expression is upregulated in FRDA fibroblasts as a natural intrinsic response to DNA 
errors, perhaps including GAA repeat expansion mutation itself. These findings are 
compatible with the known role of the MMR system, which involves recruitment of MMR 
proteins to repair damaged DNA. Since frataxin deficiency is mainly caused by GAA repeat 
expansion, it is possible that expansion of this repeat may be involved in upregulation of 
MMR expression. To investigate this, GAA repeat sizes were compared with the level of 
MMR expression in individual FRDA fibroblast cells. However, no correlation was observed, 
suggesting that GAA repeat expansion is not directly involved in upregulation of different 
MMR expression. 
In contrast to the human fibroblast results, studies of human cerebellum tissues identified 
significantly reduced levels of MMR transcription in FRDA patients compared with 
unaffected individuals, which was once again not related to GAA repeat size. This indicates 
that frataxin deficiency may cause reduced MMR gene expression in the cerebellum.                    
The discrepancy between the results from human cerebellum tissues (in vivo) compared with 
human fibroblast cell lines (in vitro) could be explained in two ways. Firstly, it may be due to 
the use of different cell systems: in vivo versus in vitro. Secondly, since FRDA is known to 
be a tissue selective disorder, different cell types may respond differently to frataxin 
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deficiency. Indeed, further investigations have been performed on the FXN
GAA+
 transgenic 
mouse cell lines in the Pook laboratory showing that the levels of Msh2, Msh3, Msh6, and 
Pms2 mRNA expression are all significantly reduced in GAA repeat-containing YG8 and 
YG22 differentiated neural stem cells (NSCs), compared with Y47 transgenic mice that carry 
the normal human FXN gene (C. Sandi, personal communication). This is consistent with the 
observations of human cerebellum tissues, suggesting comparable effects in human 
cerebellum tissue and mouse differentiated NSC cell lines. Moreover, investigation of 
transgenic mouse kidney fibroblast cell lines showed that Msh2, Msh3, Msh6, and Pms2 
mRNA expression levels were either not significantly changed (YG8) or increased (YG22) 
compared with Y47 fibroblasts (C. Sandi, personal communication). This finding is also 
comparable with data obtained from analysis of human FRDA fibroblasts, suggesting similar 
effects in both human FRDA and FXN
GAA+ 
transgenic mouse fibroblast cell lines. These 
findings support the notion that different cell types respond differently to frataxin deficiency. 
Thus, tissues that have higher sensitivity to frataxin deficiency, such as cerebellum, show 
reduced levels of MMR expression, while tissues that are less-sensitive (e.g. skin, the source 
of human fibroblasts) show increased levels of MMR expression.  
The principle cause of downregulation of MMR gene expression in tissues that are highly 
sensitive to frataxin deficiency is not yet clear. Studies have shown that non-cytotoxic levels 
of H2O2, which is an important source of oxidative stress, can inactivate MMR functions in a 
dose dependent manner (Chang et al. 2002). Other studies have also reported that oxidative 
stress can lead to the induction of frameshift mutations within MMR genes in human 
colorectal epithelial cell lines, subsequently inactivating MMR functions (Gasche et al. 
2001). It is not exactly clear how oxidative stress could inhibit MMR gene transcription. 
However, studies have indicated that oxidative stress can affect Mlh1 mRNA expression in 
malignant cells in a histone deacetylase-dependent manner. Thus, induction of oxidative 
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stress overactivates histone deacetylation, consequently leading to downregulation of Mlh1 
mRNA expression. Treatment of these cells with HDACi agents, such as TSA, restored the 
normal levels of Mlh1 mRNA expression, confirming the role of oxidative stress on 
downregulation of Mlh1 transcription (Mihaylova et al. 2003).  
Since oxidative stress is one of the consequences of frataxin deficiency, it is proposed that 
reduced MMR transcription in tissues that are highly sensitive to frataxin deficiency might be 
due to increased levels of oxidative stress. This may then lead to the induction of epigenetic 
changes, particularly deacetylation of histones, within the MMR genes. Future investigations 
of such epigenetic changes within the MMR genes may provide valuable insights into the 
possible mechanisms involved in downregulation of MMR gene expression in the frataxin 
deficient cells. 
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7.1 - General discussion 
This thesis aimed to investigate the relationships between MMR genes, GAA repeat 
instability and FXN gene expression in the inherited neurodegenerative disorder FRDA. The 
reasoning was that MMR proteins are known to play a critical role in correcting DNA 
replication errors, while investigations of the other TNR disorders (e.g. CAG and CTG 
repeats in HD and DM1, respectively) have previously demonstrated an important role of 
MMR proteins in the stability of these microsatellite repeats. Furthermore, frataxin deficiency 
has also been associated with malignant cell transformation, which may be due to modulation 
of DNA repair gene expression (in the case of this project, MMR gene expression). 
The novel findings of this thesis have been categorised into four sections. Firstly, 
observations from genetically altered mouse studies demonstrated the importance of MMR 
proteins in intergenerational GAA repeat instability. Thus, the mutability frequency of GAA 
repeats was shown to generally increase in the offspring of mice that lack MMR proteins. 
Furthermore, the results indicated that neither Msh2 nor Msh3 is involved in causing GAA 
expansions, but rather they appear to protect against contraction of GAA repeats. In contrast, 
Pms2 acts by a different mechanism to Msh2 and Msh3, promoting GAA repeat contractions 
and preventing GAA repeat expansions. Msh6 confers some protection against both GAA 
repeat expansions and contractions, but it has a less obvious role to play in intergenerational 
GAA repeat dynamics. Mlh1 appears to protect against contractions and promote expansions, 
but further investigations are required to confirm the exact role of this protein. 
Secondly, investigations of the same genetically altered mice showed that MMR proteins also 
play an important role in somatic GAA repeat instability. Thus, loss of Msh2, Msh3, Msh6 or 
Mlh1 was shown to cause a reduction of progressive GAA repeat expansion within CNS 
tissues, particularly the cerebellum. Conversely, Pms2 deficiency produced even larger GAA 
repeat expansions. Comparing intergenerational and somatic GAA repeat instability systems 
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revealed different effects of Msh2, Msh3, Msh6 or Mlh1 proteins, while the effects of Pms2 
were similar for both systems.  
Thirdly, MMR proteins were found to have an effect on FXN transcription in CNS tissues.  
Thus, Msh6-, Pms2- and Mlh1-deficient brain and cerebellum tissues showed downregulation 
of FXN transcription, while Msh2-deficient tissues showed increased FXN transcription and 
Msh3-deficient cells showed no change. The Msh2- and Pms2-deficient FXN transcription 
changes could be accounted for by corresponding changes in GAA repeat sizes. However, 
analysis of Msh6- or Mlh1-defective brain and cerebellum tissues did not reveal a direct link 
between GAA repeat sizes and FXN transcription levels, suggesting that regulation of FXN 
transcription occurs through mechanisms that do not involve GAA repeat instability. 
Finally, investigations showed that frataxin deficiency has varying effects on MMR mRNA 
expression depending on the type of cell or tissue. Thus, cells that are less sensitive to 
frataxin deficiency (e.g. fibroblast cells isolated from skin) show upregulation of MMR 
expression, perhaps in response to DNA replication errors, while tissues that contain         
non-dividing cells that are highly sensitive to frataxin deficiency (e.g. CNS tissues) show 
reduced MMR expression. Overall, these findings suggest that various mechanisms may 
contribute to the interaction of MMR proteins and GAA repeat instability, and in turn, to the 
level of frataxin and MMR transcription. These mechanisms will now be discussed further by 
proposing models that may explain the relationships between GAA repeat expansion, FXN 
transcription and MMR gene transcription.  
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7.2 - How might MMR proteins affect GAA repeat 
instability? 
 Data from this thesis and other in vitro and in vivo studies (Bourn et al. 2012; Du et al. 2012; 
Ezzatizadeh et al. 2012; Halabi et al. 2012) have put emphasis on a critical role of MMR 
proteins in GAA repeat instability and FXN gene expression. Although the exact mechanisms 
of action are unknown, observations would suggest a complicated system of interactions. 
Since dsDNA is only normally opened up during replication or transcription, two models are 
proposed to explain the effect of MMR proteins on GAA repeat expansions. 
 
7.2.1 - How could the MMR system induce GAA repeat 
expansion during DNA replication? 
It is generally accepted that repeat expansions can adopt different types of non-B DNA 
structures during DNA replication. Investigations have shown that GAA repeat expansions 
may form triplexes between intermolecular GAA.GAA.TTC (R.R.Y) sequences (Vetcher et 
al. 2002) or a more complicated form of sticky DNA by the binding of two separate GAA 
repeat runs in naked supercoiled DNA (Sakamoto et al. 1999; Chandok et al. 2012). Such 
sequences may lead to inefficient DNA replication. Therefore, it is proposed that the MMR 
system could be recruited to attempt the repair such non-canonical DNA structural errors.         
In the initial stage of repair, a small loop that is produced as a result of GAA triplex 
formation (Figure 7.1B-C) could be recognised by the MutSα or the MutSβ complex (Figure 
7.1D). Interestingly, ChIP assays have demonstrated that both of the MutSβ complex 
proteins, Msh2 and Msh3, and to a lesser extent Msh6, show increased occupancy in the 
downstream region of expanded GAA repeat sequences, which could indicate binding to the 
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GAA repeat itself (Du et al. 2012; Ezzatizadeh et al. 2012). However, the results shown in 
chapter 4 of this thesis, together with the results from another study (Bourn et al. 2012), 
suggest that Msh2, Msh3 and Msh6 all have roles to play in somatic GAA repeat instability. 
Therefore, it is proposed that MutSβ (Msh2-Msh3) most likely plays the more important role 
in binding to a triplex DNA loop, while MutSα (Msh2-Msh6) plays a somewhat lesser role. 
Following binding of the MutS complex to the triplex DNA loop, a MMR-directed excision 
may be made by endonuclease activity within the single-strand of DNA that occurs opposite 
the loop (Figure 7.1D). This event may then recruit the MutLα complex and other 
coordinating proteins to proceed with MMR system (Figure 7.1E). Providing both Mlh1 and 
Pms2 are present, the MutLα complex is recruited to continue and terminate the MMR 
procedure. Simultaneously, an alternative enzyme (most likely a helicase) may open up the 
triplex sequences, creating a gap in the nicked opposing single strand of DNA, which is then 
filled with additional sequence by a DNA polymerase (Figure 7.1E). Hence, this event not 
only resolves the GAA repeat triplex structure, but at the same time causes further GAA 
repeat expansions. However, this mechanism does not account for how loss of Pms2 can 
cause the observed increased expansion of GAA repeats. Therefore, it is proposed that Pms2 
can induce GAA repeat contractions by a separate mechanism. 
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Figure 7.1 - MMR proteins may act on DNA triplex structures to cause GAA 
expansions. 
 
 
 
 
 
 
 
 
 
 
  
Schematic images representing: (A) normal GAA repeat structure, (B) triplex Y.R.R structure 
of the expanded GAA repeats, (C) focus on the small loop caused by triplex DNA structure 
(D) recognition of the loop by MutSβ/MutLα and cleavage with endonuclease, (E) opening of 
the loop, recruiting MMR complexes and synthesis of DNA by DNA polymerase δ, and        
(F) ending repair by ligation of the further expanded strand and release of MMR proteins and 
protein assemblies (e.g. RFC, PCNA and RPA).  
 
 
A) B) 
F) E) 
 C) D) 
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7.2.2 - How could the MMR system induce GAA repeat 
expansion during transcription? 
Another hypothesis that could explain the formation of progressive GAA repeat expansions is 
the involvement of MMR proteins during FXN transcription. Previous studies have shown 
that there is a direct link between GAA repeat expansion and transcription (Greene et al. 
2007; Al-Mahdawi et al. 2008; Ditch et al. 2009). Furthermore, evidence suggests that 
transcription of GAA repeats can produce unusual RNA.DNA hybrid sequences in vitro 
(Grabczyk and Usdin 2000; Grabczyk et al. 2007) and in bacteria (Grabczyk et al. 2007), 
resulting in RNA polymerase II stalling. Non-canonical DNA/RNA hybrid structures may be 
created during transcription by the binding of single-stranded template TTC repeat sequences 
to premature transcribed GAA mRNA sequences forming loop outs of the single-stranded 
non-template GAA repeats (Figure 7.2B-D). These loop outs may then be recognised by one 
of the MutS complexes (Figure 7.2E). As part of the resolution process, a MMR-directed 
excision may be made in the TTC template strand of DNA (Figure 7.2E) and the mRNA may 
be released from the template strand by helicase enzyme activity. Subsequently, the MutS 
complex may recruit MutLα and other MMR system proteins to repair the cut TTC strand of 
DNA, but with the introduction of expanded repeat sequences (Figure 7.2F). Since somatic 
GAA repeat expansions occur predominantly in tissues that contain mainly non-dividing 
cells, such as brain and cerebellum, a transcription-based mechanism is indeed the most 
pertinent model to explain the role of the MMR system in somatic GAA repeat expansions.    
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Figure 7.2 - MMR proteins may act on RNA/DNA triplex structures to cause GAA 
expansions. 
 
 
 
 
 
 
 
 
 
 
Images illustrating: (A) normal structure of expanded GAA repeats, (B) a small triplex 
DNA.RNA structure formed within GAA repeats, (C) focus on the unwound region during 
transcription (D) focus on the small loop caused by DNA.RNA binding, (E) recognition of 
the loop by MutS heterodimers and cleavage of the opposite DNA strand with an 
endonuclease, (F) release of the RNA and synthesis of expanded DNA by DNA polymerase δ 
and (G) ending repair by ligation of the expanded strand and release of MMR proteins as well 
as protein assemblies (e.g. PCNA, RFC and RPA).   
 
 
A) B)
 
D)
 
C) 
F) E) 
G) 
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7.3 - How could MMR proteins affect FXN transcription?  
The previous hypotheses may explain how somatic GAA repeat expansions could arise due to 
MMR activity. However, they do not explain why the level of FXN mRNA expression is not 
increased to correspond with the reduced size of GAA repeats in Msh6- or Mlh1-deficient 
genetically altered mouse tissues, as previously reported for FRDA cells and tissues that are 
MMR proficient (Greene et al. 2007; Al-Mahdawi et al. 2008; Ditch et al. 2009). Therefore, 
it is proposed that another mechanism, separate from the canonical MMR system, might be in 
operation, whereby defects of Msh6 or Mlh1 cause both a reduction of FXN mRNA 
expression as well as a reduced level of expanded GAA repeats. Previous studies have 
highlighted the importance of MSH6 and MLH1 proteins in TC-NER (Mellon et al. 1996; 
Kobayashi et al. 2005) and defects of TC-NER can result in reduced gene transcription 
(Michalowski et al. 2001). Therefore, it is proposed that deficiencies of MSH6 or MLH1 may 
have dual effects, reducing GAA repeat expansions via the MMR system and reducing FXN 
transcription via the TC-NER system.  
In this model, a complex of primary FXN mRNA sequences and RNA polymerase II may 
bind to form an unusual RNA/DNA triplex structure (Figure 7.3A). This abnormal structure 
may be able to cause further GAA expansions, on the one hand, and block transcription of the 
FXN gene, on the other. It is not certain how MSH6 or MLH1 may participate in FXN 
transcription via the TC-NER system. However, the findings presented in chapter 5 of this 
thesis would suggest that MSH6 and MLH1 can act, perhaps as a complex with other 
proteins, to enhance FXN transcription. MSH6 and MLH1 proteins may bind to the abnormal 
DNA/RNA hybrid structure and, by acting through the TC-NER system, they may assist in 
the release of stalled RNA polymerase II enzyme (Figure 7.3B), resulting in the resumption 
of FXN transcription (Figure 7.3C). In contrast, in the absence of MSH6 or MLH1 proteins,  
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RNA polymerase II would not be released due to the failure of the TC-NER system             
(Figure 7.3D) and blockage of FXN transcription would persist.    
 
 
Figure 7.3 - The effect of MSH6 and MLH1 on FXN transcription via TC-NER. 
 
A) 
 
B) 
 
C) 
 
D) 
 
Images showing: (A) inhibition of transcription by stalling RNA polymerase II activity due to 
RNA.DNA triplex formation, (B) binding of MLH1 and MSH6 to the triplex, (C) release of 
premature mRNA and continuation of transcription, and (D) inhibition of transcription in the 
absence of MSH6 or MLH1. 
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7.4 - How could frataxin deficiency cause downregulation 
of MMR gene transcription? 
The mechanism that causes downregulation of MMR gene transcription in FRDA cerebellum 
tissue is not yet clear. However, it is proposed that frataxin deficiency may downregulate 
mRNA expression of MMR genes due to induction of oxidative stress. It is known that 
frataxin deficiency increases the levels of iron and H2O2 through two mechanisms. Firstly, 
there is impairment of the ISC synthesis pathway, which leads to increased levels of Fe
3+
, 
causing iron accumulation. Secondly, there is impairment of ISC-containing MRC I, II and 
III activities, resulting in an increase of the ROS superoxide (O2
-
) and consequently 
accumulation of H2O2. Under normal physiological conditions, H2O2 is generated from 
dismutation of O2
-
,
 
which is catalysed in mitochondria by SOD2 (Pandolfo 2009). H2O2 is 
then converted into H2O in the mitochondria by glutathione peroxidase (GPX) (Figure 7.4) 
(Tozzi et al. 2002). 
It is known that defects of frataxin hinder GPX activity, which then leads to an accumulation 
of H2O2 and subsequent hypoxia (i.e. a reduced level of O2) of the cell. Investigations of 
frataxin deficiency in eukaryotic cells have revealed a high sensitivity to the accumulation of 
H2O2 (Babcock et al. 1997; Wong et al. 1999), with the generation of highly toxic hydroxyl 
radicals (OH
•
) in the presence of Fe
2+
 (Tozzi et al. 2002). This eventually culminates in the 
induction of oxidative stress (Tozzi et al. 2002; Guccini et al. 2011). 
Furthermore, other studies have demonstrated a role for H2O2 in dysfunction of the MMR 
system by the induction of hypoxia (Chang et al. 2002). Hypoxia is recognised as a 
characteristic feature of most solid tumours, causing either an adaptive response to cell 
malignancy or cell death through apoptosis and/or necrosis.                 
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Figure 7.4 - ROS generation in mitochondria.  
 
 
 
 
 
 
 
 
An image representing the major production sites of superoxide anions (O2
-
) at MRC 
complexes I and III along with one of the major ROS scavenging pathways, in normal cells. 
Antioxidant enzymes include mitochondrial superoxide dismutase (SOD2) and glutathione 
peroxidase (GPX). Image adapted from (Balaban et al. 2005).  
   
 
The responsibility for maintaining the balance between adaptation and cell death in response 
to hypoxia is mainly performed by the hypoxia-inducible factor (HIF) family of molecules 
(Guccini et al. 2011). HIF complexes contain two subunits, HIF-1α and HIF-2α, which form 
a heterodimer by binding with HIF-β. In normal physiological conditions, both HIF-α 
subunits are degraded by the proteasome. However, hypoxia inhibits degradation of HIF-α 
subunits, leading to the hypoxic adaptation response. It is reported that HIFs can regulate the 
expression of several genes containing a conserved hypoxia-responsive element (HRE) 
(Guccini et al. 2011). Interestingly, several studies have shown that protection of HIF-1α 
ROS antioxidant scavenger reaction: 
  O2
-
                H2O2             H2O + O2 
GPX SOD2 • 
• 
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from degradation causes downregulation of MMR gene transcription, possibly by affecting 
the relevant HREs (Mihaylova et al. 2003; Koshiji et al. 2005; Lehtonen et al. 2007; 
Rodriguez-Jimenez et al. 2008). These investigations suggest an interesting potential pathway 
in which defects of frataxin may cause downregulation of MMR mRNA expression in tissues 
that are highly sensitive to frataxin deficiency and subsequent hypoxia, such as brain. 
Therefore a model is proposed whereby defects of frataxin may inhibit GPX function, 
causing an accumulation of H2O2, which then leads to oxidative stress and the induction of 
hypoxia (Figure 7.5). Hypoxia may then induce stabilisation of HIF-1α protein, leading to 
HIF complex hyperactivation and subsequent binding to HRE sequences within individual 
MMR genes, leading to transcription inhibition (Figure 7.5). To confirm this hypothesis, 
several experimental studies would be required to determine the activity of SOD2, GPX and 
HIF-1α proteins and the levels of oxidative stress and hypoxia in the brain cells. 
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Figure 7.5 – Downregulation of MMR expression due to frataxin deficiency. 
 
 
 
 
Images representing potential mechanism of MMR protein downregulation in FRDA brain 
tissues. (A) Shows the mechanisms in a brain cell with normal frataxin expression, and          
(B) shows the mechanisms in a brain cell with defective frataxin expression. SOD2= 
superoxide dismutase, GPX= glutathione peroxidase, HIF-1α= hypoxia-inducible factor-1α.     
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7.5 - Future investigations 
The results presented in this thesis open new avenues for further studies. For example, data 
has now been generated using FRDA mouse model tissues, human cells and human tissues 
that reveal some similarities, but also some differences, between the different model systems. 
Therefore, further studies would be useful to more fully understand the compatibility of 
different FRDA model systems and to determine which models are most representative of 
FRDA disease. This may reveal insights into which are the most efficient models to study the 
interaction between MMR, GAA repeat instability and frataxin expression. Thus, mouse 
models may be the most effective way to investigate tissue-specific mechanisms and 
therapies for FRDA. Alternatively, human or mouse cell models may, under certain 
circumstances, be able to replace the use of mouse models for the investigation of other 
aspects of FRDA pathogenesis and therapy. 
Some of the data in this thesis also indicates that Mlh1 may have a significant role to play in 
FRDA disease progression, but further investigations are now required. For example, further 
mouse model genomic DNA studies would be useful to determine the effect of Mlh1 on the 
dynamics of intergenerational transmission of GAA repeats. In addition, applying advanced 
techniques, such as SP-PCR, may be able to more accurately quantify the effects of Mlh1 on 
somatic GAA repeat expansions.  
Other useful studies could include the detection of MMR protein occupancy at the FXN locus 
using ChIP assays and identification of the epigenetic status of MMR genes in FRDA 
compared with non-FRDA cells and tissues. These studies would be useful to unravel the 
mechanisms by which MMR proteins may affect GAA repeat expansions and FXN 
transcription, or in turn, by which frataxin may contribute to MMR gene regulation. The 
investigation of MMR protein expression levels and enzyme activities would also result in       
a broader understanding of MMR effects on GAA repeat instability and FXN gene 
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expression, or in turn, frataxin effects on the regulation of MMR proteins. Furthermore, 
investigating the role of other relevant molecules or mechanisms, such as SOD2 and GPX 
proteins or oxidative stress and hypoxia, could gain further insights into the exact relationship 
between MMR and FXN gene regulation. 
Since mutation of the MSH3 does not cause tumour formation, unlike mutations of the other 
MMR proteins (MSH2, MSH6, PMS2 and MLH1), it has previously been suggested that 
targeting MSH3 to reduce somatic instability of the GAA repeats could be considered as a 
potential FRDA therapy (Halabi et al. 2012). However, my results did not reveal any 
significant change in FXN transcription in CNS tissues upon loss of Msh3, despite the 
decrease of somatic GAA repeat expansions. Therefore, further studies are required to clarify 
the potential role of MSH3 as a therapeutic target for FRDA. Ultimately, combining the 
findings of this thesis with other studies may lead to the identification of novel mechanisms 
and therapeutic approaches for FRDA. 
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